<SEC-DOCUMENT>0001193125-25-147339.txt : 20250626
<SEC-HEADER>0001193125-25-147339.hdr.sgml : 20250626
<ACCEPTANCE-DATETIME>20250625211809
ACCESSION NUMBER:		0001193125-25-147339
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		25
CONFORMED PERIOD OF REPORT:	20250625
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250626
DATE AS OF CHANGE:		20250625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39979
		FILM NUMBER:		251074904

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d27026d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vor="http://www.vor.com/20250625" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-522">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-06-25_to_2025-06-25">0001817229</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="vor-20250625.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-06-25_to_2025-06-25"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001817229</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-25</xbrli:startDate> <xbrli:endDate>2025-06-25</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-533">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt:datemonthdayyearen" id="ixv-534">June 25, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-535">Vor Biopharma Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:stateprovnameen" id="ixv-536">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-537">001-39979</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-538">81-1591163</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-539">100 Cambridgepark Drive</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-540">Suite 101</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-541">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:stateprovnameen" id="ixv-542">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-543">02140</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-544">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-545">655-6580</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:boolballotbox" id="ixv-546">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:boolballotbox" id="ixv-547">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:boolballotbox" id="ixv-548">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:boolballotbox" id="ixv-549">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-550">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-551">VOR</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:exchnameen" id="ixv-552">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:boolballotbox" id="ixv-553">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-06-25_to_2025-06-25" format="ixt-sec:boolballotbox" id="ixv-554">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.01 Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Telitacicept License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;25, 2025, Vor Biopharma Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) and RemeGen Co., Ltd. (&#8220;<span style="font-weight:bold"><span style="font-style:italic">RemeGen</span></span>&#8221;) entered into a license agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">License Agreement</span></span>&#8221;)<span style="font-weight:bold"><span style="font-style:italic"> </span></span>granting the Company exclusive rights to develop and commercialize RemeGen&#8217;s proprietary fusion protein product, telitacicept, and related products (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Licensed Products</span></span>&#8221;) outside of the People&#8217;s Republic of China (&#8220;<span style="font-weight:bold"><span style="font-style:italic">PRC</span></span>&#8221;), Hong Kong, Macau and Taiwan (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Greater China</span></span>&#8221;). RemeGen retains all rights to the Licensed Products in Greater China. Under the License Agreement, the Company received an exclusive (even as to RemeGen) license under RemeGen&#8217;s patents and <span style="white-space:nowrap">know-how</span> to exploit, develop and commercialize the Licensed Products in all territories other than Greater China, with the right to grant sublicenses. The Company also received a <span style="white-space:nowrap">non-exclusive</span> license to manufacture the Licensed Products worldwide solely for use in the licensed territory. In exchange, RemeGen received an exclusive, perpetual and irrevocable license under Company intellectual property to exploit and manufacture the Licensed Products in Greater China, as well as a <span style="white-space:nowrap">non-exclusive,</span> fully <span style="white-space:nowrap">paid-up</span> license to manufacture the Licensed Products worldwide for use in Greater China. The Company is responsible for all development, regulatory and commercialization activities and costs in the licensed territory, including the conduct of clinical trials and regulatory submissions. The License Agreement established a joint steering committee to oversee collaboration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the rights granted, the Company will pay RemeGen an upfront payment of $125&#160;million, consisting of a cash payment of $45&#160;million and the issuance of $80&#160;million in equity to a subsidiary of RemeGen (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">RemeGen Warrantholder</span></span>&#8221;) in the form of a warrant<span style="font-weight:bold"> </span>to purchase 320,000,000 shares of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221;), at an exercise price of $0.0001 per share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">RemeGen Warrant</span></span>&#8221;). The RemeGen Warrant was issued pursuant to a securities purchase agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">RemeGen Purchase Agreement</span></span>&#8221;) and will become exercisable upon approval by the Company&#8217;s stockholders of the issuance of the shares of Common Stock underlying the RemeGen Warrant, any required filings with or approvals from regulatory authorities of the PRC for overseas direct investment (&#8220;<span style="font-weight:bold"><span style="font-style:italic">ODI Approval</span></span>&#8221;) and a charter amendment that has the effect of increasing the Company&#8217;s authorized but unissued shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RemeGen is eligible to receive up to $330&#160;million in regulatory milestone payments and up to $3.775&#160;billion in sales milestone payments. In addition, RemeGen is entitled to receive tiered royalties on net sales of the Licensed Products in the licensed territory, ranging from high single digit to <span style="white-space:nowrap">mid-teen</span> percentages of net sales, subject to customary reductions. If the Company enters into a sublicense or divests rights to the Licensed Products prior to a specified development event and other than in connection with a change of control, RemeGen is entitled to receive a single digit percentage of certain net proceeds from such transaction. The License Agreement also provides for technology transfer, mutual indemnification and confidentiality. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement may be terminated, in its entirety or on a <span style="white-space:nowrap"><span style="white-space:nowrap">region-by-region</span></span> basis, by either party for material breach (subject to cure periods and dispute resolution) or insolvency of the other party, by the Company for convenience with advance notice, or by RemeGen if the Company challenges the validity of licensed patents. Upon termination, all rights and licenses in the terminated region will revert to RemeGen, with a wind-down period for the Company to cease activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the License Agreement, RemeGen Warrant and RemeGen Purchase Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the License Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ending June&#160;30, 2025, and the forms of RemeGen Warrant and RemeGen Purchase Agreement, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;25, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Purchase Agreement</span></span>&#8221;) with accredited investors (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Investors</span></span>&#8221;) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors <span style="white-space:nowrap">pre-funded</span> warrants (the &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Funded</span> Warrants</span></span>&#8221;) to purchase up to 700,000,000 shares of Common Stock at a price per <span style="white-space:nowrap">Pre-Funded</span> Warrant of $0.25 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Funded</span></span></span> <span style="font-weight:bold"><span style="font-style:italic">Warrant Shares</span></span>&#8221;), for gross proceeds of $175&#160;million (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Private Placement</span></span>&#8221;). The <span style="white-space:nowrap">Pre-Funded</span> Warrants have an </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise price of $0.0001 per share and will become exercisable upon approval by the Company&#8217;s stockholders of the issuance of the shares of Common Stock underlying the <span style="white-space:nowrap">Pre-Funded</span> Warrants and a charter amendment that has the effect of increasing the Company&#8217;s authorized but unissued shares of Common Stock (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Stockholder Approval</span></span>&#8221;) and, to the extent applicable to an Investor, ODI Approval. The Company has agreed to prepare and file a preliminary proxy statement with the Securities and Exchange Commission (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">SEC</span></span>&#8221;) within sixty (60)&#160;days of the date of the Purchase Agreement. The Company intends to use the net proceeds from the Private Placement to advance development of its clinical pipeline and for general corporate purposes. The Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Investors, on the other hand, and customary conditions to closing. The closing of the Private Placement is expected to occur on June&#160;27, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the Purchase Agreement and <span style="white-space:nowrap">Pre-Funded</span> Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of the forms of Purchase Agreement and <span style="white-space:nowrap">Pre-Funded</span> Warrants, which are filed as Exhibits 10.3 and 10.1, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registration Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement and the License Agreement, the Company also entered into a Registration Rights Agreement, dated June&#160;25, 2025 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Registration Rights Agreement</span></span>&#8221;), with the Investors and with the RemeGen Warrantholder. Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the SEC a registration statement on Form <span style="white-space:nowrap">S-3</span> (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Registration Statement</span></span>&#8221;) to register for resale the shares of Common Stock underlying the RemeGen Warrant and the <span style="white-space:nowrap">Pre-Funded</span> Warrants within 30 days after Stockholder Approval, and to use its reasonable best efforts to have the registration statement declared effective as soon as possible, but no later than 75 days after the initial filing date of the Registration Statement, subject to extension under the terms of the Registration Rights Agreement. The Registration Rights Agreement provides for liquidated damages payable to the Investors and the RemeGen Warrantholder if the Company fails to meet certain filing or effectiveness deadlines, subject to specified caps. The Company will bear all registration expenses, including reasonable fees and expenses of outside counsel for the Investors and RemeGen up to specified caps, while the Investors will bear any selling expenses. The Registration Rights Agreement includes customary provisions regarding payment of fees and expenses and indemnification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Registration Rights Agreement, which is filed as Exhibit 10.4 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting and Support Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement and the License Agreement, certain stockholders of the Company entered into Voting and Support Agreements (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Support Agreements</span></span>&#8221;) pursuant to which, among other things, each stockholder has agreed, on the terms and subject to the conditions set forth therein, to vote all of their shares in favor of (i)&#160;the issuance of the shares of Common Stock underlying the RemeGen Warrant and the <span style="white-space:nowrap">Pre-Funded</span> Warrants and (ii)&#160;an amendment to the Company&#8217;s charter that has the effect of increasing the Company&#8217;s authorized but unissued shares of Common Stock. The Support Agreements also restrict the signing stockholders from transferring, selling or otherwise disposing of their shares or related securities except as permitted in the Support Agreement. The shares subject to the Support Agreements collectively represent approximately 63% of the total voting power of the Common Stock as of the date hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Support Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Support Agreement, which is filed as Exhibit 10.5 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants contained in the License Agreement, RemeGen Purchase Agreement, Purchase Agreement, Registration Rights Agreement and Support Agreements were made solely for the benefit of the parties to those agreements and may be subject to limitations agreed upon by the contracting parties. Accordingly, the License Agreement, RemeGen Purchase Agreement, Purchase Agreement, Registration Rights Agreement and Support Agreements are incorporated herein by reference only to provide investors with information regarding the terms thereof and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.02 Termination of a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;20, 2025, the Company entered into a Termination Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Termination Agreement</span></span>&#8221;) with PPF Off 100 Cambridge Park Drive, LLC, a Delaware limited liability company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Landlord</span></span>&#8221;), pursuant to which the Company and the Landlord agreed to terminate that certain lease agreement (as amended, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Lease</span></span>&#8221;) originally dated as of December&#160;17, 2019, as amended by that certain First Amendment to Lease, dated as of June&#160;15, 2021, and that certain Second Amendment to Lease, dated as of June&#160;15, 2021, related to the Company&#8217;s office, laboratory and manufacturing space located at 100 Cambridgepark Drive, Cambridge, Massachusetts. Prior to the Termination Agreement, the term of the Lease was set to expire in August 2030. Pursuant to the Termination Agreement, the Lease was terminated effective as of 5:00 p.m. Eastern Time on June&#160;20, 2025 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Early Termination Date</span></span>&#8221;), and the Company has until August&#160;4, 2025 to yield-up and surrender the premises. On the Early Termination Date, the Company paid the Landlord a $8.5 million termination fee, and the Landlord agreed to cancel and return to the Company the approximately $2.4 million letter of credit held as security for the Lease within 15&#160;days of the Early Termination Date. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;3.02 Unregistered Sales of Equity Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosures set forth in Item 1.01 above regarding the License Agreement and Private Placement are incorporated into this Item 3.02. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RemeGen Warrant and the <span style="white-space:nowrap">Pre-Funded</span> Warrants have not been registered under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Securities Act</span></span>&#8221;), in reliance on the exemption from registration afforded by Section&#160;4(a)(2) of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RemeGen Warrantholder has represented that it is an institutional &#8220;accredited investor&#8221; as defined in Rule 501 under the Securities Act, that it is acquiring the RemeGen Warrant solely for its own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and that the RemeGen Warrantholder has no present intention of selling, granting any participation in, or otherwise distributing the RemeGen Warrant in violation of the Securities Act. The sale of the RemeGen Warrant did not involve a public offering and was made without general solicitation or general advertising. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Private Placement, each of the Investors has represented that it is a &#8220;qualified institutional buyer,&#8221; as defined in Rule 144A under the Securities Act, that it is purchasing the <span style="white-space:nowrap">Pre-Funded</span> Warrants solely for the Investor&#8217;s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and that the Investor has no present intention of selling, granting any participation in, or otherwise distributing the <span style="white-space:nowrap">Pre-Funded</span> Warrants in violation of the Securities Act. The sale of the <span style="white-space:nowrap">Pre-Funded</span> Warrants did not involve a public offering and was made without general solicitation or general advertising. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this Current Report on Form <span style="white-space:nowrap">8-K</span> nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Resignation of Dr.&#160;Robert Ang as Chief Executive Officer, President, Director, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer; Transition Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;25, 2025, Robert Ang, M.B.B.S., M.B.A. notified the Company of his resignation from the positions of Chief Executive Officer, President, Director, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately. Dr.&#160;Ang will continue with the Company to assist in the transition through October&#160;14, 2025. Dr.&#160;Ang&#8217;s resignation is not because of a disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his resignation, on June&#160;25, 2025, Dr.&#160;Ang and the Company entered into a transition agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Transition Agreement</span></span>&#8221;). Under the Transition Agreement, subject to his execution of a release of claims, Dr.&#160;Ang will receive severance benefits including lump sum payments equal to 18 months of base salary and 150% of his 2025 target annual bonus, reimbursement of COBRA premiums for up to 18 months, accelerated vesting of all outstanding time-based equity awards and a <span style="white-space:nowrap">12-month</span> post-termination exercise period for vested stock options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Transition Agreement is not complete and is qualified in its entirety by reference to the full text of the Transition Agreement, a copy of which is filed as Exhibit 10.6 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Appointment of Jean-Paul Kress, M.D.</span></span><span style="font-weight:bold">, </span><span style="font-weight:bold"><span style="font-style:italic">as Chief Executive Officer, President, Principal Executive Officer and Chairman of the Board</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;25, 2025, the board of directors (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Board</span></span>&#8221;) of the Company appointed Jean-Paul Kress, M.D., as the Company&#8217;s Chief Executive Officer, President and Principal Executive Officer effective immediately. The Board also appointed Dr.&#160;Kress to the Board to serve as a Class&#160;III director to hold office until the 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal. Dr.&#160;Kress was also appointed as Chairman of the Board. Matthew Patterson, the prior Chairman of the Board, will continue to serve as a director on the Board. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no arrangement or understanding between Dr.&#160;Kress and any other person pursuant to which he was selected as an officer or director of the Company, and there is no family relationship between Dr.&#160;Kress and any of the Company&#8217;s directors or other executive officers. There are no related party transactions between Dr.&#160;Kress and the Company that would require disclosure under Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biographical information about Dr.&#160;Kress is set forth below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jean-Paul Kress</span></span>, M.D., age 59, most recently served as Chief Executive Officer of MorphoSys AG from September 2019 until August 2024 when it was acquired by Novartis. Dr.&#160;Kress currently serves the board of directors of Sanofi and previously served as chairman of the board of Erytech Pharma (now Phaxiam) from June 2019 until its merger with Pherecydes in June 2023. He served as President and Chief Executive Officer of Syntimmune Inc. from January 2018 until November 2018. Prior to joining Syntimmune, Dr.&#160;Kress served as Executive Vice President of International and Head of Global Therapeutic Operations at Biogen Inc from June 2017 to January 2018. He previously served as a member of the board of directors of Sarepta Therapeutics, Inc. from September 2015 to June 2017. From September 2015 to June 2017, Dr.&#160;Kress served as Senior Vice President, Head of North America at Sanofi Genzyme. From July 2011 to September 2015, Dr.&#160;Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, one of the leading European vaccine companies. Prior to then, Dr.&#160;Kress worked at Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe. Dr.&#160;Kress holds an M.D. degree from Facult&#233; Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in pharmacology and immunology from &#201;cole Normale Sup&#233;rieure in Paris. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Kress Employment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an employment agreement with Dr.&#160;Kress, dated June&#160;25, 2025 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Kress Employment Agreement</span></span>&#8221;). Under the terms of the Kress Employment Agreement, Dr.&#160;Kress will receive an initial annual base salary of $700,000, subject to annual review and potential increase, and will be eligible for a discretionary annual cash bonus targeted at 60% of his then-current base salary. Dr.&#160;Kress will also receive a <span style="white-space:nowrap">one-time</span> signing bonus of $400,000, subject to repayment if his employment terminates under certain circumstances within the first twelve months. In addition, Dr.&#160;Kress will be granted an option to purchase 83,296,638 shares of the Company&#8217;s common stock. In the event of termination by the Company without cause or by Dr.&#160;Kress for good reason, Dr.&#160;Kress will be entitled to severance benefits, including 18 months of base salary, a prorated target bonus, continued health coverage and an extended period to exercise vested stock options, subject to his execution of a release of claims. If such a termination occurs in connection with a change in control, severance benefits increase to lump sum payments equal to 24 months of base salary and 150% of the target bonus, accelerated vesting of equity awards and 24 months of continued health coverage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Kress has also entered into the Company&#8217;s standard form of indemnification agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Kress Employment Agreement is not complete and is qualified in its entirety by reference to the full text of the Kress Employment Agreement, a copy of which is filed as Exhibit 10.7 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of 2023 Inducement Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;25, 2025, the Board amended the Company&#8217;s 2023 Inducement Plan to increase the number of shares of Common Stock reserved for issuance under the plan from 3,500,000 shares to 153,726,683 shares in the aggregate. The 2023 Inducement Plan is a <span style="white-space:nowrap">non-stockholder</span> approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;25, 2025, the Company issued a press release announcing, among other things, entry into the License Agreement and the appointment of Dr.&#160;Kress as Chief Executive Officer and Chairman of the Board. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;25, 2025, the Company also issued a press release announcing the Private Placement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of the press releases are furnished as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2. of Form <span style="white-space:nowrap">8-K,</span> the information in this Item 7.01 and Exhibit 99.1 and Exhibit 99.2 hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Exchange Act</span></span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company&#8217;s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d)&#160;Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit&#160;Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex101.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant to Purchase Common Stock. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex102.htm">Form of Securities Purchase Agreement, dated June&#160;25, 2025, by and between the Company and Yantai Rongpu Investment Partnership (Limited Partnership). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex103.htm">Form of Securities Purchase Agreement, dated June&#160;25, 2025, by and between the Company and the investors named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex104.htm">Form of Registration Rights Agreement, dated June&#160;25, 2025, by and between the Company and the investors named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex105.htm">Form of Support Agreement, dated June&#160;25, 2025, by and between the Company and the stockholders named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex106.htm">Transition Agreement, dated as of June&#160;25, 2025, by and between the Company and Robert Ang. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex107.htm">Employment Agreement, dated as of June&#160;25, 2025, by and between the Company and Jean-Paul Kress. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex991.htm">Press Release dated June&#160;25, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27026dex992.htm">Press Release dated June&#160;25, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap;text-align:center">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Portions of the exhibit have been omitted as the Registrant has determined that: (i)&#160;the omitted information is not material; and (ii)&#160;the omitted information is the type that the Registrant treats as private or confidential. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Vor Biopharma Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;25, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jean-Paul Kress</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Jean-Paul Kress</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d27026dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE &#147;SECURITIES&#148;) HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;SUCH
SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II)&nbsp;SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT, (III)&nbsp;THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT
THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL
REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION). </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE
COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Warrant No. [&#149;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&#149;]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Original
Issue Date: [&#149;], 2025</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Vor Biopharma Inc.</B>,<B> </B>a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies
that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#149;] or its registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of [&#149;] shares of common stock, $0.0001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant
Shares</B>&#148;) at an exercise price per share equal to $0.0001 (the &#147;<B>Exercise Price</B>&#148;), in each case as adjusted from time to time as provided in <U>Section</U><U></U><U>&nbsp;9</U>, upon surrender of this <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on
or after the date that the following three conditions have been satisfied: (i)&nbsp;such date, if ever, that the Company&#146;s stockholders approve the issuance of the Warrant Shares pursuant to Nasdaq Stock Market Rule 5635(d), (ii) if required to
be obtained by the Holder in order for the Holder to hold the Warrant Shares, receipt by such Holder of ODI Approval (as defined below), and (iii)&nbsp;the effective time of an amendment to the Company&#146;s certificate of incorporation (the
&#147;<B>Certificate Amendment</B>&#148;) that has the effect of increasing the number of authorized and unreserved shares of Common Stock, whether through an increase of the number of authorized shares of Common Stock or through effecting a reverse
stock split, sufficient for the exercise in full of each warrant issued by the Company pursuant to (x)&nbsp;that certain Securities Purchase Agreement, dated as of June 25, 2025, by and among the Company, the Holder and the other investors party
thereto, and (y)&nbsp;that certain Securities Purchase Agreement, dated as of June 25, 2025, by and between the Company and Yantai Rongpu Investment Partnership (Limited Partnership), a subsidiary of RemeGen Co., Ltd. (the date on which (i), (ii)
(if required for the Holder) and (iii)&nbsp;have all occurred, the &#147;<B>Initial Exercise Date</B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. </B><B><U>Definitions</U></B>. For purposes of this Warrant, the following terms shall
have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person that, directly or indirectly
through one or more intermediates, controls, is controlled by or is under common control with such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Attribution
Parties</B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any direct or indirect Affiliates of the Holder, (ii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any
Attribution Parties and (iii)&nbsp;any other Persons whose beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and/or any other Attribution Parties for purposes of Section&nbsp;13(d) or
Section&nbsp;16 of the Exchange Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the last trade price for such security on the Principal Trading
Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to
4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for
a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Group</B>&#148; shall have the meaning ascribed to it in Section&nbsp;13(d) of the Exchange Act, and all related
rules, regulations and jurisprudence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ODI Approval</B>&#148; means the completion of the overseas direct investment filing and
the obtaining of the relevant approval from the National Development and Reform Commission of the PRC and the Ministry of Commerce of the PRC and/or the competent local counterparts, as well as the obtaining of relevant approvals and consents from
the State Administration of Foreign Exchange of the PRC or the related foreign exchange bank with respect to the acquisition of the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Original Issue Date</B>&#148; means the &#147;Original Issue Date&#148; set forth on the first page of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, partnership, corporation, limited liability company, business trust, joint stock company,
trust, unincorporated association, joint venture or any other entity or organization. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PRC</B>&#148; means People&#146;s Republic of China (excluding, for the purposes of
this Agreement, the Hong Kong Special Administrative Region, the Macau Special Administrative Region, or Taiwan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Principal
Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the U.S. Securities Act of 1933, as amended, and all of the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Standard Settlement Period</B>&#148; means the standard settlement period, expressed in a number of Trading Days,
for the Principal Trading Market with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date was &#147;T+1.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is normally open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the Company&#146;s transfer agent and registrar for the Common
Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><U>Issuance of Securities; Registration of Warrants</U></B>. The
Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may
be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><U>Registration of Transfers</U></B>.
Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for
all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this
Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and
deliver at the Company&#146;s own expense any New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all
purposes, and the Company shall not be affected by any notice to the contrary. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>4. </B><B><U>Exercise of Warrants</U></B>.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant (including
<U>Section</U><U></U><U>&nbsp;11</U>) at any time and from time to time on or after the Initial Exercise Date, and such rights shall not expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U>
(the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#147;cashless exercise&#148;
if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof) is an
<B>&#147;Exercise Date</B>.&#148; The Company shall not require an <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be
required by the Company. The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and
issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Holder and any
assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this section, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U>Delivery of Warrant Shares</U></B>.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than the number of Trading Days comprising the Standard
Settlement Period following the Exercise Date), upon the request of the Holder, cause the Transfer Agent to credit such aggregate number of shares of Common Stock specified by the Holder in the Exercise Notice and to which the Holder is entitled
pursuant to such exercise (the &#147;<B>Exercise Shares</B>&#148;) to (i)&nbsp;the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal At Custodian system or
(ii)&nbsp;in book-entry form via a direct registration system (&#147;<B>DRS</B>&#148;) maintained by or on behalf of the Transfer Agent, in each case, so long as either (A)&nbsp;there is an effective registration statement permitting the issuance of
the Warrant Shares to or the resale of such Warrant Shares by the Holder or (B)&nbsp;the Exercise Shares are eligible for resale by the Holder without volume or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 promulgated under the Securities Act (assuming cashless exercise of this Warrant). If (A)&nbsp;and (B) above are not
true, the Company shall cause the Transfer Agent to either (i)&nbsp;record the Exercise Shares in the name of the Holder or its designee on the certificates reflecting the Exercise Shares with an appropriate legend regarding restriction on
transferability, which shall be issued and dispatched by overnight courier to the address as specified in the Exercise Notice, and on the Company&#146;s share register or (ii)&nbsp;issue such Exercise Shares in the name of the Holder or its designee
in restricted book-entry form in the Company&#146;s share register. The Holder, or any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date,
irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account, the date of the book entry positions or the date of delivery of the certificates evidencing such Exercise Shares, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In addition to any other rights available to the Holder, if the Company fails to cause
the Transfer Agent to deliver to the Holder or its designee Exercise Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> within the Standard Settlement Period following the Exercise Date (other than a failure caused by
incorrect or incomplete information provided by Holder to the Company) and the Holder or the Holder&#146;s broker on its behalf purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the
Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;) but did not receive within the Standard Settlement Period, then the Company shall, within
two Trading Days after the Holder&#146;s request and in the Holder&#146;s sole discretion, promptly honor its obligation to deliver to the Holder or its designee the Exercise Shares pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> and pay cash to
the Holder in an amount equal to the excess (if any) of the Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> less the
product of (A)&nbsp;the number of shares of Common Stock purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date. The Holder shall provide the Company
written notice promptly after the occurrence of a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> together with applicable confirmations
and other evidence reasonably requested by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to
<U>Section</U><U></U><U>&nbsp;5(b)</U>, the Company&#146;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are
absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or
any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section</U><U></U><U>&nbsp;5(b)</U>, nothing herein shall limit the
Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver
Exercise Shares; provided, however, that the Holder shall not be entitled to both (i)&nbsp;require the Company to reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not timely honored and
(ii)&nbsp;receive the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements under Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. </B><B><U>Charges, Taxes and Expenses</U></B><U>.</U> Issuance and delivery of Exercise Shares shall be made without charge to the
Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; provided,
however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The
Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. </B><B><U>Replacement of Warrant</U></B>. If this Warrant is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable contractual indemnity, if requested by the Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the
Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. </B><B><U>Reservation of Warrant Shares</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company covenants that, subject to and following the effectiveness of the Certificate Amendment, it will, at all times while this
Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein
provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account
the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms
hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued
as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not,
without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, notwithstanding <U>Section</U><U></U><U>&nbsp;8(a)</U>, and not in limitation thereof, at any time while any of the Warrants remain
outstanding, the Company does not have a sufficient number of authorized and unreserved shares of Common Stock that are then deliverable upon the exercise of all such outstanding Warrants (an &#147;<B>Authorized Share Failure</B>&#148;), then the
Company shall immediately take all action necessary to increase the Company&#146;s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve such number of shares of Common Stock. Without limiting the generality of
the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90)&nbsp;days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting
of its shareholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each shareholder with a proxy statement and shall use its best efforts to solicit its
shareholders&#146; approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the shareholders that they approve such proposal. After the Initial Exercise Date, in the event that the Company is
prohibited from issuing shares of Common Stock upon an exercise of this Warrant due to the failure by the Company to have sufficient shares of Common Stock available out of the authorized but unissued shares of Common Stock (such unavailable number
of shares of Common Stock, the &#147;<B>Authorization </B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Failure Shares</B>&#148;), in lieu of delivering such Authorization Failure Shares to the Holder, the Company shall pay cash in exchange for the cancellation of such portion of this Warrant
exercisable into such Authorization Failure Shares at a price equal to the sum of (i)&nbsp;the product of (A)&nbsp;such number of Authorization Failure Shares and (B)&nbsp;the greatest Closing Sale Price of the Common Stock on any Trading Day during
the period commencing on the date the Holder delivers the applicable Exercise Notice with respect to such Authorization Failure Shares to the Company and ending on the date of such issuance and payment under this
<U>Section</U><U></U><U>&nbsp;8(b)</U>; and (ii)&nbsp;to the extent the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of Authorization Failure Shares, any <FONT
STYLE="white-space:nowrap">Buy-In</FONT> payment amount, brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any, of the Holder incurred in connection therewith.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><U>Certain Adjustments</U></B>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the
&#147;<B>Number of Warrant Shares</B>&#148;) are subject to adjustment from time to time as set forth in this <U>Section</U><U></U><U>&nbsp;9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its
Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue Date or as amended, that is payable in shares of
Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues
by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of
Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the
date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual
payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv)&nbsp;of this paragraph shall become effective immediately after the effective date of such subdivision, combination or issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If, on or after the Original Issue Date, the Company shall declare or make any dividend or other pro rata
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, options,
evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, but, for the avoidance of doubt, excluding any distribution of shares of
Common Stock subject to <U>Section</U><U></U><U>&nbsp;9(a)</U>,<U> </U>any distribution of Purchase Rights (as defined below) subject to <U>Section</U><U></U><U>&nbsp;9(c)</U> and any Fundamental Transaction (as defined below) subject to
<U>Section</U><U></U><U>&nbsp;9(d))</U> (a &#147;<B>Distribution</B>&#148;) then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage (as defined below))
immediately before the date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(provided, that to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in
such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to such extent) and the portion of such Distribution shall be held in
abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such
Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchase Rights</U>. If at any time on or after the Original Issue Date, the Company grants, issues or sells any Options, Convertible
Securities or rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any class of Common Stock (the &#147;<B>Purchase Rights</B>&#148;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any
limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is
taken, the date as of which the record holders of Common Stock are to be determined for the grant, issuance or sale of such Purchase Rights (provided, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would
result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such Common
Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and at the Holder&#146;s election, in its sole discretion, either (1)&nbsp;such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder
until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or
sold on such initial Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation or (2)&nbsp;the Company shall offer the Holder the right upon exercise of such
Purchase Right to acquire a security (e.g. a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant) that would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage but will otherwise to the extent possible
have economic and other rights, preferences and privileges substantially consistent and on par with the securities or other property issuable upon exercise of the originally offered Purchase Rights). As used in this
<U>Section</U><U></U><U>&nbsp;9(c)</U>, (i) &#147;Options&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities and (ii) &#147;Convertible Securities&#148; mean any stock or
securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding
(i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity or in which the stockholders of the Company immediately prior to such merger or consolidation do
not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one or a
series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the
Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the voting power of the capital stock of the Company (except for any such
transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of
shares of Common Stock covered by <U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise
of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of
the number of Warrant Shares then issuable upon exercise in full of this Warrant (including any Distributions or Purchase Rights then held in abeyance pursuant to <U>Sections 9(b)</U> or <U>9(c)</U> above) without regard to any limitations on
exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another
Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below or (ii)&nbsp;prior to or
simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in
accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (d)&nbsp;shall similarly apply to subsequent transactions analogous to a Fundamental
Transaction type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to
<U>Section</U><U></U><U>&nbsp;9</U>, the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be
the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made to the nearest <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of one cent or the nearest share, as applicable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this
<U>Section</U><U></U><U>&nbsp;9</U>, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such
adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments
and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#146;s transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then, except if such notice and the contents thereof shall be deemed to constitute <FONT STYLE="white-space:nowrap">material&nbsp;non-public&nbsp;information,</FONT> the Company shall deliver to the Holder a notice of such transaction at least ten
days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect
therein shall not affect the validity of the corporate action required to be described in such notice. In the event such notice and the contents thereof shall be deemed to constitute
<FONT STYLE="white-space:nowrap">material&nbsp;non-public&nbsp;information,</FONT> the Company shall (on the same time frame set forth in the immediately prior sentence) offer the Holder the ability to sign a confidentiality agreement related
thereto sufficient to allow the Holder to receive such notice, and the Company shall deliver such notice immediately upon execution of such confidentiality agreement. If the holder does not sign the confidentiality agreement, then the Holder shall
not receive such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by
<U>Section</U><U></U><U>&nbsp;9(d)</U>, other than a Fundamental Transaction under clause (iii)&nbsp;of <U>Section</U><U></U><U>&nbsp;9(d),</U> the Company shall deliver to the Holder a notice of such Fundamental Transaction at least 30 days prior
to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;9(h)</U> in confidence until such information is publicly available, and shall comply with
applicable law with respect to trading in the Company&#146;s securities following receipt of any such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.
</B><B><U>Payment of Exercise Price</U></B>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise&#148;, in which event
the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities Act, determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">where: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be issued to the Holder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price of the shares of Common Stock as
of the Trading Day on the date immediately preceding the Exercise Date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price then
in effect for the applicable Warrant Shares at the time of such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended,
understood and acknowledged that the Warrant Shares issued in a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the
Original Issue Date (provided<I> </I>that the Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant Shares is, for any
reason, not effective at the time of exercise of this Warrant, then this Warrant may only be exercised through a cashless exercise, as set forth in this <U>Section</U><U></U><U>&nbsp;10</U>. If the Warrant Shares are issued in such a cashless
exercise, the Company acknowledges and agrees that, in accordance with Section&nbsp;3(a)(9) of the Securities Act, the Exercise Shares issued in such exercise shall take on the registered characteristics of the Warrants being exercised and may be
tacked on to the holding period of the Warrants being exercised. Except as set forth in <U>Section</U><U></U><U>&nbsp;5(b)</U> <FONT STYLE="white-space:nowrap">(buy-in</FONT> remedy) and <U>Section</U><U></U><U>&nbsp;12</U> (No Fractional Shares),
in no event will the exercise of this Warrant be settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><U>Limitations on Exercise</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and
the Holder of this Warrant shall not exercise any portion of the Warrant, and any such exercise shall be null and void ab initio and treated as if the exercise had not been made, to the extent that immediately prior to or following such exercise,
the Holder, together with the Attribution Parties, beneficially owns or would beneficially own as determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder, in excess of 9.99% (the &#147;<B>Maximum
Percentage</B>&#148;) of the Common Stock that would be issued and outstanding following such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum Percentage is or will be exceeded, the aggregate number of
shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties, shall include the number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties plus the
number of shares of Common Stock issuable upon exercise of the relevant Warrant with respect to which the determination is being made but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the
remaining, unexercised Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Company held and/or beneficially
owned by such Holder or any Attribution Party (including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous to the limitation contained herein. For purposes
of this <U>Paragraph 11(a)</U>, beneficial ownership of the Holder or the Attribution Parties shall, except as set forth in the immediately preceding sentence, be calculated and determined in accordance with Section&nbsp;13(d) of the Exchange Act
and the rules promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, a Holder of this Warrant may rely on the number of outstanding shares of Common Stock as reflected in (1)&nbsp;the
Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public filing
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the Securities and Exchange Commission, as the case may be, (2)&nbsp;a more recent public announcement by the Company or (3)&nbsp;any other notice by the Company or the Company&#146;s
transfer agent setting forth the number of shares of Common Stock outstanding (such issued and outstanding shares, the &#147;<B>Reported Outstanding Share Number</B>&#148;). For any reason at any time, upon the written or oral request of the Holder,
the Company shall within one Trading Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that it,
together with the Attribution Parties holds and/or beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise or conversion analogous to the limitation contained herein
contemporaneously or immediately prior to submitting an Exercise Notice for the relevant Warrant. If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the
Reported Outstanding Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&#146;s, together with
the Attribution Parties&#146;, beneficial ownership, as determined pursuant to this <U>Section</U><U></U><U>&nbsp;11(a)</U>, to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased
pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the &#147;<B>Reduction Shares</B>&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the
Holder for the Reduction Shares. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and the
Attribution Parties since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder, together with the Attribution
Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which
the Holder&#146;s, together with the Attribution Parties&#146;, aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder
and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the
exercise price paid by the Holder for the Excess Shares. By written notice to the Company, a Holder of this Warrant may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified in such
notice; provided<I> </I>that any increase in the Maximum Percentage will not be effective until the 61st day after such notice is delivered to the Company and shall not negatively affect any partial exercise effected prior to such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not restrict the number of shares of Common Stock which a Holder or the Attribution
Parties may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder or the Attribution Parties may receive in the event of a Fundamental Transaction as contemplated in
<U>Section</U><U></U><U>&nbsp;9(c)</U> of this Warrant. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall be deemed not to be beneficially owned by the Holder
or the Attribution Parties for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder or Section&nbsp;16 of the Exchange Act and the rules promulgated thereunder, including Rule <FONT
STYLE="white-space:nowrap">16a-1(a)(1).</FONT> No prior inability to exercise this Warrant </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this <U>Section</U><U></U><U>&nbsp;11</U> to the extent necessary to correct this paragraph or any portion of this paragraph which may be
defective or inconsistent with the intended beneficial ownership limitation contained in this <U>Section</U><U></U><U>&nbsp;11</U> or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation
contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. </B><B><U>No Fractional
Shares</U></B>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the
next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13. </B><B><U>Notices</U></B>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any
Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT
STYLE="white-space:nowrap">e-mail</FONT> address specified by the Company prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via
confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified by the Company on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day,
(iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given,
if by hand delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14. </B><B><U>Warrant Agent</U></B>. The Company shall initially serve as warrant agent under this Warrant. Upon
30 days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new
warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any
further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15. </B><B><U>Miscellaneous</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&#146;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such
Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to
receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of
the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Further Assurances</U>. Except and to the extent as waived or consented to by the
Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in
the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This
Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their
respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors
and assigns. Except as otherwise provided herein, the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND
INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED
HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. If any part or provision of this Warrant is held unenforceable or in
conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or
provision in a valid and enforceable manner, and the remainder of this Warrant shall remain binding upon the parties hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Vor Biopharma Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1<U> </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of Warrant No. <U>&#8195;</U> (the &#147;Warrant&#148;) issued by Vor Biopharma Inc., a Delaware corporation
(the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The
undersigned hereby exercises its right to purchase <U>&#8195;&#8195;&#8195;</U> Warrant Shares pursuant to the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that
payment of the Exercise Price shall be made as (check one): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Cashless Exercise&#148; under <U>Section</U><U></U><U>&nbsp;10</U> of the Warrant </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ <U>&#8195;&#8195;&#8195;</U> in immediately available funds to the Company in
accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in
accordance with the terms of the Warrant. The Warrant Shares shall be delivered (check one):</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the following DWAC Account Number:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in book-entry form via a direct registration system </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by physical delivery of a certificate to:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in restricted book-entry form in the Company&#146;s share register </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the
Holder (i)&nbsp;the Holder is an &#147;accredited investor&#148; as defined in Regulation D promulgated under the Securities Act of 1933, as amended and (ii)&nbsp;will not beneficially own in excess of the number of shares of Common Stock (as
determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under <U>Section</U><U></U><U>&nbsp;11(a)</U> of the Warrant to which this notice relates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Holder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d27026dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Portions of this agreement (indicated by &#147;[***]&#148;) have been omitted as the Registrant has determined that: (i)&nbsp;the omitted
information is not material; and (ii)&nbsp;the omitted information is the type that the Registrant treats as private or confidential. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SECURITIES PURCHASE AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is dated as of June&nbsp;25, 2025, by and among Vor Biopharma
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), and Yantai Rongpu Investment Partnership (Limited Partnership) (the &#147;<B>Investor</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section&nbsp;4(a)(2) of the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, contemporaneously with the execution of this
Agreement, the Company and RemeGen Co., Ltd. are entering into the RemeGen License pursuant to which the Company has agreed to issue to the Investor, a subsidiary of RemeGen Co., Ltd., certain securities of the Company, as partial consideration of
the rights granted by RemeGen Co., Ltd. to the Company under the RemeGen License, which consist of a warrant to purchase 320,000,000 shares of Common Stock at an exercise price of $0.0001 per share in the form attached hereto as <U>Exhibit A</U>
(the &#147;<B>Warrant</B>&#148; or the &#147;<B>Securities</B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, contemporaneously with the sale of the
Warrant, the parties hereto will execute and deliver a Registration Rights Agreement, substantially in the form attached hereto as <U>Exhibit B</U>, pursuant to which the Company will agree to provide certain registration rights in respect of the
Warrant Shares (as defined below) under the Securities Act and applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>, in consideration
of the mutual agreements, representations, warranties and covenants herein contained, the Company and the Investor, severally and not jointly, agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this Agreement, the following terms shall have the following respective meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person that, directly or indirectly through one or more
intermediates, controls, is controlled by or is under common control with such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning set
forth in the recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended and Restated Bylaws</B>&#148; means the Bylaws of the Company, as currently in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended and Restated Certificate of Incorporation</B>&#148; means the Certificate of Incorporation of the Company, as currently in
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Benefit Plan</B>&#148; or &#147;<B>Benefit Plans</B>&#148; means employee benefit plans as defined in Section&nbsp;3(3)
of ERISA and all other employee benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for disability, retirement benefits, deferred
compensation, bonus pay, incentive </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pay, stock options or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by the Company or to which
the Company or any of its subsidiaries is obligated to contribute for employees or former employees of the Company and its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board of Directors</B>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate Amendment</B>&#148; means an amendment to the Amended and Restated Certificate of Incorporation that has the effect of
increasing the number of authorized and unreserved shares of Common Stock, whether through an increase of the number of authorized shares of Common Stock or through effecting a reverse stock split, sufficient for the exercise in full of
(i)&nbsp;each warrant issued by the Company pursuant to the PIPE Agreement (ii)&nbsp;the Warrant issued pursuant to this Agreement as contemplated by the RemeGen License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Date</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock</B>&#148; means the Company&#146;s common stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock Equivalents</B>&#148; means any securities of the Company that would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Stockholders Meeting</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.12(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Data</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.30</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosure Document</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Drug Regulatory Agency</B>&#148; means the U.S. Food and Drug Administration (&#147;<B>FDA</B>&#148;) or other foreign, state, local
or comparable governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or biological
products and drug or biological product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Laws</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.15</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; means the U.S. Employee Retirement Income Security Act of 1974, as
amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the U.S. Securities Exchange Act of 1934, as amended,
and all of the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financial Statements</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.8(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Fundamental Representations&#148; </B>means the representations and warranties made by
the Company in <U>Sections 3.1 (Organization and Power)</U>, <U>3.2 (Capitalization)</U>, <U>3.4 (Authorization)</U>, <U>3.5 (Valid Issuance)</U>, <U>3.6 (No Conflict)</U>, <U>3.7 (Consents)</U>, <U>3.8 (SEC Filings; Financial Statements)</U>,
<U>3.18 (Nasdaq Stock Market)</U>, <U>3.19 (Sarbanes-Oxley Act)</U>, <U>3.23 (Price Stabilization of Common Stock)</U>, <U>3.24 (Investment Company Act)</U>, <U>3.25 (General Solicitation; No Integration or Aggregation)</U>, <U>3.26 (Brokers and
Finders)</U>, <U>3.27 (Reliance by the Investor)</U> and <U>3.28 (No Additional Agreements)</U><B>. </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;3.8(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GDPR</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.31</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authorizations</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.11</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>HIPAA</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.21</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnified Person&#148; </B>has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor</B>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IT Systems</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.30</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licenses</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.21</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.10</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Adverse Effect</B>&#148; means any change, event, circumstance, development, condition, occurrence or effect that,
individually or in the aggregate, (a)&nbsp;was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities, stockholders&#146; equity or results of operations of the Company
and its subsidiaries, taken as a whole, or (b)&nbsp;materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under this Agreement, the other Transaction Agreements, or
with respect to the Closing, or would reasonably be expected to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Nasdaq</B>&#148; means the Nasdaq Stock Market LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>National Exchange</B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question, together with any successor thereto: the NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market and the Nasdaq Capital Market. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, partnership, corporation, limited liability
company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Personal Data</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.30</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Agreement</B>&#148; means that certain Securities Purchase Agreement, dated as of June&nbsp;25, 2025, by and among the Company
and the investors party thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Laws</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.31</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Statements</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.31</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Process</B>&#148; or &#147;<B>Processing</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.31</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Proxy Statement</B>&#148; means the proxy statement filed by the Company with the SEC in connection with the Company Stockholders
Meeting, including any amendments and supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Rights Agreement</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.1(j)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RemeGen License</B>&#148; means that certain License Agreement, by and between the
Company and RemeGen Co., Ltd., dated June&nbsp;25, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 144</B>&#148; means Rule 144 promulgated by the SEC pursuant to
the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC Clearance Date</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.12(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;SEC Reports</B>&#148; means (a)&nbsp;the Company&#146;s most recently filed Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and (b)&nbsp;all Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed or furnished (as applicable) by the
Company following the end of the most recent fiscal year for which an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> has been filed and prior to the execution of this Agreement, together in each case with any documents
incorporated by reference therein or exhibits thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the U.S. Securities Act of 1933, as
amended, and all of the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Short Sales</B>&#148; include, without limitation,
(a)&nbsp;all &#147;short sales&#148; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls,
short sales, swaps, &#147;put equivalent positions&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) and similar arrangements (including on a total return basis), and (b)&nbsp;sales and other
transactions through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of
Common Stock). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Returns</B>&#148; means returns, reports, information statements and other
documentation (including any additional or supporting material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any amended returns
required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; or
&#147;<B>Taxes</B>&#148; means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with
respect thereto), whether or not imposed on the Company, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property,
capital stock, license, payroll, withholding, employment, social security, workers&#146; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and
customs duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreements</B>&#148; means this Agreement, the RemeGen License, the Warrant, and the Registration
Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Agent</B>&#148; means, with respect to the Common Stock, Computershare Trust Company, N.A., or such
other financial institution that provides transfer agent services as the Company may engage from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant
Shares</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant</B>&#148; has the meaning set forth
in the recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Issuance of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <U>Issuance</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to issue to the
Investor the Warrant in partial consideration of the rights granted by RemeGen Co., Ltd. to the Company under the RemeGen License. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2
<U>Closing</U>. Subject to the satisfaction or waiver of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U> of this Agreement, the closing of the purchase and sale of the Warrant (the &#147;<B>Closing</B>&#148; and the date on which the
Closing occurs, the &#147;<B>Closing Date</B>&#148;) shall occur remotely via the exchange of documents and signatures on the date of this Agreement at such time as agreed to by the Company and the Investor. At the Closing, the Company shall deliver
to the Investor (or such Investor&#146;s designated custodian per its delivery instructions), or in such nominee name(s) as designated by such Investor, the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports (other than as to the Fundamental
Representations, which are not so qualified), the Company hereby represents and warrants to the Investor that the statements contained in this <U>Section</U><U></U><U>&nbsp;3</U> are true and correct as of the Closing Date (except for the
representations and warranties that speak as of a specific date, which shall be made as of such date). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Organization and Power</U>. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described in the SEC Reports and is qualified to
do business in each jurisdiction in which the character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not
reasonably be expected to have a Material Adverse Effect. Each of the Company&#146;s subsidiaries is (i)&nbsp;duly incorporated and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite
power and authority to carry on its business as now conducted and to own or lease its properties and (ii)&nbsp;qualified to do business as a foreign corporation and in good standing in each jurisdiction in which such qualification is required,
except in each case as would not cause a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Capitalization</U>. The Company&#146;s disclosure of its
authorized, issued and outstanding capital stock in the SEC Reports containing such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common Stock have been
duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of
any securityholder of the Company which have not been waived, and such shares were issued in compliance in all material respects with applicable state and federal securities laws and any rights of third parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <U>Registration Rights</U>. Except as set forth in the Transaction Agreements or as disclosed in the SEC Reports, the Company is presently
not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company&#146;s presently outstanding securities or any of its securities that may hereafter be issued, other than such rights and obligations
that have expired or been satisfied or waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <U>Authorization</U>. The Company has all requisite corporate power and authority to
enter into the Transaction Agreements and to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Warrant and the issuance of the shares of Common Stock issuable upon exercise of
the Warrant (the &#147;<B>Warrant Shares</B>&#148;), provided that the issuance of the Warrant Shares is subject to the approval of the Company&#146;s stockholders of (i)&nbsp;the issuance of the Warrant Shares in accordance with Nasdaq Stock Market
Rule 5635(d) and (ii)&nbsp;the Certificate Amendment ((i) and (ii)&nbsp;together, the &#147;<B>Company Stockholder Approval</B>&#148;) and the filing and effectiveness of the Certificate Amendment. Other than Company Stockholder Approval and the
filing and effectiveness of the Certificate Amendment, all corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of the Warrant and the Warrant Shares, the authorization, execution,
delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated herein, including the issuance and sale of the Warrant and the Warrant Shares, has been taken. This Agreement has been duly executed and
delivered by the Company and, assuming the due authorization, execution and delivery by the Investor and that this Agreement constitutes the legal, valid and binding agreement of the Investor, this Agreement and the Warrant constitutes a legal,
valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting
creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). Upon its execution by the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and the other parties thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement will constitute a legal,
valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting
creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 <U>Valid Issuance</U>. Subject to and upon the effectiveness of the Certificate Amendment, the Warrant Shares will be duly and validly
authorized and reserved for issuance and, upon issuance pursuant to the terms of the Warrant against full payment therefor in accordance with the terms of the Warrant, will be duly and validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal
securities laws), and the holder of the Warrant Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties made by the Investor in <U>Section</U><U></U><U>&nbsp;4</U>,
the offer and sale of the Warrant to the Investor is and will be in compliance with applicable exemptions from (i)&nbsp;the registration and prospectus delivery requirements of the Securities Act and (ii)&nbsp;the registration and qualification
requirements of applicable securities laws of the states of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6 <U>No Conflict</U>. The execution, delivery and
performance of the Transaction Agreements by the Company, the issuance and sale of the Warrant and the consummation of the other transactions contemplated by the Transaction Agreements will not (i)&nbsp;violate any provision of the Amended and
Restated Certificate of Incorporation or Amended and Restated Bylaws of the Company, (ii)&nbsp;conflict with or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to
the Company or any of its subsidiaries or their respective properties or assets,&nbsp;or (iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or any of its subsidiaries is subject (including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, or by
which any property or asset of the Company or any of its subsidiaries is bound or affected,&nbsp;except (A)&nbsp;in the case of clause (i), assuming and contingent on the filing and effectiveness of the Certificate Amendment, (B)&nbsp;in the case of
clauses (ii)&nbsp;and (iii), as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect, and (C)&nbsp;in the case of clause (iii), assuming and contingent on Company Stockholder Approval and the filing
and effectiveness of the Certificate Amendment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7 <U>Consents</U>. Assuming the accuracy of the representations and warranties of the
Investor, no consent, approval, authorization, filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization, execution or delivery by the Company of the Transaction
Agreements, the issuance and sale of the Warrant and the performance by the Company of its other obligations under the Transaction Agreements, except such as (a)&nbsp;have been or will be obtained or made under the Securities Act or the Exchange
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Act, (b)&nbsp;the filing of any requisite notices and/or application(s) to the National Exchange for the issuance and sale of the Warrant or the Warrant Shares and the listing of the Warrant
Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (c)&nbsp;customary post-closing filings with the SEC or pursuant to state securities laws in connection with the offer and sale of the Warrant or
the Warrant Shares by the Company in the manner contemplated herein, which will be filed on a timely basis, and (d)&nbsp;the filing of the registration statement required to be filed by the Registration Rights Agreement, or (e)&nbsp;such that the
failure of which to obtain would not have a Material Adverse Effect. All notices, consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant to the preceding sentence
have been obtained or made or will be delivered or obtained or effected, and shall remain in full force and effect, on or prior to the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8 <U>SEC Filings; Financial Statements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has filed all forms, statements, certifications, reports and documents required to be filed by it with the SEC under
Section&nbsp;13, 14(a) and 15(d) of the Exchange Act for the one year preceding the date of this Agreement and is in compliance with General Instruction I.A.3 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> As of the time it was filed with the
SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of the Exchange Act, and, as of the
time they were filed, none of the filed SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the SEC Reports. To the Company&#146;s knowledge, none of the SEC Reports are the subject of an ongoing SEC
review. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The financial statements of the Company included in the SEC Reports (collectively, the &#147;<B>Financial
Statements</B>&#148;) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement)
and fairly present in all material respects the consolidated financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods therein specified, all in accordance with United States
generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) (except as otherwise noted therein, and in the case of unaudited financial statements, as permitted by Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of the SEC, and except that
the unaudited financial statements may not contain footnotes and are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments) applied on a consistent basis throughout the periods therein specified (unless
otherwise noted therein). Except as set forth in the Financial Statements filed prior to the date of this Agreement, the Company has not incurred any liabilities, contingent or otherwise, except (i)&nbsp;those incurred in the ordinary course of
business, consistent with past practices since the date of such financial statements or (ii)&nbsp;liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have
had or would reasonably be expected to have a Material Adverse Effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9 <U>Absence of Changes</U>. Between December&nbsp;31, 2024 and the date of this
Agreement, (a)&nbsp;the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company (except for the execution and performance of this Agreement, the RemeGen
License and the discussions, negotiations and transactions related thereto); (b) no material change to any material contract or arrangement by which the Company is bound or to which any of its assets or properties is subject has been entered into
that has not been disclosed in the SEC Reports; and (c)&nbsp;there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect; provided, however, that none of the
following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under this
<U>Section</U><U></U><U>&nbsp;3.9</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any change generally affecting the economy, financial markets or political, economic or
regulatory conditions in the United States or any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that
the Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any change that generally affects industries in which the Company and its
subsidiaries conduct business, provided that the Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) earthquakes, hurricanes,
tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, epidemic or similar health emergency, and other force majeure events in the United States or any other location, provided that the
Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) national or international political or social conditions (or changes in such
conditions), whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) material changes in laws after the date of this Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses,
earnings or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in
determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v) of this definition). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10 <U>Absence of Litigation</U>. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry
pending or, to the Company&#146;s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders,
writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that have had or would reasonably be expected to have a Material Adverse Effect.
Neither the Company nor any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been, the subject of any action involving a claim
of violation of or liability under federal or state securities laws relating to the Company or such subsidiary or a claim of breach of fiduciary duty relating to the Company or such subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <U>Compliance with Law; Permits</U>. Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of
violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, &#147;<B>Governmental Authorizations</B>&#148;) from such federal,
state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess currently such
Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. Neither the Company nor any subsidiary has received any written (or, to the Company&#146;s knowledge, oral) notice regarding any revocation or
material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <U>Intellectual Property</U>. Except as otherwise disclosed in the SEC Reports, the Company owns or has valid and enforceable licenses or
other rights to all patents, copyrights, copyrightable works, trademarks, service marks, trade names, and service names (including all applications and registrations relating to any of the foregoing), and all
<FONT STYLE="white-space:nowrap">inventions,&nbsp;know-how,&nbsp;trade</FONT> secrets and other proprietary or confidential information (whether or not patentable), systems or procedures and all other technology and intellectual property rights
necessary for the conduct, or the proposed conduct, of the business of the Company in the manner described in the SEC Reports (collectively, the &#147;<B>Company Intellectual Property</B>&#148;); the Company Intellectual Property disclosed in the
SEC Reports as being owned by the Company is owned by the Company free and clear of all material liens, security interests, and encumbrances, and to the Company&#146;s knowledge, there are no rights of third parties to such Company Intellectual
Property; to the Company&#146;s knowledge, the Company Intellectual Property is valid, enforceable and subsisting; and other than as disclosed in the SEC Reports, (i)&nbsp;the Company is not obligated to pay a material royalty, grant a material
license, or provide other material consideration to any third party in connection with the Company Intellectual Property, (ii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, alleging
that the conduct of the business of the Company in the manner described in the SEC Reports is infringing, misappropriating, diluting or otherwise violating any intellectual property rights of others, (iii)&nbsp;no action, suit, claim or other
proceeding is pending or, to the knowledge of the Company, is threatened, challenging the validity, enforceability, scope, registration, ownership or use of any of the Company Intellectual Property, (iv)&nbsp;no action, suit, claim or other
proceeding is pending or, to the knowledge of the Company, is threatened, challenging the Company&#146;s rights in or to any Company Intellectual Property, (v)&nbsp;to the Company&#146;s knowledge, no third party has any ownership right in or to any
Company Intellectual Property in any field of use that is exclusively licensed to the Company, other than any licensor to the Company of such Company Intellectual Property, (vi)&nbsp;no employee, consultant or independent contractor of the Company
is, to the Company&#146;s knowledge, in violation in any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer or independent contractor where the basis of such violation relates to such employee&#146;s employment or
independent contractor&#146;s engagement with the Company or actions undertaken while employed or engaged with the Company, (vii)&nbsp;the Company has taken reasonable measures to protect its material confidential information and material trade
secrets and to maintain and safeguard the material Company Intellectual Property, including the execution of appropriate nondisclosure and confidentiality agreements, and (viii)&nbsp;the Company has complied with the material terms of each agreement
pursuant to which the Company Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect; except in each of (i)&#150;(viii) such as would not, if determined adversely to the Company, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect. All patents and patent applications within the Company Intellectual Property disclosed in the SEC Reports as being owned by the Company have, to the knowledge of the
Company, been duly and properly filed and maintained; to the knowledge of the Company, there are no material defects in any of such patents or patent applications; to the knowledge of the Company, the parties prosecuting such applications have
complied with their duty of candor and disclosure to the United States Patent and Trademark Office (the &#147;<B>USPTO</B>&#148;) in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO
that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such
applications; except such as would not, if determined adversely to the Company, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13 <U>Employee Benefits</U>. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been
established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection and Affordable Care Act of 2010, as amended, and other applicable laws, rules and regulations. The
Company and its subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding employment, except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have
a Material Adverse Effect. There is no labor dispute, strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may interfere with the business activities of the Company, except
where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.14 <U>Taxes</U>. All Tax Returns of the Company and its subsidiary required by law to be filed have been filed and all Taxes shown as due on
such returns or that otherwise have been assessed, which are due and payable, have been paid, except: (i)&nbsp;assessments against which appeals have been or will be promptly taken in good faith and as to which adequate reserves have been provided
in accordance with the applicable accounting principles, or (ii)&nbsp;as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any
material amounts of Taxes of the Company and its subsidiaries are presently in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on any of the assets of the Company. At
all times since inception, the Company has been and continues to be classified as a corporation for U.S. federal income tax purposes. Neither the Company nor any of its subsidiaries has been a United States real property holding corporation within
the meaning of Code Section&nbsp;897(c)(2) during the period specified in Code Section&nbsp;897(c)(1)(A)(ii). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.15 <U>Environmental Laws</U>. The Company and its subsidiaries (i)&nbsp;are in compliance
with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental
Laws</B>&#148;), (ii)&nbsp;have received all permits and other Governmental Authorizations required under applicable Environmental Laws to conduct their business and (iii)&nbsp;are in compliance with all terms and conditions of any such permit,
license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company nor any of its subsidiaries has received since January&nbsp;1, 2025, any written notice or other communication (in writing or otherwise),
whether from a governmental authority or other Person, that alleges that the Company or any subsidiary is not in compliance with any Environmental Law and, to the knowledge of the Company, there are no circumstances that may prevent or interfere
with the Company&#146;s or any subsidiary&#146;s compliance in any material respects with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material Adverse Effect. To the knowledge
of the Company: (i)&nbsp;no current or (during the time a prior property was leased or controlled by the Company) prior property leased or controlled by the Company or any subsidiary has received since January&nbsp;1, 2025, any written notice or
other communication relating to property owned or leased at any time by the Company, whether from a governmental authority, or other Person, that alleges that such current or prior owner or the Company or any subsidiary is not in compliance with or
violated any Environmental Law relating to such property and (ii)&nbsp;the Company has no material liability under any Environmental Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.16 <U>Title</U>. Each of the Company and its subsidiaries has good and marketable title to all personal property owned by it that is material
to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company
or its subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with
the use made and proposed to be made of such property and buildings by the Company or its subsidiaries, as the case may be. The Company does not own any real property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.17 <U>Insurance</U>. The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is
customary for comparably situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased) and tangible assets, and each of such insurance policies is in full force and effect and
the Company is in compliance in all material respects with the terms of such insurance policies. Other than customary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-policy</FONT></FONT> notifications from insurance
carriers, since January&nbsp;1, 2025, the Company has not received any notice or other communication regarding any actual or possible: (i)&nbsp;cancellation or invalidation of any material insurance policy or (ii)&nbsp;refusal or denial of any
coverage, reservation of rights or rejection of any material claim under any insurance policy. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.18 <U>Nasdaq Stock Market</U>. The issued and outstanding shares of Common Stock are
registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on the Nasdaq Global Select Market under the symbol &#147;VOR&#148;. The Company is in compliance with all listing requirements of Nasdaq applicable to the
Company other than Nasdaq Listing Rule 5450(a)(1), as disclosed in the SEC Reports. As of the date of this Agreement, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company
by Nasdaq or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Global Select Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date of this
Agreement that is designed to terminate the registration of the Common Stock under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.19 <U>Sarbanes-Oxley Act</U>. The
Company is, and since January&nbsp;1, 2025 has been, in compliance in all material respects with all applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.20 <U>Clinical Data and Regulatory Compliance</U>. <FONT STYLE="white-space:nowrap">The&nbsp;pre-clinical&nbsp;studies</FONT> and clinical
trials that are described in the SEC Reports were conducted in all material respects in accordance with the protocols submitted to the FDA or any foreign governmental body exercising comparable authority, and all applicable laws and regulations; the
descriptions of <FONT STYLE="white-space:nowrap">the&nbsp;pre-clinical&nbsp;studies</FONT> and clinical trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company or by a licensor, and the results thereof, contained in SEC
Reports are accurate and complete in all material respects; the Company is not aware of any <FONT STYLE="white-space:nowrap">other&nbsp;pre-clinical&nbsp;studies</FONT> or clinical trials, the results of which materially call into question the
results described in SEC Reports; and the Company has not received any written notices or correspondence from the FDA, any foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or ethics
committee or similar body requiring the termination, suspension, material adverse modification or clinical hold of <FONT STYLE="white-space:nowrap">any&nbsp;pre-clinical&nbsp;studies</FONT> or clinical trials conducted by or on behalf of the Company
or by a licensor. Neither the Company or its subsidiary nor any of their respective officers, employees or directors, nor, to the Company&#146;s knowledge, any of its respective agents or clinical investigators, or licensors, has, for the past three
(3)&nbsp;years, been excluded, suspended or debarred from participation in any U.S. federal or foreign health care program or human clinical research or, is subject to a governmental inquiry, investigation, proceeding, or other similar action that
could reasonably be expected to result in debarment, suspension, or exclusion, or convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.21 <U>Compliance with Health Care Laws</U>. The Company, its subsidiary and their respective directors, officers and employees, are and for
the past three (3)&nbsp;years have been, in compliance with applicable Health Care Laws (defined herein), including, but not limited to, the rules and regulations of the FDA, the U.S. Department of Health and Human Services Office of Inspector
General, the Centers for Medicare&nbsp;&amp; Medicaid Services, the Office for Civil Rights, and the Department of Justice, except for such noncompliance that would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; shall mean, as applicable, the federal Anti-kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(b)),&nbsp;the</FONT> Physician Payments
Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7h),&nbsp;the</FONT> civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Act (42 U.S.C.
<FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(a)),&nbsp;applicable</FONT> criminal laws relating to health care fraud and abuse, including, without </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation, those set forth at 18 U.S.C. &#167;&#167; 286, 287 and 1349, the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7),&nbsp;the</FONT> civil monetary
penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7a),&nbsp;the</FONT> Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d et seq.), as amended by the Health Information Technology for
Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.) (&#147;<B>HIPAA</B>&#148;), and the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 201 et seq.)
and comparable state, local and foreign laws, each as amended from time and the regulations promulgated thereunder. The Company is not a party to or does not have any ongoing reporting obligations pursuant to any corporate integrity agreement,
deferred <FONT STYLE="white-space:nowrap">or&nbsp;non-prosecution&nbsp;agreement,</FONT> monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority. The Company has not
received any written notification, correspondence or any other written or oral communication, including, without limitation, any Form FDA 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA
or any similar regulatory authority, or any notification of any pending or, to the Company&#146;s knowledge, threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action, from any governmental authority
alleging or asserting potential or actual <FONT STYLE="white-space:nowrap">material&nbsp;non-compliance&nbsp;by,</FONT> or material liability of, the Company under any Health Care Laws. Each of the Company and its subsidiary possesses, and is in
compliance with the terms of, all applications, certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations issued by the appropriate governmental authorities and necessary to
conduct its business (collectively, &#147;<B>Licenses</B>&#148;), including, without limitation, all Licenses required by the Drug Regulatory Agencies. All such Licenses are in full force and effect and the Company is not in violation of any term or
conditions of any such License. Each of the Company and its subsidiary and has fulfilled and performed all of its respective obligations with respect to such Licenses and, no event has occurred which allows, or after notice or lapse of time would
allow, revocation or termination thereof or results in any other impairment of the rights of the holder of any such License. The Company has not received any written notice of proceedings from the applicable Drug Regulatory Agency proposing to
revoke or materially adversely modify any such Licenses and, to the Company&#146;s knowledge, no Drug Regulatory Agency has taken any action to limit, suspend or revoke any such License possessed by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.22 <U>Accounting Controls and Disclosure Controls and Procedures</U>. The Company maintains a system of internal control over financial
reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&nbsp;that the Company maintains records that in reasonable detail
accurately and fairly reflect the Company&#146;s transactions and dispositions of assets, (ii)&nbsp;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)&nbsp;that receipts and
expenditures are made only in accordance with authorizations of management and the Board of Directors and (iv)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&#146;s assets that could
have a material effect on the Company&#146;s financial statements. Except as disclosed in the Company&#146;s SEC Reports filed prior to the date of this Agreement, the Company has not identified any material weaknesses in the design or operation of
the Company&#146;s internal control over financial reporting. The Company&#146;s &#147;disclosure controls and procedures&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and
<FONT STYLE="white-space:nowrap">15d-15(e)</FONT> of the Exchange Act) are designed to provide reasonable assurance that all information (both financial </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and <FONT STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required
disclosure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.23 <U>Price Stabilization of Common Stock</U>. The Company has not taken, nor will it take, directly or indirectly, any
action designed to stabilize or manipulate the price of the Common Stock to facilitate the sale or resale of the Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.24
<U>Investment Company Act</U>. The Company is not, and immediately after receipt of payment for the Securities will not be, an &#147;investment company&#148; within the meaning of the U.S. Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.25 <U>General </U><U>Solicitation; No</U><U> Integration or Aggregation</U>. Neither the Company nor any other person or entity authorized by
the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to the offer or sale of the Warrant pursuant to this Agreement. The
Company has not, directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which, to its knowledge, is or will be (i)&nbsp;integrated with the
Securities sold pursuant to this Agreement for purposes of the Securities Act or (ii) aggregated with prior offerings by the Company for the purposes of the rules and regulations of the Nasdaq Global Select Market other than the securities to be
issued by the Company pursuant to the PIPE Agreement. Assuming the accuracy of the representations and warranties of the Investor set forth in <U>Section</U><U></U><U>&nbsp;4</U>, neither the Company nor any of its Affiliates, its subsidiaries nor
any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on
Section&nbsp;4(a)(2) for the exemption from registration for the transactions contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.26 <U>Brokers and Finders</U>.
Neither the Company nor any other Person authorized by the Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.27 <U>Reliance by the Investor</U>. The Company has a reasonable basis for making each of the representations set forth in this <U>Section
3</U>. The Company acknowledges that the Investor will rely upon the truth and accuracy of, and the Company&#146;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.28 <U>No Additional Agreements</U>. There are no agreements or understandings between the Company and any party to the PIPE Agreement
with respect to the transactions contemplated by the PIPE Agreement other than (i)&nbsp;as specified in the PIPE Agreement and Registration Rights Agreement and (ii)&nbsp;any side letter agreements with any of the parties to the PIPE Agreement,
which side letters the Company has shared with the Investor. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.29 <U>Anti-Bribery and Anti-Money Laundering Laws</U>. Each of the Company, its
subsidiaries and, to the knowledge of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate:
(A)&nbsp;anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign
Public Officials in International Business Transactions, signed December&nbsp;17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and
scope or (B)&nbsp;anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18
US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of
which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of
the foregoing, or any orders or licenses issued thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.30 <U>Cybersecurity</U>. The Company and its subsidiaries&#146; information
technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all material respects as required in
connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its subsidiaries have
implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data
(&#147;<B>Confidential Data</B>&#148;) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability continuous operation, redundancy and security of all IT Systems. &#147;<B>Personal
Data</B>&#148; means the following data used in connection with the Company&#146;s and its subsidiaries&#146; businesses and in their possession or control: (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or other tax identification number, driver&#146;s license number, passport number, credit card number or bank information; (ii)&nbsp;information that identifies or
may reasonably be used to identify an individual; (iii)&nbsp;any information that would qualify as &#147;protected health information&#148; under HIPAA; and (iv)&nbsp;any information that would qualify as &#147;personal data,&#148; &#147;personal
information&#148; (or similar term) under the Privacy Laws. To the Company&#146;s knowledge, there have been no breaches, outages or unauthorized uses of or accesses to the Company&#146;s IT Systems, Confidential Data, or Personal Data that would
require notification under Privacy Laws (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.31 <U>Compliance with Data Privacy Laws</U>. The Company and its
subsidiaries are, and at all prior times were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or
any other processing (collectively &#147;<B>Process</B>&#148; or &#147;<B>Processing</B>&#148;) of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (Regulation (EU)
No.&nbsp;2016/679), all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its subsidiaries, and the regulations </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure material
compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data privacy and
security, and the Processing of Personal Data and Confidential Data (the &#147;<B>Privacy Statements</B>&#148;). The Company and its subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a
Material Adverse Effect, at all times since inception provided accurate notice of their Privacy Statements then in effect to its customers, employees, third party vendors and representatives. None of such disclosures made or contained in any Privacy
Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.32 <U>Transactions
with Affiliates and Employees</U>. No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be
described in the SEC Reports that is not so described. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of </U><U>the Investor</U>. The Investor
represents and warrants to the Company that the statements contained in this <U>Section</U><U></U><U>&nbsp;4</U> are true and correct as of the Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <U>Organization</U>. The Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Authorization</U>. The Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other
Transaction Agreements to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership action on the part of such Investor or its stockholders, members or partners necessary for
the authorization, execution, delivery and performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions contemplated in this Agreement has been taken. The execution,
delivery and performance by such Investor of the Transaction Agreements has been duly authorized and each has been duly executed. Assuming this Agreement constitutes the legal and binding agreement of the Company, this Agreement constitutes a legal,
valid and binding obligation of such Investor, enforceable against such Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>No Conflict</U><U>s</U>. The execution, delivery and performance of the Transaction Agreements by the Investor, the purchase of the
Warrant or Warrant Shares in accordance with their terms and the consummation by the Investor of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by such Investor (with or without
notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefit under (i)&nbsp;any provision of the organizational documents of the Investor, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or
partnership or operating agreement, as may be applicable or (ii)&nbsp;any agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Investor
or its respective properties or assets, except, in the case of clause (ii), as would not, individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of the Investor to perform its obligations under the
Transaction Agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Residency</U>. The Investor&#146;s residence (if an individual) or offices in which its investment decision
with respect to the Warrant was made (if an entity) are located at the address immediately below the Investor&#146;s name on the signature page hereto, except as otherwise communicated by the Investor to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <U>Brokers and Finders</U>. The Investor has not retained, utilized or been represented by any broker or finder in connection with the
transactions contemplated by this Agreement whose fees the Company would be required to pay. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <U>Investment Representations and
Warranties</U>. The Investor hereby represents and warrants that, it (i)&nbsp;as of the date of this Agreement is, if an entity, either a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act) or an
institutional &#147;accredited investor&#148; as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act; or (ii)&nbsp;if an individual, is an &#147;accredited investor&#148; as that term is defined in Rule
501(a) of Regulation D of the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Securities. The Investor further represents and
warrants that it is capable of evaluating the merits and risk of such investment. The Investor understands and agrees that the offering and sale of the Warrant has not been registered under the Securities Act or any applicable state securities laws
and is being made in reliance upon federal and state exemptions for transactions not involving a public offering, which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor&#146;s
representations as expressed herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <U>Intent</U>. The Investor is purchasing the Warrant solely for the Investor&#146;s own account
and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of selling, granting any participation in, or otherwise
distributing the same in violation of the Securities Act without prejudice, however, to the Investor&#146;s right at all times to sell or otherwise dispose of all or any part of the Warrant in compliance with applicable federal and state securities
laws. Notwithstanding the foregoing, if the Investor is purchasing Warrant as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and authority to
make the acknowledgements, representations and agreements herein on behalf of each owner of each such account. The Investor has no present arrangement to sell the Warrant to or through any person or entity. The Investor understands that the Warrant
and Warrant Shares must be held indefinitely unless such Warrant and Warrant Shares are resold pursuant to a registration statement under the Securities Act or an exemption from registration is available. Nothing contained herein shall be deemed a
representation or warranty by the Investor to hold the Warrant or Warrant Shares for any period of time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <U>Investment Experience; Ability to Protect Its Own Interests and Bear Economic
Risks</U>. The Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Warrant and Warrant Shares and has knowledge and experience in finance, securities, taxation, investments and other business matters
as to be capable of evaluating the merits and risks of investments of the kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice as
the Investor has considered necessary to make an informed investment decision. The Investor acknowledges that the Investor (i)&nbsp;is a sophisticated investor, experienced in investing in private placements of equity securities and capable of
evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii)&nbsp;has exercised independent judgment in evaluating its participation in the
purchase of the Warrant and Warrant Shares. The Investor acknowledges that the Investor is aware that there are substantial risks incident to the purchase and ownership of the Warrant and Warrant Shares, including those set forth in the
Company&#146;s filings with the SEC. Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment in the Warrant and Warrant Shares and determined that the Securities are a
suitable investment for the Investor. The Investor is, at this time and in the foreseeable future, able to afford the loss of the Investor&#146;s entire investment in the Warrant and Warrant Shares and the Investor acknowledges specifically that a
possibility of total loss exists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.9 <U>Independent Investment Decision</U>. The Investor understands that nothing in the Transaction
Agreements or any other materials presented by or on behalf of the Company to the Investor in connection with the purchase of the Warrant and Warrant Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in such Investor&#146;s sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10 <U>Securities Not Registered; Legends</U>. The Investor acknowledges and agrees that the Warrant is being offered in a transaction not
involving any public offering within the meaning of the Securities Act, and the Investor understands that the Warrant has not been registered under the Securities Act, by reason of its issuance by the Company in a transaction exempt from the
registration requirements of the Securities Act, and that the Warrant must continue to be held and may not be offered, resold, transferred, pledged or otherwise disposed of by the Investor unless a subsequent disposition thereof is registered under
the Securities Act or is exempt from such registration and in each case in accordance with any applicable securities laws of any state of the United States. The Investor understands that the exemptions from registration afforded by Rule 144 (the
provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various conditions including, but not limited to, the time and manner of sale, the holding period and on requirements relating to the Company
which are outside of the Investor&#146;s control and which the Company may not be able to satisfy, and that, if applicable, Rule 144 may afford the basis for sales only in limited amounts. The Investor acknowledges and agrees that it has been
advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Warrant. The Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the
Warrant or made any findings or determination as to the fairness of this investment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor understands that any certificates or book entry notations evidencing the
Warrant may bear one or more legends in substantially the following form and substance: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THIS WARRANT AND THE SHARES OF COMMON STOCK
ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE &#147;SECURITIES&#148;) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES
HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II)&nbsp;SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE
COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH
HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, the Warrant may contain a legend regarding affiliate status of the Investor, if applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11 <U>No </U><U>General
Solicitation</U>. The Investor acknowledges and agrees that the Investor is purchasing the Warrant directly from the Company. Investor became aware of this offering of the Warrant solely by means of direct contact from the Company as a result of a <FONT
STYLE="white-space:nowrap">pre-existing,</FONT> substantive relationship with the Company, and/or its advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons,
representatives, affiliates, directors, officers, managers, members, and/or employees, and/or the representatives of such persons. The Warrant was offered to the Investor solely by direct contact between the Investor and the Company and/or its
representatives. The Investor did not become aware of this offering of the Warrant, nor was the Warrant offered to the Investor, by any other means, and none of the Company and/or its representatives acted as investment advisor, broker or dealer to
the Investor. The Investor is not purchasing the Warrant as a result of any general or public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Securities published in
any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement, including any of the methods described in Section&nbsp;502(c) of
Regulation D under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12 <U>Access to Information</U>. The Investor acknowledges and agrees that the Investor and the
Investor&#146;s professional advisor(s), if any, have had the opportunity to ask such questions, receive such answers and obtain such information from the Company regarding the Company, its business and the terms and conditions of the offering of
the Warrant as the Investor and the Investor&#146;s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Warrant and that the Investor has independently made its own analysis and decision to
invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by the Investor shall modify, limit or otherwise affect the Investor&#146;s right to rely on the Company&#146;s representations and warranties
contained in this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.13 <U>Certain Trading Activities</U>. Other than consummating the transaction contemplated
hereby, the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with the Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the
period commencing as of the time that the Investor was first contacted by the Company or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date of this Agreement. Notwithstanding the foregoing, if the
Investor is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Investor&#146;s assets, the representation set forth above shall only apply with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Warrant covered
by this Agreement. Other than to other Persons party to this Agreement and to its advisors and agents who had a need to know such information, the Investor has maintained the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the
identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Covenants</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1
<U>Further Assurances</U>. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary
to effectuate the intents and purposes of this Agreement and the RemeGen License, subject to the terms and conditions of this Agreement and the RemeGen License and compliance with applicable law, including taking reasonable action to facilitate the
filing of any document or the taking of reasonable action to assist the other parties hereto in complying with the terms of this Agreement or assist the other party in complying with such party&#146;s reporting obligations under applicable law or
regulation, the listing standards of the National Exchange or other securities exchange on which such party&#146;s securities may be listed from time to time, or as required by the SEC, including without limitation assistance in preparing regulatory
reports or filings, public disclosures, financial statements or other information required to be filed, reported, disclosed or otherwise prepared under such applicable law, regulation or listing standards. The Investor acknowledges that the Company
will rely on the acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2
<U>Listing</U>. The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Global Select Market and, in accordance therewith, will use reasonable best efforts to comply in all material
respects with the Company&#146;s reporting, filing and other obligations under the rules and regulations of Nasdaq. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Disclosure of Transactions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day immediately following the date of this Agreement,
file with the SEC a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (including all exhibits thereto, the &#147;<B>Disclosure Document</B>&#148;) disclosing (i)&nbsp;all material terms of the transactions contemplated hereby and by
the other Transaction Agreements and attaching a copy of the form of this Agreement and the other Transaction Agreements as exhibits to such Disclosure Document and (ii)&nbsp;all material <FONT STYLE="white-space:nowrap">non-public</FONT>
information concerning the Company disclosed to the Investor. Following the filing of the Disclosure Document, the Investor will not be in possession of any material <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the
Company disclosed to the Investor by the Company or its representatives. The Company understands and confirms that the Investor will rely on the foregoing representation in effecting securities transactions. Notwithstanding anything in this
Agreement to the contrary, the Company shall not publicly disclose the name of the Investor or any of its affiliates or advisers, or include the name of the Investor or any of its affiliates or advisers in any press release or filing with the SEC
(other than any registration statement contemplated by the Registration Rights Agreement) or any regulatory agency, without the prior written consent of the Investor, except (i)&nbsp;as required by the federal securities laws in connection with
(A)&nbsp;any registration statement contemplated by the Registration Rights Agreement and (B)&nbsp;the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii)&nbsp;to the extent
such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Integration</U>. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that will be integrated with the offer or sale of the Warrant in a manner that would require
the registration under the Securities Act of the sale of the Warrant to the Investor, or that will be integrated with the offer or sale of the Warrant for purposes of the rules and regulations of any National Exchange such that it would require
stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction, and other than the issuance of securities pursuant to the PIPE Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <U>Removal of Legends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In connection with any sale, assignment, transfer or other disposition of the Warrant Shares by the Investor pursuant to Rule 144 or
pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the
Company shall request the Transfer Agent to remove any restrictive legends related to the book entry account holding such shares and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends as soon as
reasonably practicable following any such request therefor from the Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection
therewith. The Company shall be responsible for the fees of its Transfer Agent and its legal counsel associated with such legend removal. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to receipt from the Investor by the Company and the Transfer Agent of customary
representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Warrant Shares (i)&nbsp;have been registered under the Securities Act pursuant to an
effective registration statement; (ii)&nbsp;have been sold pursuant to Rule 144, or (iii)&nbsp;are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information requirements
under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;5.5(b)</U> and as soon as reasonably practicable following any request therefor from the Investor
accompanied by such customary and reasonably acceptable documentation referred to above, (A)&nbsp;deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry shares, and
(B)&nbsp;cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of
the legend in accordance with the provisions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <U>Withholding Taxes</U>. The Investor agrees to furnish the Company
with any information, representations and forms as shall reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7 <U>Fees and Commissions</U>. The Company shall be solely responsible for the payment of any placement agent&#146;s fees, financial advisory
fees, or broker&#146;s commissions (other than for Persons engaged by the Investor) relating to or arising out of the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8 <U>No Conflicting Agreements</U>. The Company will not take any action, enter into any agreement or make any commitment that would conflict
or interfere in any material respect with the Company&#146;s obligations to the Investor under the Transaction Agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9
<U>Indemnification.</U><U> </U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless the Investor and its Affiliates, and their
respective directors, officers, trustees, members, managers, employees, investment advisers and agents (collectively, the &#147;<B>Indemnified Persons</B>&#148;), from and against any and all losses, claims, damages, liabilities and expenses
(including without limitation reasonable and documented attorney fees and disbursements and other documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred in connection
with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or
agreement made by or to be performed on the part of the Company under the Transaction Agreements, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally
judicially determined not to have resulted from such Person&#146;s fraud or willful misconduct. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any person entitled to indemnification hereunder shall (i)&nbsp;give prompt written
notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided
that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless
(a)&nbsp;the indemnifying party has agreed in writing to pay such fees or expenses, (b)&nbsp;the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c)&nbsp;in the
reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party
in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the
failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the
indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of
attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter
into any settlement unless such judgment or settlement (i)&nbsp;imposes no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such
indemnified claims of all liability of the indemnified party in respect of such claim or litigation in favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing, or malfeasance by or on behalf of, the indemnified
party. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10 <U>Subsequent Equity Sales</U>. From the date of this Agreement until the earlier of (a)&nbsp;sixty (60) days after the Closing Date and
(b)&nbsp;the Business Day immediately following the effective date of the registration statement filed pursuant to the Registration Rights Agreement (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;), the Company shall
not (A)&nbsp;issue shares of Common Stock or Common Stock Equivalents, (B)&nbsp;effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Stock or (C)&nbsp;file with
the SEC a registration statement under the Securities Act relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement. Notwithstanding the foregoing, the provisions of this
<U>Section</U><U></U><U>&nbsp;5.10</U> shall not apply to (i)&nbsp;the issuance of the Securities hereunder, (ii)&nbsp;the issuance of securities pursuant to the PIPE Agreement, (iii)&nbsp;the issuance of Common Stock or Common Stock Equivalents
upon the conversion, exercise or vesting of any securities of the Company outstanding on the date of this Agreement or outstanding pursuant to clauses (i), (ii) or (iv)&nbsp;on this sentence, (iv)&nbsp;the issuance of any Common Stock or Common
Stock Equivalents pursuant to any Company stock-based compensation plans or in accordance with Nasdaq Stock Market Rule 5635(c)(4) or (v)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act to register the offer and sale of securities pursuant to an inducement plan, equity incentive plan or employee stock purchase plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11 <U>Reservation of Common Stock</U>. As of the date of this Agreement, the Company has
reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Warrant Shares that are issuable upon
the exercise of the Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12 <U>Stockholder Approval</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall prepare and file with the SEC as promptly as practicable, and in any event within 60 days after the date of this
Agreement, the Proxy Statement in preliminary form. The Company shall use reasonable efforts to respond as promptly as practicable to any comments of the SEC with respect to the Proxy Statement. Each of the parties hereto shall reasonably assist and
cooperate with the other in connection with any of the actions contemplated by this <U>Section</U><U></U><U>&nbsp;5.12(a)</U>, including the preparation, filing and distribution of the Proxy Statement and the resolution of any comments in respect
thereof received from the SEC. The Company shall ensure that the Proxy Statement complies in all material respects with the applicable provisions of the Exchange Act and the rules and regulations thereunder. The Company shall, as promptly as
reasonably practicable and permitted by applicable law following confirmation from the SEC that it will not review, or has completed its review of, the Proxy Statement, which confirmation will be deemed to occur if the SEC has not affirmatively
notified the Company prior to the tenth calendar day after filing the Proxy Statement that the SEC will or will not be reviewing the Proxy Statement (such date, the &#147;<B>SEC Clearance Date</B>&#148;), file a definitive Proxy Statement and
related proxy materials with the SEC and thereafter promptly commence mailing the Proxy Statement to the Company&#146;s stockholders of record as of the record date for the Company Stockholders Meeting. The Company shall use reasonable efforts to
obtain the Company Stockholder Approval. The Company shall be responsible for 100% of its fees, costs and expenses (including all filing, printing and mailing expenses) associated with the Proxy Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to <U>Section</U><U></U><U>&nbsp;5.12(a)</U>, the Company shall take all necessary actions, including in accordance with
applicable law, the Amended and Restated Certificate of Incorporation, the Amended and Restated Bylaws and the rules of the National Exchange, to duly call, give notice of, convene and hold a meeting of the Company&#146;s stockholders (including any
adjournment, recess, reconvening or postponement thereof, the &#147;<B>Company Stockholders Meeting</B>&#148;) for the purpose of obtaining the Company Stockholder Approval, as soon as reasonably practicable after the SEC Clearance Date. The Company
shall not postpone or adjourn the Company Stockholders Meeting, except to the extent advised by counsel to be necessary to comply with applicable law. Notwithstanding anything to the contrary contained in this Agreement, the Company may adjourn,
recess, reconvene or postpone the Company Stockholders Meeting if the Company reasonably believes that (i)&nbsp;such adjournment, recess, reconvening or postponement is necessary to ensure that any supplement or amendment to the Proxy Statement that
is required by applicable law is provided to the Company&#146;s stockholders within a reasonable amount of time in advance of the Company Stockholders Meeting, (ii)&nbsp;as of the time for which the Company Stockholders Meeting is originally
scheduled (as set forth in the Proxy Statement), (A) there will be an insufficient number of shares of Common Stock present (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders Meeting
or (B)&nbsp;there will be an insufficient number of proxies to obtain the Company Stockholder Approval or approve any other matter to be voted upon at the Company Stockholders Meeting, or (iii)&nbsp;such adjournment, recess, reconvening or
postponement is required by applicable law or a court or other governmental entity of competent jurisdiction or has been requested in writing by the SEC or its staff. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Closing</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>Conditions to the Obligation of the Investor</U>. The obligations of the Investor to consummate the transactions to be consummated at
the Closing, and to purchase the Warrant at the Closing pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all
material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the Closing Date, except to the extent any such representation or warranty
expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date, except for those representations and warranties qualified by materiality or Material
Adverse Effect, which shall be true and correct in all respects as of such earlier date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. The Company shall have
performed in all material respects the obligations and conditions herein required to be performed or observed by the Company on or prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>No Injunction</U>. The purchase of the Warrant by the Investor shall not be prohibited or enjoined by any law or governmental or court
order or regulation and no such prohibition shall have been threatened in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Consents</U>. The Company shall have obtained
any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Warrant, all of which shall be in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) [Reserved] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) [Reserved]
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>Opinion of Company Counsel</U>. The Company shall have delivered to the Investor the opinion of Cooley LLP, dated as of the
Closing Date, in customary form and substance to be reasonably agreed upon with the Investor and addressing such legal matters as the Investor and the Company reasonably agree. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) <U>Compliance Certificate</U>. An authorized officer of the Company shall have delivered to the Investor at the Closing Date a certificate
certifying that the conditions specified in <U>Sections 6.1(a) (Representations and Warranties)</U>, <U>6.1(b) (Performance)</U>, <U>6.1(c) (No Injunction)</U>, <U>6.1(d) (Consents)</U>, <U>6.1(k) (Listing Requirements)</U> and <U>6.1(l) (No
Injunction)</U> of this Agreement have been fulfilled. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Secretary&#146;s Certificate</U>. The Secretary of the Company shall have delivered
to the Investor at the Closing Date a certificate certifying (i)&nbsp;the Amended and Restated Certificate of Incorporation; (ii)&nbsp;the Amended and Restated Bylaws; and (iii)&nbsp;resolutions of the Company&#146;s Board of Directors (or an
authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the Warrant and the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) <U>Registration Rights Agreement</U>. The Company shall have executed and delivered the Registration Rights Agreement in the form attached
hereto as <U>Exhibit A</U> (the &#147;<B>Registration Rights Agreement</B>&#148;) to the Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) <U>Listing Requirements</U>. No
stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. The Common Stock shall be listed on a National Exchange and shall not
have been suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the SEC or the National Exchange have been threatened, as of the Closing Date, in writing by the SEC or the National
Exchange; and the Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Warrant Shares and Nasdaq shall have raised no objection to such notice and the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) <U>No Injunction</U>. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including
any bankruptcy court or judge, or any order of or by any governmental entity, shall have been issued, and no action or proceeding shall have been instituted by any governmental entity, enjoining or preventing the consummation of the transactions
contemplated hereby or in the other Transaction Agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) <U>License Agreement</U>. The Company shall have executed and delivered
the RemeGen License to RemeGen Co., Ltd. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Voting and Support Agreements</U>. The Company shall have entered into a Voting and
Support Agreement in substantially the form attached hereto as <U>Exhibit C</U> with each of [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Conditions to the Obligation of
the Company</U>. The obligation of the Company to consummate the transactions to be consummated at the Closing, and to issue and sell to the Investor the Warrant at the Closing pursuant to this Agreement, is subject to the satisfaction or waiver in
writing of the following conditions precedent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of the
Investor in <U>Section</U><U></U><U>&nbsp;4</U> hereto shall be true and correct on and as of the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>.
The Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed or observed by such Investor on or prior to the Closing Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Injunction</U>. The purchase of the Warrant by the Investor shall not be prohibited
or enjoined by any law or governmental or court order or regulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Registration Rights Agreement</U>. The Investor shall have
executed and delivered the Registration Rights Agreement to the Company in the form attached as <U>Exhibit</U><U></U><U>&nbsp;A</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)
<U>License Agreement</U>. RemeGen Co., Ltd. shall have executed and delivered the RemeGen License to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Termination</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1 <U>Termination</U>. The obligations of the Company, on the one hand, and the Investor, on the other hand, to effect the Closing shall
terminate as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Upon the mutual written consent of the Company and the Investor; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) By the Company if any of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6.2</U> shall have become incapable of fulfillment,
and shall not have been waived by the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) By the Investor if any of the conditions set forth in
<U>Section</U><U></U><U>&nbsp;6.1</U> shall have become incapable of fulfillment, and shall not have been waived by such Investor; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">provided, however, that, in the case of clauses (ii)&nbsp;and (iii) above, the party seeking to terminate its obligation to effect the Closing
shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted in the circumstances giving rise to such party&#146;s seeking to terminate its
obligation to effect the Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <U>Notice</U>. Nothing in this <U>Section</U><U></U><U>&nbsp;7</U> shall be deemed to release any
party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party of its other obligations under the
Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Miscellaneous Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <U>Public Statements or Releases</U>. Except as set forth in <U>Section</U><U></U><U>&nbsp;5.3</U>, neither the Company nor the Investor
shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld). Notwithstanding the
foregoing, and subject to compliance with <U>Section</U><U></U><U>&nbsp;5.3</U>, nothing in this <U>Section</U><U></U><U>&nbsp;8.1</U> shall prevent any party from making any public announcement it considers necessary in order to satisfy its
obligations under the law, including applicable securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall allow the Investor reasonable time to comment on such release or
announcement in advance of such issuance, and the Company will consider in good faith any Investor comments. The Company shall not include the name of the Investor in any press release or public announcement (which, for the avoidance of doubt, shall
not include any filing with the SEC) without the prior written consent of the Investor, except as </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company shall allow the Investor, to the extent reasonably
practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;8.1</U>, Investor review shall not be required
for Company disclosures that are substantially consistent with prior Company disclosures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <U>Notices</U>. Any notices or other
communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)&nbsp;when delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by electronic mail
during normal business hours of the recipient, and if not sent during normal business hours, then the earlier of (x)&nbsp;confirmation of receipt or (y)&nbsp;on the open of business on the recipient&#146;s next Business Day, (c)&nbsp;three (3) days
after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d)&nbsp;one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day
delivery, with written verification of receipt: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If to the Company, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Vor Biopharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">100
Cambridgepark Drive, Suite 101 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attention: Jean-Paul Kress </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">with a copy (which
shall not constitute notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">New York, New
York 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attention: Divakar Gupta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If to the Investor,
at its address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth on the signature pages hereto, or such address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;8.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <U>Consent to Electronic Notice</U>. The Investor consents to the delivery of any stockholder notice pursuant to the Delaware General
Corporation Law (the &#147;<B>DGCL</B>&#148;), as amended or superseded from time to time, by electronic mail pursuant to Section&nbsp;232 of the DGCL (or any successor thereto) at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth
below the Investor&#146;s name on the signature pages hereto, as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent
shall be deemed to have been revoked until a new or corrected <FONT STYLE="white-space:nowrap">e-mail</FONT> address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to
promptly notify the other parties of any change in its <FONT STYLE="white-space:nowrap">e-mail</FONT> address, and that failure to do so shall not affect the foregoing. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <U>Severability</U>. If any part or provision of this Agreement is held unenforceable or
in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or
provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5
<U>Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed
in accordance with, the laws of the State of New York without regard to choice of laws or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles
of Delaware law may apply. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company and the Investor hereby irrevocably and unconditionally: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated
hereby, to the general jurisdiction of the any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in the State of New York; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to
the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified
mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in <U>Section</U><U></U><U>&nbsp;8.2</U> or at such other address of which the other party shall have been notified
pursuant thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by
law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i)&nbsp;are not available despite the intentions of the parties
hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of
any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) agrees that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal
process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) irrevocably and unconditionally waives trial by jury in any legal action or
proceeding in relation to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <U>Waiver</U>. No waiver of any term, provision or condition of this Agreement, whether by
conduct or otherwise, in any one or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <U>Expenses</U>. Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses, including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed
investment in the Warrant and the consummation of the transactions contemplated thereby; provided, however, that the Company shall pay all Transfer Agent fees (including, without limitation, any fees required for
<FONT STYLE="white-space:nowrap">same-day</FONT> processing of any instruction letter delivered by the Company), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of the Warrant to the Investor.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <U>Assignment</U>. None of the parties may assign its rights or obligations under this Agreement or designate another person
(i)&nbsp;to perform all or part of its obligations under this Agreement or (ii)&nbsp;to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of (x)&nbsp;the Company, in the case of the
Investor, and (y)&nbsp;the Investor, in the case of the Company, provided that the Investor may, without the prior consent of the Company, assign its rights to purchase the Warrant hereunder to any of its affiliates (provided each such assignee
agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4</U>). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall
specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page to this Agreement and,
notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <U>Confidential Information</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Investor covenants that until such time as the transactions contemplated by this Agreement and any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information provided to such Investor are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction), other than to such Investor&#146;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or
required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company may request from the Investor such reasonable and customary additional
information as the Company may deem necessary to evaluate the eligibility of the Investor to acquire the Warrant, and the Investor shall promptly provide such information as may reasonably be requested to the extent readily available; provided, that
the Company agrees to keep any such information provided by the Investor confidential, except (i)&nbsp;as required by the federal securities laws, rules or regulations and (ii)&nbsp;to the extent such disclosure is required by other laws, rules or
regulations, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq. The Investor acknowledges that the Company may file a copy of this Agreement and the Registration Rights Agreement with the SEC as exhibit
to a periodic report or a registration statement of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10 [Reserved] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.11 <U>Third Parties</U>. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this
Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director,
officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to
this Agreement or the transactions contemplated hereby. Notwithstanding the foregoing, the Indemnified Persons are intended third-party beneficiaries of <U>Section</U><U></U><U>&nbsp;5.9</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.12 <U>[Reserved]</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.13
<U>Headings</U>. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.14 <U>Counterparts</U>. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of
2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a)
signature. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.15 <U>Entire Agreement; Amendments</U>. This Agreement and the other Transaction Agreements (including all schedules and
exhibits hereto and thereto), together with any side letter agreements with the Investor, constitute the entire agreement between the parties hereto respecting the subject matter of this Agreement and supersedes all prior agreements, negotiations,
understandings, representations and statements respecting the subject matter of this Agreement, whether written or oral. No amendment, modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the
parties hereto unless made in writing and duly executed by the Company and the Investor. The Company, on the one hand, and the Investor, on the other hand, may by an instrument signed in writing by such parties waive the performance, compliance or
satisfaction by such Investor or the Company, respectively, with any term or provision of this Agreement or any condition hereto to be performed, complied with or satisfied by such Investor or the Company, respectively. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.16 <U>Survival</U>. The covenants, representations and warranties made by each party
hereto contained in this Agreement shall survive the Closing and the delivery of the Warrant in accordance with their respective terms. The Investor shall be responsible only for its own representations, warranties, agreements and covenants
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.17 <U>Contract Interpretation</U><U>.</U> This Agreement is the joint product of the Investor and the Company and each
provision of this Agreement has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.18 <U>Arm</U><U>&#146;</U><U>s Length Negotiations</U>. For the avoidance of doubt, the parties acknowledge and confirm that the terms and
conditions of the Warrant were determined as a result of <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank.] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Vor Biopharma Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&#8195;&#8195;Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&#8195;&#8195;Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Yantai Rongpu Investment Partnership (Limited Partnership)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: [&#9679;]</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d27026dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SECURITIES PURCHASE AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is dated as of June 25, 2025, by and among Vor Biopharma Inc., a
Delaware corporation (the &#147;<B>Company</B>&#148;), and each of the purchasers listed on <U>Exhibit A</U> attached to this Agreement (each, an &#147;<B>Investor</B>&#148; and together, the &#147;<B>Investors</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section&nbsp;4(a)(2) of the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to sell to the Investors, and
each Investor desires to purchase from the Company, severally and not jointly, upon the terms and subject to the conditions stated in this Agreement, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of Common Stock (as
defined below) substantially in the form attached hereto as <U>Exhibit B</U> (the &#147;<B>Warrants</B>&#148; or the &#147;<B>Securities</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, contemporaneously with the sale of the Warrants, the parties hereto will execute and deliver a Registration Rights Agreement,
substantially in the form attached hereto as <U>Exhibit C</U>, pursuant to which the Company will agree to provide certain registration rights in respect of the Warrant Shares (as defined below) under the Securities Act and applicable state
securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>, in consideration of the mutual agreements, representations, warranties and covenants herein
contained, the Company and each Investor, severally and not jointly, agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this Agreement,
the following terms shall have the following respective meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any
other Person that, directly or indirectly through one or more intermediates, controls, is controlled by or is under common control with such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended and Restated Bylaws</B>&#148; means the Bylaws of the Company, as currently in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended and Restated Certificate of Incorporation</B>&#148; means the Certificate of Incorporation of the Company, as currently in
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Benefit Plan</B>&#148; or &#147;<B>Benefit Plans</B>&#148; means employee benefit plans as defined in Section&nbsp;3(3)
of ERISA and all other employee benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for disability, retirement benefits, deferred
compensation, bonus pay, incentive pay, stock options or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by the Company or to which the Company or any
of its subsidiaries is obligated to contribute for employees or former employees of the Company and its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board of Directors</B>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate Amendment</B>&#148; means an amendment to the Amended and Restated Certificate of Incorporation that has the effect of
increasing the number of authorized and unreserved shares of Common Stock, whether through an increase of the number of authorized shares of Common Stock or through effecting a reverse stock split, sufficient for the exercise in full of
(i)&nbsp;each Warrant issued by the Company pursuant to this Agreement and (ii)&nbsp;the warrant issued pursuant to that certain Securities Purchase Agreement, dated as of June 25, 2025, by and between the Company and Yantai Rongpu Investment
Partnership (Limited Partnership), a subsidiary of RemeGen Co., Ltd., as contemplated by the RemeGen License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing</B>&#148;
has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Date</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.2</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S.
Internal Revenue Code of 1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock</B>&#148; means the Company&#146;s common stock, par value $0.0001 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock Equivalents</B>&#148; means any securities of the Company that would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Stockholders Meeting</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.12(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Data</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.30</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosure Document</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Drug Regulatory Agency</B>&#148; means the U.S. Food and Drug Administration (&#147;<B>FDA</B>&#148;) or other foreign, state, local
or comparable governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or biological
products and drug or biological product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Laws</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.15</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; means the U.S. Employee Retirement Income Security Act of 1974, as
amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the U.S. Securities Exchange Act of 1934, as amended,
and all of the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financial Statements</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.8(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Fundamental Representations&#148; </B>means the representations and warranties made by
the Company in <U>Sections 3.1 (Organization and Power)</U>, <U>3.2 (Capitalization)</U>, <U>3.4 (Authorization)</U>, <U>3.5 (Valid Issuance)</U>, <U>3.6 (No Conflict)</U>, <U>3.7 (Consents)</U>, <U>3.8 (SEC Filings; Financial Statements)</U>,
<U>3.18 (Nasdaq Stock Market)</U>, <U>3.19 (Sarbanes-Oxley Act)</U>, <U>3.23 (Price Stabilization of Common Stock)</U>, <U>3.24 (Investment Company Act)</U>, <U>3.25 (General Solicitation; No Integration or Aggregation)</U>, <U>3.26 (Brokers and
Finders)</U>, <U>3.27 (Reliance by the Investors)</U>, <U>3.28 (No Additional Agreements)</U>, <U>3.33 (No Bulk U.S. Sensitive Personal Data or Government-Related Data Collection</U>) and <U>3.34 (No TID U.S. Business)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.8(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GDPR</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.31</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authorizations</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>HIPAA</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.21</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnified Person&#148; </B>has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor</B>&#148; and &#147;<B>Investors</B>&#148; have the meanings set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IT Systems</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.30</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licenses</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.21</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.10</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Adverse Effect</B>&#148; means any change, event, circumstance, development, condition, occurrence or effect that,
individually or in the aggregate, (a)&nbsp;was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities, stockholders&#146; equity or results of operations of the Company
and its subsidiaries, taken as a whole, or (b)&nbsp;materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under this Agreement, the other Transaction Agreements, or
with respect to the Closing, or would reasonably be expected to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Nasdaq</B>&#148; means the Nasdaq Stock Market LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>National Exchange</B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question, together with any successor thereto: the NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market and the Nasdaq Capital Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, partnership, corporation, limited liability
company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Personal Data</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.30</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Laws</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.31</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Statements</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.31</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Process</B>&#148; or &#147;<B>Processing</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.31</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Proxy Statement</B>&#148; means the proxy statement filed by the Company with the SEC in connection with the Company Stockholders
Meeting, including any amendments and supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Rights Agreement</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.1(j)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RemeGen License</B>&#148; means that certain License Agreement, by and between the
Company and RemeGen Co., Ltd., dated June 25, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 144</B>&#148; means Rule 144 promulgated by the SEC pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC Clearance Date</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.12(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;SEC Reports</B>&#148; means (a)&nbsp;the Company&#146;s most recently filed Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and (b)&nbsp;all Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed or furnished (as applicable) by the
Company following the end of the most recent fiscal year for which an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> has been filed and prior to the execution of this Agreement, together in each case with any documents
incorporated by reference therein or exhibits thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities</B>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the U.S. Securities Act of 1933, as amended, and all of the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Short Sales</B>&#148; include, without limitation, (a)&nbsp;all &#147;short sales&#148; as defined in Rule 200
promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, &#147;put equivalent positions&#148; (as
defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) and similar arrangements (including on a total return basis), and (b)&nbsp;sales and other transactions through <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
broker dealers or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Returns</B>&#148; means returns, reports, information statements and other
documentation (including any additional or supporting material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any amended returns
required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; or
&#147;<B>Taxes</B>&#148; means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with
respect thereto), whether or not imposed on the Company, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property,
capital stock, license, payroll, withholding, employment, social security, workers&#146; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and
customs duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreements</B>&#148; means this Agreement, the Warrants, and the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Agent</B>&#148; means, with respect to the Common Stock, Computershare Trust Company, N.A., or such other financial
institution that provides transfer agent services as the Company may engage from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant Shares</B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrants</B>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale of Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <U>Purchase and Sale</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Investors, severally and not jointly, agree to purchase, the number and type of Securities, for the aggregate purchase price, set forth opposite the Investor&#146;s name on <U>Exhibit A</U>. The price per Warrant is $0.25. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <U>Closing</U>. Subject to the satisfaction or waiver of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U> of this
Agreement, the closing of the purchase and sale of the Securities (the &#147;<B>Closing</B>&#148; and the date on which the Closing occurs, the &#147;<B>Closing Date</B>&#148;) shall occur remotely via the exchange of documents and signatures at
such time as agreed to by the Company and the Investors but (i)&nbsp;in no event earlier than the first Business Day after the date of this Agreement and (ii)&nbsp;in no event later than the fifth Business Day after the date of this Agreement. At
the Closing, the Company shall deliver to the Investor (or such Investor&#146;s designated custodian per its delivery instructions), or in such nominee name(s) as designated by such Investor, a Warrant exercisable for a number of shares of Common
Stock as set forth in <U>Exhibit A</U> with respect to such Investor against payment to the Company of the purchase price therefor in full, by wire transfer to the Company of immediately available funds, at or prior to the Closing, in accordance
with wire instructions provided by the Company to the Investors no less than one Business Day prior to the Closing. In the event that the Closing has not occurred within one Business Day after the expected Closing Date, unless otherwise agreed by
the Company and such Investor, the Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promptly (but no later than one Business Day thereafter) return the previously wired amounts to each respective Investor by wire transfer of United States dollars in immediately available funds
to the account specified by each Investor, and each Investor&#146;s Warrants shall be deemed cancelled; provided that, unless this Agreement has been terminated pursuant to <U>Section</U><U></U><U>&nbsp;7</U>, such return of funds shall not
terminate this Agreement or relieve such Investor of its obligation to purchase, or the Company of its obligation to issue and sell, the Securities at the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports (other than as to the Fundamental
Representations, which are not so qualified), the Company hereby represents and warrants to each of the Investors that the statements contained in this <U>Section</U><U></U><U>&nbsp;3</U> are true and correct as of the date of this Agreement and as
of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Organization and Power</U>. The Company is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described in the SEC Reports and is qualified to do business in each jurisdiction in which the
character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not reasonably be expected to have a Material Adverse
Effect. Each of the Company&#146;s subsidiaries is (i)&nbsp;duly incorporated and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite power and authority to carry on its business as now
conducted and to own or lease its properties and (ii)&nbsp;qualified to do business as a foreign corporation and in good standing in each jurisdiction in which such qualification is required, except in each case as would not cause a Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Capitalization</U>. The Company&#146;s disclosure of its authorized, issued and outstanding capital stock in the SEC
Reports containing such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and
such shares were issued in compliance in all material respects with applicable state and federal securities laws and any rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <U>Registration Rights</U>. Except as set forth in the Transaction Agreements or as disclosed in the SEC Reports, the Company is presently
not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company&#146;s presently outstanding securities or any of its securities that may hereafter be issued, other than such rights and obligations
that have expired or been satisfied or waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <U>Authorization</U>. The Company has all requisite corporate power and authority to
enter into the Transaction Agreements and to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Securities and the issuance of the shares of Common Stock issuable upon exercise
of the Warrants (the &#147;<B>Warrant Shares</B>&#148;), provided that the issuance of the Warrant Shares is subject to the approval of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company&#146;s stockholders of (i)&nbsp;the issuance of the Warrant Shares in accordance with Nasdaq Stock Market Rule 5635(d) and (ii)&nbsp;the Certificate Amendment (the &#147;<B>Company
Stockholder Approval</B>&#148;) and the filing and effectiveness of the Certificate Amendment. Other than Company Stockholder Approval and the filing and effectiveness of the Certificate Amendment, all corporate action on the part of the Company,
its officers, directors and stockholders necessary for the authorization of the Securities and the Warrant Shares, the authorization, execution, delivery and performance of the Transaction Agreements and the consummation of the transactions
contemplated herein, including the issuance and sale of the Securities and the Warrant Shares, has been taken, including, without limitation, the approval of the Board of Directors (or a committee thereof) in accordance with Section&nbsp;144(a)(1)
of the Delaware General Corporation Law (the &#147;<B>DGCL</B>&#148;). This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by each Investor and that this Agreement
constitutes the legal, valid and binding agreement of each Investor, this Agreement and each of the Warrants constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as
such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a
proceeding in equity or at law). Upon its execution by the Company and the other parties thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement will constitute a
legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or
affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 <U>Valid Issuance</U>. Subject to and upon the effectiveness of the Certificate Amendment, the Warrant Shares will be duly and validly
authorized and reserved for issuance and, upon issuance pursuant to the terms of the Warrants against full payment therefor in accordance with the terms of the Warrants, will be duly and validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal
securities laws), and the holder of the Warrant Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties made by the Investors in <U>Section</U><U></U><U>&nbsp;4</U>,
the offer and sale of the Securities to the Investors is and will be in compliance with applicable exemptions from (i)&nbsp;the registration and prospectus delivery requirements of the Securities Act and (ii)&nbsp;the registration and qualification
requirements of applicable securities laws of the states of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6 <U>No Conflict</U>. The execution, delivery and
performance of the Transaction Agreements by the Company, the issuance and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Agreements will not (i)&nbsp;violate any provision of the Amended and
Restated Certificate of Incorporation or Amended and Restated Bylaws of the Company, (ii)&nbsp;conflict with or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to
the Company or any of its subsidiaries or their respective properties or assets,&nbsp;or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any of its
subsidiaries is subject (including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, or by which any property or asset of the
Company or any of its subsidiaries is bound or affected,&nbsp;except (A)&nbsp;in the case of clause (i), assuming and contingent on the filing and effectiveness of the Certificate Amendment, (B)&nbsp;in the case of clauses (ii)&nbsp;and (iii), as
would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect, and (C)&nbsp;in the case of clause (iii), assuming and contingent on Company Stockholder Approval and the filing and effectiveness of the
Certificate Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7 <U>Consents</U>. Assuming the accuracy of the representations and warranties of the Investors, no consent,
approval, authorization, filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization, execution or delivery by the Company of the Transaction Agreements, the issuance and
sale of the Securities and the performance by the Company of its other obligations under the Transaction Agreements, except such as (a)&nbsp;have been or will be obtained or made under the Securities Act or the Exchange Act, (b)&nbsp;the filing of
any requisite notices and/or application(s) to the National Exchange for the issuance and sale of the Securities or the Warrant Shares and the listing of the Warrant Shares for trading or quotation, as the case may be, thereon in the time and manner
required thereby, (c)&nbsp;customary post-closing filings with the SEC or pursuant to state securities laws in connection with the offer and sale of the Securities or the Warrant Shares by the Company in the manner contemplated herein, which will be
filed on a timely basis, and (d)&nbsp;the filing of the registration statement required to be filed by the Registration Rights Agreement, or (e)&nbsp;such that the failure of which to obtain would not have a Material Adverse Effect. All notices,
consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall
remain in full force and effect, on or prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8 <U>SEC Filings; Financial Statements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has filed all forms, statements, certifications, reports and documents required to be filed by it with the SEC under
Section&nbsp;13, 14(a) and 15(d) of the Exchange Act for the one year preceding the date of this Agreement and is in compliance with General Instruction I.A.3 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> As of the time it was filed with the
SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of the Exchange Act, and, as of the
time they were filed, none of the filed SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the SEC Reports. To the Company&#146;s knowledge, none of the SEC Reports are the subject of an ongoing SEC
review. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The financial statements of the Company included in the SEC Reports (collectively, the
&#147;<B>Financial Statements</B>&#148;) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a
subsequent restatement) and fairly present in all material respects the consolidated financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods therein specified, all in accordance
with United States generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) (except as otherwise noted therein, and in the case of unaudited financial statements, as permitted by Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of the
SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments) applied on a consistent basis throughout the periods therein
specified (unless otherwise noted therein). Except as set forth in the Financial Statements filed prior to the date of this Agreement, the Company has not incurred any liabilities, contingent or otherwise, except (i)&nbsp;those incurred in the
ordinary course of business, consistent with past practices since the date of such financial statements or (ii)&nbsp;liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in
the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9 <U>Absence of Changes</U>. Between
December&nbsp;31, 2024 and the date of this Agreement, (a)&nbsp;the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company (except for the execution and
performance of this Agreement, the RemeGen License and the discussions, negotiations and transactions related thereto); (b) no material change to any material contract or arrangement by which the Company is bound or to which any of its assets or
properties is subject has been entered into that has not been disclosed in the SEC Reports; and (c)&nbsp;there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect;
provided, however, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse
Effect under this <U>Section</U><U></U><U>&nbsp;3.9</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any change generally affecting the economy, financial markets or political,
economic or regulatory conditions in the United States or any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that
the Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any change that generally affects industries in which the Company and its
subsidiaries conduct business, provided that the Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) earthquakes, hurricanes,
tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, epidemic or similar health emergency, and other force majeure events in the United States or any other location, provided that the
Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) national or international political or social conditions (or changes in such
conditions), whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) material changes in laws after the date of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses,
earnings or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in
determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v) of this definition). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10 <U>Absence of Litigation</U>. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry
pending or, to the Company&#146;s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders,
writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that have had or would reasonably be expected to have a Material Adverse Effect.
Neither the Company nor any subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been, the subject of any action involving a claim of violation of or
liability under federal or state securities laws relating to the Company or such subsidiary or a claim of breach of fiduciary duty relating to the Company or such subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <U>Compliance with Law; Permits</U>. Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of
violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, &#147;<B>Governmental Authorizations</B>&#148;) from such federal,
state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess currently such
Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. Neither the Company nor any subsidiary has received any written (or, to the Company&#146;s knowledge, oral) notice regarding any revocation or
material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <U>Intellectual Property</U>. Except as otherwise disclosed in the SEC Reports, the Company owns or has valid and enforceable licenses or
other rights to all patents, copyrights, copyrightable works, trademarks, service marks, trade names, and service names (including all applications and registrations relating to any of the foregoing), and all
<FONT STYLE="white-space:nowrap">inventions,&nbsp;know-how,&nbsp;trade</FONT> secrets and other proprietary or confidential information (whether or not patentable), systems or procedures and all other technology and intellectual property rights
necessary for the conduct, or the proposed conduct, of the business of the Company in the manner described in the SEC Reports </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#147;<B>Company Intellectual Property</B>&#148;); the Company Intellectual Property disclosed in the SEC Reports as being owned by the Company is owned by the Company free and
clear of all material liens, security interests, and encumbrances, and to the Company&#146;s knowledge, there are no rights of third parties to such Company Intellectual Property; to the Company&#146;s knowledge, the Company Intellectual Property is
valid, enforceable and subsisting; and other than as disclosed in the SEC Reports, (i)&nbsp;the Company is not obligated to pay a material royalty, grant a material license, or provide other material consideration to any third party in connection
with the Company Intellectual Property, (ii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, alleging that the conduct of the business of the Company in the manner described in the SEC
Reports is infringing, misappropriating, diluting or otherwise violating any intellectual property rights of others, (iii)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging the
validity, enforceability, scope, registration, ownership or use of any of the Company Intellectual Property, (iv)&nbsp;no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging the
Company&#146;s rights in or to any Company Intellectual Property, (v)&nbsp;to the Company&#146;s knowledge, no third party has any ownership right in or to any Company Intellectual Property in any field of use that is exclusively licensed to the
Company, other than any licensor to the Company of such Company Intellectual Property, (vi)&nbsp;no employee, consultant or independent contractor of the Company is, to the Company&#146;s knowledge, in violation in any material respect of any term
of any employment contract, patent disclosure agreement, invention assignment <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">agreement,&nbsp;non-competition&nbsp;agreement,&nbsp;non-solicitation&nbsp;agreement,</FONT></FONT>
nondisclosure agreement, or any restrictive covenant to or with a former employer or independent contractor where the basis of such violation relates to such employee&#146;s employment or independent contractor&#146;s engagement with the Company or
actions undertaken while employed or engaged with the Company, (vii)&nbsp;the Company has taken reasonable measures to protect its material confidential information and material trade secrets and to maintain and safeguard the material Company
Intellectual Property, including the execution of appropriate nondisclosure and confidentiality agreements, and (viii)&nbsp;the Company has complied with the material terms of each agreement pursuant to which the Company Intellectual Property has
been licensed to the Company, and all such agreements are in full force and effect; except in each of (i)&#150;(viii) such as would not, if determined adversely to the Company, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. All patents and patent applications within the Company Intellectual Property disclosed in the SEC Reports as being owned by the Company have, to the knowledge of the Company, been duly and properly filed and maintained; to
the knowledge of the Company, there are no material defects in any of such patents or patent applications; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the
United States Patent and Trademark Office (the &#147;<B>USPTO</B>&#148;) in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would
preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications; except such as would not, if determined
adversely to the Company, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13 <U>Employee Benefits</U>. Except as would not be reasonably likely to result in a
Material Adverse Effect, each Benefit Plan has been established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection and Affordable Care Act of 2010, as amended,
and other applicable laws, rules and regulations. The Company and its subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding employment, except for any failures to comply that are not
reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. There is no labor dispute, strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may
interfere with the business activities of the Company, except where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.14 <U>Taxes</U>. All Tax Returns of the Company and its subsidiary required by law to be filed have been filed and all Taxes shown as due on
such returns or that otherwise have been assessed, which are due and payable, have been paid, except: (i)&nbsp;assessments against which appeals have been or will be promptly taken in good faith and as to which adequate reserves have been provided
in accordance with the applicable accounting principles, or (ii)&nbsp;as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any
material amounts of Taxes of the Company and its subsidiaries are presently in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on any of the assets of the Company. At
all times since inception, the Company has been and continues to be classified as a corporation for U.S. federal income tax purposes. Neither the Company nor any of its subsidiaries has been a United States real property holding corporation within
the meaning of Code Section&nbsp;897(c)(2) during the period specified in Code Section&nbsp;897(c)(1)(A)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.15 <U>Environmental
Laws</U>. The Company and its subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;), (ii)&nbsp;have received all permits and other Governmental Authorizations required under applicable Environmental Laws to conduct their business and
(iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with
the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company nor any of its subsidiaries has received since January&nbsp;1,
2025, any written notice or other communication (in writing or otherwise), whether from a governmental authority or other Person, that alleges that the Company or any subsidiary is not in compliance with any Environmental Law and, to the knowledge
of the Company, there are no circumstances that may prevent or interfere with the Company&#146;s or any subsidiary&#146;s compliance in any material respects with any Environmental Law in the future, except where such failure to comply would not
reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company: (i)&nbsp;no current or (during the time a prior property was leased or controlled by the Company) prior property leased or controlled by the Company or any
subsidiary has received since January&nbsp;1, 2025, any written notice or other communication relating to property owned or leased at any time by the Company, whether from a governmental authority, or other Person, that alleges that such current or
prior owner or the Company or any subsidiary is not in compliance with or violated any Environmental Law relating to such property and (ii)&nbsp;the Company has no material liability under any Environmental Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.16 <U>Title</U>. Each of the Company and its subsidiaries has good and marketable title to
all personal property owned by it that is material to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company or its subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or its subsidiaries, as the case may be. The Company does not own any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.17 <U>Insurance</U>. The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is
customary for comparably situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased) and tangible assets, and each of such insurance policies is in full force and effect and
the Company is in compliance in all material respects with the terms of such insurance policies. Other than customary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-policy</FONT></FONT> notifications from insurance
carriers, since January&nbsp;1, 2025, the Company has not received any notice or other communication regarding any actual or possible: (i)&nbsp;cancellation or invalidation of any material insurance policy or (ii)&nbsp;refusal or denial of any
coverage, reservation of rights or rejection of any material claim under any insurance policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.18 <U>Nasdaq Stock Market</U>. The
issued and outstanding shares of Common Stock are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on the Nasdaq Global Select Market under the symbol &#147;VOR&#148;. The Company is in compliance with all
listing requirements of Nasdaq applicable to the Company other than Nasdaq Listing Rule 5450(a)(1), as disclosed in the SEC Reports. As of the date of this Agreement, there is no suit, action, proceeding or investigation pending or, to the knowledge
of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Global Select Market or to deregister the Common Stock under the Exchange Act. The Company has
taken no action as of the date of this Agreement that is designed to terminate the registration of the Common Stock under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.19 <U>Sarbanes-Oxley Act</U>. The Company is, and since January&nbsp;1, 2025 has been, in compliance in all material respects with all
applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.20
<U>Clinical Data and Regulatory Compliance</U>. <FONT STYLE="white-space:nowrap">The&nbsp;pre-clinical&nbsp;studies</FONT> and clinical trials that are described in the SEC Reports were conducted in all material respects in accordance with the
protocols submitted to the FDA or any foreign governmental body exercising comparable authority, and all applicable laws and regulations; the descriptions of <FONT STYLE="white-space:nowrap">the&nbsp;pre-clinical&nbsp;studies</FONT> and clinical
trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company or by a licensor, and the results thereof, contained in SEC Reports are accurate and complete in all material respects; the Company is not aware of any <FONT
STYLE="white-space:nowrap">other&nbsp;pre-clinical&nbsp;studies</FONT> or clinical trials, the results of which materially call into question the results described in SEC Reports; and the Company has not received any written notices or
correspondence from the FDA, any foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or ethics committee or similar body requiring the termination, suspension, material adverse modification or
clinical hold of <FONT STYLE="white-space:nowrap">any&nbsp;pre-clinical&nbsp;studies</FONT> or clinical trials conducted by or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on behalf of the Company or by a licensor. Neither the Company or its subsidiary nor any of their respective officers, employees or directors, nor, to the Company&#146;s knowledge, any of its
respective agents or clinical investigators, or licensors, has, for the past three (3)&nbsp;years, been excluded, suspended or debarred from participation in any U.S. federal or foreign health care program or human clinical research or, is subject
to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion, or convicted of any crime or engaged in any conduct that would reasonably be expected
to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.21 <U>Compliance with Health Care Laws</U>. The Company,
its subsidiary and their respective directors, officers and employees, are and for the past three (3)&nbsp;years have been, in compliance with applicable Health Care Laws (defined herein), including, but not limited to, the rules and regulations of
the FDA, the U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare&nbsp;&amp; Medicaid Services, the Office for Civil Rights, and the Department of Justice, except for such noncompliance that would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; shall mean, as applicable, the federal Anti-kickback Statute (42 U.S.C. <FONT
STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(b)),&nbsp;the</FONT> Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7h),&nbsp;the</FONT> civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the
criminal False Claims Act (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(a)),&nbsp;applicable</FONT> criminal laws relating to health care fraud and abuse, including, without limitation, those set forth at 18 U.S.C. &#167;&#167;
286, 287 and 1349, the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7),&nbsp;the</FONT> civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7a),&nbsp;the</FONT> Health Insurance
Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.) (&#147;<B>HIPAA</B>&#148;), and the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 201 et seq.) and comparable state, local and foreign laws, each as amended from time and the regulations promulgated
thereunder. The Company is not a party to or does not have any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred <FONT STYLE="white-space:nowrap">or&nbsp;non-prosecution&nbsp;agreement,</FONT> monitoring
agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority. The Company has not received any written notification, correspondence or any other written or oral communication, including,
without limitation, any Form FDA 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any similar regulatory authority, or any notification of any pending or, to the Company&#146;s
knowledge, threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action, from any governmental authority alleging or asserting potential or actual
<FONT STYLE="white-space:nowrap">material&nbsp;non-compliance&nbsp;by,</FONT> or material liability of, the Company under any Health Care Laws. Each of the Company and its subsidiary possesses, and is in compliance with the terms of, all
applications, certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations issued by the appropriate governmental authorities and necessary to conduct its business (collectively,
&#147;<B>Licenses</B>&#148;), including, without limitation, all Licenses required by the Drug Regulatory Agencies. All such Licenses are in full force and effect and the Company is not in violation of any term or conditions of any such License.
Each of the Company and its subsidiary and has fulfilled and performed all of its respective obligations with respect to such Licenses and, no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination
thereof or results in any other impairment of the rights of the holder of any such License. The Company has not received any written notice of proceedings from the applicable Drug Regulatory Agency proposing to revoke or materially adversely modify
any such Licenses and, to the Company&#146;s knowledge, no Drug Regulatory Agency has taken any action to limit, suspend or revoke any such License possessed by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.22 <U>Accounting Controls and Disclosure Controls and Procedures</U>. The Company
maintains a system of internal control over financial reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) that is designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&nbsp;that the
Company maintains records that in reasonable detail accurately and fairly reflect the Company&#146;s transactions and dispositions of assets, (ii)&nbsp;that transactions are recorded as necessary to permit preparation of financial statements in
accordance with GAAP, (iii)&nbsp;that receipts and expenditures are made only in accordance with authorizations of management and the Board of Directors and (iv)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or
disposition of the Company&#146;s assets that could have a material effect on the Company&#146;s financial statements. Except as disclosed in the Company&#146;s SEC Reports filed prior to the date of this Agreement, the Company has not identified
any material weaknesses in the design or operation of the Company&#146;s internal control over financial reporting. The Company&#146;s &#147;disclosure controls and procedures&#148; (as defined in Rules
<FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> of the Exchange Act) are designed to provide reasonable assurance that all information (both financial and
<FONT STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
rules and forms of the SEC, and that all such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.23 <U>Price Stabilization of Common Stock</U>. The Company has not taken, nor will it take, directly or indirectly, any action designed to
stabilize or manipulate the price of the Common Stock to facilitate the sale or resale of the Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.24 <U>Investment Company
Act</U>. The Company is not, and immediately after receipt of payment for the Securities will not be, an &#147;investment company&#148; within the meaning of the U.S. Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.25 <U>General Solicitation; No Integration or Aggregation</U>. Neither the Company nor any other person or entity authorized by the Company
to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to offers or sales of Securities pursuant to this Agreement. The Company has not,
directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which, to its knowledge, is or will be (i)&nbsp;integrated with the Securities sold
pursuant to this Agreement for purposes of the Securities Act or (ii)&nbsp;aggregated with prior offerings by the Company for the purposes of the rules and regulations of the Nasdaq Global Select Market, other than the securities to be issued to
Yantai Rongpu Investment Partnership (Limited Partnership), a subsidiary of RemeGen Co., Ltd., as contemplated by the RemeGen License. Assuming the accuracy of the representations and warranties of the Investors set forth in
<U>Section</U><U></U><U>&nbsp;4</U>, neither the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy
any Company security, under circumstances that would adversely affect reliance by the Company on Section&nbsp;4(a)(2) for the exemption from registration for the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.26 <U>Brokers and Finders</U>. Neither the Company nor any other Person authorized by the
Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.27 <U>Reliance by the Investors</U>. The Company has a reasonable basis for making each of the representations set forth in this
<U>Section</U><U></U><U>&nbsp;3</U>. The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company&#146;s compliance with, the representations, warranties, agreements, acknowledgements and
understandings of the Company set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.28 <U>No Additional Agreements</U>. There are no agreements or understandings between
the Company and any Investor with respect to the transactions contemplated by the Transaction Agreements other than (i)<U></U>&nbsp;as specified in the Transaction Agreements and (ii)<U></U>&nbsp;any side letter agreements with any of the Investors,
which side letters the Company has shared with all Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.29 <U>Anti-Bribery and Anti-Money Laundering Laws</U>. Each of the
Company, its subsidiaries and, to the knowledge of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not
violate: (A)&nbsp;anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery
of Foreign Public Officials in International Business Transactions, signed December<U></U>&nbsp;17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of
similar purposes and scope or (B)<U></U>&nbsp;anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including,
without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task
Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation
pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.30 <U>Cybersecurity</U>. The Company
and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform
in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The
Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all
sensitive, confidential or regulated data (&#147;<B>Confidential Data</B>&#148;) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability continuous
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operation, redundancy and security of all IT Systems. &#147;<B>Personal Data</B>&#148; means the following data used in connection with the Company&#146;s and its subsidiaries&#146; businesses
and in their possession or control: (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or other tax identification number, driver&#146;s
license number, passport number, credit card number or bank information; (ii)&nbsp;information that identifies or may reasonably be used to identify an individual; (iii)&nbsp;any information that would qualify as &#147;protected health
information&#148; under HIPAA; and (iv)&nbsp;any information that would qualify as &#147;personal data,&#148; &#147;personal information&#148; (or similar term) under the Privacy Laws. To the Company&#146;s knowledge, there have been no breaches,
outages or unauthorized uses of or accesses to the Company&#146;s IT Systems, Confidential Data, or Personal Data that would require notification under Privacy Laws (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.31 <U>Compliance with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with
all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other processing (collectively &#147;<B>Process</B>&#148; or
&#147;<B>Processing</B>&#148;) of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (Regulation (EU) No. 2016/679), all other local, state, federal, national, supranational and
foreign laws relating to the regulation of the Company or its subsidiaries, and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure
material compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data
privacy and security, and the Processing of Personal Data and Confidential Data (the &#147;<B>Privacy Statements</B>&#148;). The Company and its subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to
result in a Material Adverse Effect, at all times since inception provided accurate notice of their Privacy Statements then in effect to its customers, employees, third party vendors and representatives. None of such disclosures made or contained in
any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.32
<U>Transactions with Affiliates and Employees</U>. No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that
is required to be described in the SEC Reports that is not so described. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.33 <U>No Bulk U.S. Sensitive Personal Data or
Government-Related Data Collection</U>. The Company, does not collect, store, maintain, or have &#147;Access&#148; to &#147;Bulk U.S. Sensitive Personal Data&#148; or &#147;Government-Related Data,&#148; each as defined in 28 C.F.R. part 202, the
final rule &#147;Preventing Access to U.S. Sensitive Personal Data And Government-Related Data by Countries of Concern or Covered Persons&#148; (the Department of Justice&#146;s &#147;Data Security Program&#148; or &#147;<B>DSP</B>&#148;), and does
not currently intend to collect, store, maintain, or have &#147;Access&#148; to such data. If, at any point in the future, the Company begins to collect, maintain, or have &#147;Access&#148; to &#147;Bulk U.S. Sensitive Personal Data&#148; or
&#147;Government-Related Data,&#148; the Company will comply with the requirements of the DSP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.34 <U>No TID U.S. Business</U>. The Company does not (a)&nbsp;produce, design, test,
manufacture, fabricate, or develop &#147;critical technologies&#148; as that term is defined in 31 C.F.R. &#167; 800.215; (b) perform the functions as set forth in column 2 of Appendix A to 31 C.F.R. part 800 with respect to covered investment
critical infrastructure; or (c) maintain or collect, directly or indirectly, &#147;sensitive personal data&#148; as that term is defined in 31 C.F.R. &#167; 800.241; and, therefore, in turn, the Company is not a &#147;TID U.S. business&#148; within
the meaning of 31 C.F.R. &#167; 800.248. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of Each </U><U>Investor</U>. Each Investor, severally for
itself and not jointly with any other Investor, represents and warrants to the Company that the statements contained in this <U>Section</U><U></U><U>&nbsp;4</U> are true and correct as of the date of this Agreement and the Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <U>Organization</U>. The Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Authorization</U>. The Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other
Transaction Agreements to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership action on the part of such Investor or its stockholders, members or partners necessary for
the authorization, execution, delivery and performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions contemplated in this Agreement has been taken. The execution,
delivery and performance by such Investor of the Transaction Agreements to which such Investor is a party has been duly authorized and each has been duly executed. Assuming this Agreement constitutes the legal and binding agreement of the Company,
this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against such Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in
equity or at law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>No Conflict</U><U>s</U>. The execution, delivery and performance of the Transaction Agreements by the Investor,
the purchase of the Securities in accordance with their terms and the consummation by the Investor of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by such Investor (with or
without notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material benefit under (i)&nbsp;any provision of the
organizational documents of the Investor, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii)&nbsp;any agreement or instrument,
undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Investor or its respective properties or assets, except, in the case of clause (ii), as would not,
individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of the Investor to perform its obligations under the Transaction Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Residency</U>. The Investor&#146;s residence (if an individual) or offices in which
its investment decision with respect to the Securities was made (if an entity) are located at the address immediately below the Investor&#146;s name on <U>Exhibit A</U>, except as otherwise communicated by the Investor to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <U>Brokers and Finders</U>. The Investor has not retained, utilized or been represented by any broker or finder in connection with the
transactions contemplated by this Agreement whose fees the Company would be required to pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <U>Investment Representations and
Warranties</U>. The Investor hereby represents and warrants that, it (i)&nbsp;as of the date of this Agreement is, if an entity, a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act) or an institutional
&#147;accredited investor&#148; as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act; or (ii)&nbsp;if an individual, is an &#147;accredited investor&#148; as that term is defined in Rule 501(a) of
Regulation D of the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Securities. The Investor further represents and warrants
that (x)&nbsp;it is capable of evaluating the merits and risk of such investment, and (y)&nbsp;that it has not been organized for the purpose of acquiring the Securities and is an &#147;institutional account&#148; as defined by FINRA Rule 4512(c).
The Investor understands and agrees that the offering and sale of the Securities has not been registered under the Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for
transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor&#146;s representations as expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <U>Intent</U>. The Investor is purchasing the Securities solely for the Investor&#146;s own account and not for the account of others, and
not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the
Securities Act without prejudice, however, to the Investor&#146;s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws. Notwithstanding the foregoing,
if the Investor is purchasing the Securities as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements,
representations and agreements herein on behalf of each owner of each such account. The Investor has no present arrangement to sell the Securities to or through any person or entity. The Investor understands that the Securities must be held
indefinitely unless such Securities are resold pursuant to a registration statement under the Securities Act or an exemption from registration is available. Nothing contained herein shall be deemed a representation or warranty by the Investor to
hold the Securities for any period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <U>Investment Experience; Ability to Protect Its Own Interests and Bear Economic
Risks</U>. The Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has knowledge and experience in finance, securities, taxation, investments and other business matters as to be capable
of evaluating the merits and risks of investments of the kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Investor has considered necessary to make an informed investment decision. The Investor acknowledges that the Investor (i)&nbsp;is a sophisticated investor, experienced in investing in
private placements of equity securities and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii)&nbsp;has exercised
independent judgment in evaluating its participation in the purchase of the Securities. The Investor acknowledges that the Investor is aware that there are substantial risks incident to the purchase and ownership of the Securities, including those
set forth in the Company&#146;s filings with the SEC. Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment in the Securities and determined that the Securities are
a suitable investment for the Investor. The Investor is, at this time and in the foreseeable future, able to afford the loss of the Investor&#146;s entire investment in the Securities and the Investor acknowledges specifically that a possibility of
total loss exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.9 <U>Independent Investment Decision</U>. The Investor understands that nothing in the Transaction Agreements or any
other materials presented by or on behalf of the Company to the Investor in connection with the purchase of the Securities constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as it, in such
Investor&#146;s sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10
<U>Securities Not Registered; Legends</U>. The Investor acknowledges and agrees that the Securities are being offered in a transaction not involving any public offering within the meaning of the Securities Act, and the Investor understands that the
Securities have not been registered under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the Securities Act, and that the Securities must continue to be held and may not
be offered, resold, transferred, pledged or otherwise disposed of by the Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration and in each case in accordance with any applicable
securities laws of any state of the United States. The Investor understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of
various conditions including, but not limited to, the time and manner of sale, the holding period and on requirements relating to the Company which are outside of the Investor&#146;s control and which the Company may not be able to satisfy, and
that, if applicable, Rule 144 may afford the basis for sales only in limited amounts. The Investor acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of
the Securities. The Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Securities or made any findings or determination as to the fairness of this investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor understands that any certificates or book entry notations evidencing the Securities may bear one or more legends in substantially
the following form and substance: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE &#147;SECURITIES ACT&#148;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;SUCH SECURITIES HAVE
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II)&nbsp;SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT
SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Securities may contain a legend regarding affiliate
status of the Investor, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11 <U>No General Solicitation</U>. The Investor acknowledges and agrees that the Investor is
purchasing the Securities directly from the Company. Investor became aware of this offering of the Securities solely by means of direct contact from the Company as a result of a <FONT STYLE="white-space:nowrap">pre-existing,</FONT> substantive
relationship with the Company and/or its advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons, representatives, affiliates, directors, officers, managers, members,
and/or employees, and/or the representatives of such persons. The Securities were offered to Investor solely by direct contact between Investor and the Company and/or its representatives. Investor did not become aware of this offering of the
Securities, nor were the Securities offered to Investor, by any other means, and none of the Company and/or its representatives acted as investment advisor, broker or dealer to Investor. The Investor is not purchasing the Securities as a result of
any general or public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television,
radio or the internet or presented at any seminar or any other general solicitation or general advertisement, including any of the methods described in Section&nbsp;502(c) of Regulation D under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12 <U>Access to Information</U>. The Investor acknowledges and agrees that the Investor and the Investor&#146;s professional advisor(s), if
any, have had the opportunity to ask such questions, receive such answers and obtain such information from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities as the Investor and the
Investor&#146;s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Securities and that the Investor has independently made its own analysis and decision to invest in the Company. Neither such
inquiries nor any other due diligence investigation conducted by the Investor shall modify, limit or otherwise affect the Investor&#146;s right to rely on the Company&#146;s representations and warranties contained in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.13 <U>Certain Trading Activities</U>. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person
acting on behalf of or pursuant to any understanding with the Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that the Investor was
first contacted by the Company or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date of this Agreement. Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment
vehicle whereby separate portfolio managers manage separate portions of such Investor&#146;s assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor&#146;s assets, the representation set forth
above shall only apply with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement and to its
advisors and agents who had a need to know such information, the Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to
effect Short Sales or similar transactions in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Covenants</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <U>Further Assurances</U>. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants
and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes of this Agreement, subject to the terms and conditions of this Agreement and compliance with
applicable law, including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto in complying with the terms of this Agreement. The Investor acknowledges that the
Company will rely on the acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing, the Investor agrees to promptly notify the Company if any of the acknowledgments, understandings,
agreements, representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4</U> of this Agreement are no longer accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2
<U>Listing</U>. The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Global Select Market and, in accordance therewith, will use reasonable best efforts to comply in all material
respects with the Company&#146;s reporting, filing and other obligations under the rules and regulations of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Disclosure of
Transactions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day immediately following the
date of this Agreement, file with the SEC a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (including all exhibits thereto, the &#147;<B>Disclosure Document</B>&#148;) disclosing (i)&nbsp;all material terms of the transactions
contemplated hereby and by the other Transaction Agreements and attaching a copy of the form of this Agreement and the other Transaction Agreements as exhibits to such Disclosure Document and (ii)&nbsp;all material
<FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company disclosed to the Investors. Following the filing of the Disclosure Document, no Investor shall be in possession of any material
<FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company disclosed to the Investors by the Company or its representatives. The Company understands and confirms that the Investors will rely on the foregoing representation
in effecting securities transactions. Notwithstanding anything in this Agreement to the contrary, the Company shall not publicly disclose the name of any Investor or any of its affiliates or advisers, or include the name of any Investor or any of
its affiliates or advisers in any press release or filing with the SEC (other than any registration statement contemplated by the Registration Rights Agreement) or any regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agency, without the prior written consent of the Investor, except (i)&nbsp;as required by the federal securities laws in connection with (A)&nbsp;any registration statement contemplated by the
Registration Rights Agreement and (B)&nbsp;the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii)&nbsp;to the extent such disclosure is required by law, at the request of
the staff of the SEC or regulatory agency or under the regulations of the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Integration</U>. The
Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of
the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Investors, or that will be integrated with the offer
or sale of the Securities for purposes of the rules and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of
such subsequent transaction, and other than the issuance of securities to Yantai Rongpu Investment Partnership (Limited Partnership), a subsidiary of RemeGen Co., Ltd., as contemplated by the RemeGen License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <U>Removal of Legends</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In connection with any sale, assignment, transfer or other disposition of the Warrant Shares by an Investor pursuant to Rule 144 or
pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the
Company shall request the Transfer Agent to remove any restrictive legends related to the book entry account holding such shares and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends as soon as
reasonably practicable following any such request therefor from the Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection
therewith. The Company shall be responsible for the fees of its Transfer Agent and its legal counsel associated with such legend removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation
reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Warrant Shares (i)&nbsp;have been registered under the Securities Act pursuant to an effective registration statement;
(ii)&nbsp;have been sold pursuant to Rule 144, or (iii)&nbsp;are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information requirements under Rule 144(c)(1) (or any
successor provision), the Company shall, in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;5.5(b)</U> and as soon as reasonably practicable following any request therefor from an Investor accompanied by such customary and
reasonably acceptable documentation referred to above, (A)&nbsp;deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry shares, and (B)&nbsp;cause its counsel to deliver
to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of the legend in accordance with the
provisions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <U>Withholding Taxes</U>. Each Investor agrees to furnish the Company with any
information, representations and forms as shall reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7 <U>Fees and Commissions</U>. The Company shall be solely responsible for the payment of any placement agent&#146;s fees, financial
advisory fees, or broker&#146;s commissions (other than for Persons engaged by an Investor) relating to or arising out of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8 <U>No Conflicting Agreements</U>. The Company will not take any action, enter into any agreement or make any commitment that would
conflict or interfere in any material respect with the Company&#146;s obligations to the Investors under the Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9
<U>Indemnification.</U><U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their
respective directors, officers, trustees, members, managers, employees, investment advisers and agents (collectively, the &#147;<B>Indemnified Persons</B>&#148;), from and against any and all losses, claims, damages, liabilities and expenses
(including without limitation reasonable and documented attorney fees and disbursements and other documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred in connection
with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or
agreement made by or to be performed on the part of the Company under the Transaction Agreements, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally
judicially determined not to have resulted from such Person&#146;s fraud or willful misconduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any person entitled to
indemnification hereunder shall (i)&nbsp;give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel
reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such
counsel shall be at the expense of such person unless (a)&nbsp;the indemnifying party has agreed in writing to pay such fees or expenses, (b)&nbsp;the indemnifying party shall have failed to assume the defense of such claim and employ counsel
reasonably satisfactory to such person or (c)&nbsp;in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in
which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on
behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is
understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying
party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement (i)&nbsp;imposes
no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect of
such claim or litigation in favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing, or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying
party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10 <U>Subsequent Equity Sales</U>. From the date of this Agreement until the earlier of (a)&nbsp;sixty (60) days after the Closing Date and
(b)&nbsp;the Business Day immediately following the effective date of the registration statement filed pursuant to the Registration Rights Agreement (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;), the Company shall
not (A)&nbsp;issue shares of Common Stock or Common Stock Equivalents, (B)&nbsp;effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Stock or (C)&nbsp;file with
the SEC a registration statement under the Securities Act relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement. Notwithstanding the foregoing, the provisions of this
<U>Section</U><U></U><U>&nbsp;5.10</U> shall not apply to (i)&nbsp;the issuance of the Securities hereunder, (ii)&nbsp;the issuance of securities pursuant to the RemeGen License, (iii)&nbsp;the issuance of Common Stock or Common Stock Equivalents
upon the conversion, exercise or vesting of any securities of the Company outstanding on the date of this Agreement or outstanding pursuant to clauses (i), (ii) or (iv)&nbsp;of this sentence, (iv)&nbsp;the issuance of any Common Stock or Common
Stock Equivalents pursuant to any Company stock-based compensation plans or in accordance with Nasdaq Stock Market Rule 5635(c)(4), or (v)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act to register the offer and sale of securities pursuant to an inducement plan, equity incentive plan or employee stock purchase plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11 <U>Reservation of Common Stock</U>. As of the date of this Agreement, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Warrant Shares that are issuable upon the exercise of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12 <U>Stockholder Approval</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall prepare and file with the SEC as promptly as practicable, and in any event within 60 days after the date of this
Agreement, the Proxy Statement in preliminary form. The Company shall use reasonable best efforts to respond as promptly as practicable to any comments of the SEC with respect to the Proxy Statement. Each of the parties hereto shall reasonably
assist and cooperate with the other in connection with any of the actions contemplated by this <U>Section</U><U></U><U>&nbsp;5.12(a)</U>, including the preparation, filing and distribution of the Proxy
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statement and the resolution of any comments in respect thereof received from the SEC. The Company shall give the Investors and their counsel a reasonable opportunity to review and comment on the
Proxy Statement, including all amendments and supplements thereto, prior to filing such documents with the SEC or disseminating to the Company&#146;s stockholders and reasonable opportunity to review and comment on all responses to requests for
additional information and shall, in each case, include all timely comments reasonably requested by the Investors. The Company shall ensure that the Proxy Statement complies in all material respects with the applicable provisions of the Exchange Act
and the rules and regulations thereunder, and the Company covenants that none of the information included or incorporated in the Proxy Statement will, at the date it is filed with the SEC or first mailed to the Company&#146;s stockholders or at the
time of the Company Stockholders Meeting or at the time of any amendment or supplement thereof, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made, not misleading. The Company shall, as promptly as reasonably practicable and permitted by applicable law (but in any event within three (3)&nbsp;Business Days) following
confirmation from the SEC that it will not review, or has completed its review of, the Proxy Statement, which confirmation will be deemed to occur if the SEC has not affirmatively notified the Company prior to the tenth calendar day after filing the
Proxy Statement that the SEC will or will not be reviewing the Proxy Statement (such date, the &#147;<B>SEC Clearance Date</B>&#148;), file a definitive Proxy Statement and related proxy materials with the SEC and thereafter promptly commence
mailing the Proxy Statement to the Company&#146;s stockholders of record as of the record date for the Company Stockholders Meeting. The Company shall use reasonable best efforts to obtain the Company Stockholder Approval. The Company shall be
responsible for 100% of its fees, costs and expenses (including all filing, printing and mailing expenses) associated with the Proxy Statement, with the Company obligated to reimburse the expenses of Covington&nbsp;&amp; Burling LLP, up to a maximum
of $20,000, incurred in connection with review of the Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to <U>Section</U><U></U><U>&nbsp;5.12(a)</U>, the
Company shall take all necessary actions, including in accordance with applicable law, the Amended and Restated Certificate of Incorporation, the Amended and Restated Bylaws and the rules of the National Exchange, to duly call, give notice of,
convene and hold a meeting of the Company&#146;s stockholders (including any adjournment, recess, reconvening or postponement thereof, the &#147;<B>Company Stockholders Meeting</B>&#148;) for the purpose of obtaining the Company Stockholder
Approval, as soon as reasonably practicable after the SEC Clearance Date, and in any event within thirty (30)&nbsp;days of the SEC Clearance Date. The Company shall not postpone or adjourn the Company Stockholders Meeting, except to the extent
advised by counsel to be necessary to comply with applicable law. Notwithstanding anything to the contrary contained in this Agreement, the Company may adjourn, recess, reconvene or postpone the Company Stockholders Meeting if the Company reasonably
believes that (i)&nbsp;such adjournment, recess, reconvening or postponement is necessary to ensure that any supplement or amendment to the Proxy Statement that is required by applicable law is provided to the Company&#146;s stockholders within a
reasonable amount of time in advance of the Company Stockholders Meeting, (ii)&nbsp;as of the time for which the Company Stockholders Meeting is originally scheduled (as set forth in the Proxy Statement), (A) there will be an insufficient number of
shares of Common Stock present (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders Meeting or (B)&nbsp;there will be an insufficient number of proxies to obtain the Company Stockholder
Approval or approve any other matter to be voted upon at the Company Stockholders Meeting, or (iii)&nbsp;such adjournment, recess, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reconvening or postponement is required by applicable law or a court or other governmental entity of competent jurisdiction or has been requested in writing by the SEC or its staff. If the
Company does not obtain Company the Stockholder Approval at the first meeting, the Company shall call a meeting every ninety (90)&nbsp;days thereafter to seek Company Stockholder Approval until the Company Stockholder Approval is obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.13 <U>Board Observer Right</U>. Commencing on the date of this Agreement and ending on the date on which Forbion Growth Opportunities Fund
III Co&ouml;peratief U.A. (&#147;<B>Forbion</B>&#148;) together with its Affiliates (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act) ceases to beneficially own at any time 4.99% or more of the then
issued and outstanding Common Stock, the Company shall invite a single representative of Forbion (the &#147;<B>Forbion</B><B> Observer</B>&#148;), as designated by Forbion from time to time and reasonably acceptable to the Company to attend and
participate in all meetings of the Board of Directors, in a nonvoting observer capacity, with such designation contingent upon such Forbion Observer (i)&nbsp;entering into a confidentiality agreement with the Company (to the extent not currently in
place) and (ii)&nbsp;agreeing, solely in such individual&#146;s capacity as the Forbion Observer, to be bound by the Company&#146;s insider trading and window policies then in effect and applicable to members of the Board of Directors, and any other
policy as the Board of Directors reasonably believes is necessary in order to allow for participation in meetings of the Board of Directors. In this respect, the Company shall give the Forbion Observer (i)&nbsp;written notice of, agendas and
participation details for such meetings and (ii)&nbsp;copies of all notices, minutes, consents, and other materials, in each case, that it provides to the members of the Board of Directors, as applicable, at the same time and in the same manner as
provided to such members; provided, however, that the Company reserves the right to withhold any information and to exclude the Forbion Observer from any meeting or portion thereof if the Company believes that such exclusion is reasonably necessary
to preserve attorney-client privilege, to protect confidential proprietary information, to allow the Board of Directors to meet in executive session or for similar reasons. The Company shall notify the Forbion Observer in advance of any meeting (or
portion thereof) from which the Forbion Observer is to be excluded and shall provide such materials that do not relate to attorney-client privilege or confidential proprietary information. The Company will reimburse the Forbion Observer for their
reasonable and customary travel expenses for attendance at quarterly <FONT STYLE="white-space:nowrap">in-person</FONT> meetings of the Board of Directors, consistent with its policy for reimbursement of such expenses for directors. For purposes of
this section, the calculation of 4.99% beneficial ownership shall assume the exercise of all of the Warrants then outstanding (including Warrants held by Forbion and its Affiliates), without regard to any beneficial ownership limitations in such
Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>Conditions to the Obligation of the Investors</U>. The several obligations of each Investor to consummate the transactions to be
consummated at the Closing, and to purchase and pay for the Securities being purchased by it at the Closing pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all
material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the date of this Agreement and as of the Closing Date, as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true
and correct in all material respects as of such earlier date, except for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. The Company shall have performed in all material respects the obligations and conditions herein required to be
performed or observed by the Company on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>No Injunction</U>. The purchase of and payment for the
Securities by each Investor shall not be prohibited or enjoined by any law or governmental or court order or regulation and no such prohibition shall have been threatened in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Consents</U>. The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the
consummation of the purchase and sale of the Securities, all of which shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) [Reserved] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <U>Adverse Changes</U>. Since the date of this Agreement, no event or series of events shall have occurred that has had or would
reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>Opinion of Company Counsel</U>. The Company shall have delivered to the
Investors the opinion of Cooley LLP, dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Investors and addressing such legal matters as the Investors and the Company reasonably agree. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) <U>Compliance Certificate</U>. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a
certificate certifying that the conditions specified in <U>Sections 6.1(a) (Representations and Warranties)</U>, <U>6.1(b) (Performance)</U>, <U>6.1(c) (No Injunction)</U>, <U>6.1(d) (Consents)</U>, <U>6.1(f) (Adverse Changes)</U>, <U>6.1(k)
(Listing Requirements),</U> <U>6.1(l) (No Injunction)</U> and 6.1(m) <U>(No Sensitive Personal Data)</U> of this Agreement have been fulfilled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Secretary&#146;s Certificate</U>. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate
certifying (i)&nbsp;the Amended and Restated Certificate of Incorporation; (ii)&nbsp;the Amended and Restated Bylaws; and (iii)&nbsp;resolutions of the Company&#146;s Board of Directors (or an authorized committee thereof) approving this Agreement,
the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the Securities and the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) <U>Registration Rights Agreement</U>. The Company shall have executed and delivered the Registration Rights Agreement in the form
attached hereto as <U>Exhibit B</U> (the &#147;<B>Registration Rights Agreement</B>&#148;) to the Investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) <U>Listing Requirements</U>. No stop order or suspension of trading shall have been
imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. The Common Stock shall be listed on a National Exchange and shall not have been suspended, as of the Closing Date, by the SEC
or the National Exchange from trading thereon nor shall suspension by the SEC or the National Exchange have been threatened, as of the Closing Date, in writing by the SEC or the National Exchange; and the Company shall have filed with Nasdaq a
Notification Form: Listing of Additional Shares for the listing of the Warrant Shares and Nasdaq shall have raised no objection to such notice and the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) <U>No Injunction</U>. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate,
including any bankruptcy court or judge, or any order of or by any governmental entity, shall have been issued, and no action or proceeding shall have been instituted by any governmental entity, enjoining or preventing the consummation of the
transactions contemplated hereby or in the other Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) <U>No Sensitive Personal Data</U>. All activities of the
Company related to the Company&#146;s trem-cel, VCAR and ADC programs have been discontinued and the Company has deleted, destroyed, or otherwise no longer possesses or has access to any data that would qualify as &#147;bulk U.S. sensitive personal
data&#148; under 28 C.F.R. 202.206 derived from such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Payment</U>. The Company shall have received payment, by wire
transfer of immediately available funds, in the full amount of the purchase price for the number of Securities being purchased by each Investor at the Closing as set forth in <U>Exhibit A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Conditions to the Obligation of the Company</U>. The obligation of the Company to consummate the transactions to be consummated at the
Closing, and to issue and sell to each Investor the Securities to be purchased by it at the Closing pursuant to this Agreement, is subject to the satisfaction or waiver in writing of the following conditions precedent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of each Investor in <U>Section</U><U></U><U>&nbsp;4</U> hereto
shall be true and correct on and as of the Closing Date, with the same force and effect as though made on and as of the Closing Date and consummation of the Closing shall constitute a reaffirmation by the Investor of each of the representations,
warranties, covenants and agreements of the Investor contained in this Agreement as of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. Each
Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed or observed by such Investor on or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Injunction</U>. The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or
governmental or court order or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Registration Rights Agreement</U>. Each Investor shall have executed and delivered the
Registration Rights Agreement to the Company in the form attached as <U>Exhibit</U><U></U><U>&nbsp;B</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Payment</U>. The Company shall have received payment, by wire transfer of
immediately available funds, in the full amount of the purchase price for the number of Securities being purchased by each Investor at the Closing as set forth in <U>Exhibit A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Termination</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1
<U>Termination</U>. The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Upon the mutual written consent of the Company and the Investors that agreed to purchase a majority of the Securities prior to the
Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) By the Company if any of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6.2</U> shall have become incapable of
fulfillment, and shall not have been waived by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) By an Investor (with respect to itself only) if any of the conditions
set forth in <U>Section</U><U></U><U>&nbsp;6.1</U> shall have become incapable of fulfillment, and shall not have been waived by such Investor; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) By either the Company or an Investor (with respect to itself only) if the Closing has not occurred on or prior to the fifth Business Day
following the date of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">provided, however, that, in the case of clauses (ii)&nbsp;and (iii) above, the party seeking to
terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted in the circumstances giving rise to
such party&#146;s seeking to terminate its obligation to effect the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <U>Notice</U>. In the event of termination by the
Company or the Investor of its obligations to effect the Closing pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, written notice thereof shall be given to the other Investors by the Company. Nothing in this <U>Section</U><U></U><U>&nbsp;7</U>
shall be deemed to release any party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party of its other
obligations under the Transaction Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Miscellaneous Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <U>Public Statements or Releases</U>. Except as set forth in <U>Section</U><U></U><U>&nbsp;5.3</U>, neither the Company nor any Investor
shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld). Notwithstanding the
foregoing, and subject to compliance with <U>Section</U><U></U><U>&nbsp;5.3</U>, nothing in this <U>Section</U><U></U><U>&nbsp;8.1</U> shall prevent any party from making any public announcement it considers necessary in order to satisfy its
obligations under the law, including applicable securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall allow the Investors reasonable time to comment on such release or
announcement in advance of such issuance, and the Company will consider in good faith any Investor comments. The Company shall not include the name of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC) without the prior written consent of the Investors, except
as otherwise required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company shall allow the Investors, to the extent reasonably practicable in the circumstances, reasonable time to
comment on such release or announcement in advance of such issuance. Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;8.1</U>, Investor review shall not be required for Company disclosures that are substantially
consistent with prior Company disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <U>Notices</U>. Any notices or other communications required or permitted to be given
hereunder shall be in writing and shall be deemed to be given (a)&nbsp;when delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by electronic mail during normal business hours of the recipient,
and if not sent during normal business hours, then the earlier of (x)&nbsp;confirmation of receipt or (y)&nbsp;on the open of business on the recipient&#146;s next Business Day, (c)&nbsp;three (3) days after having been sent by certified or
registered mail, return-receipt requested and postage prepaid, or (d)&nbsp;one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of
receipt: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If to the Company, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Vor Biopharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">100
Cambridgepark Drive, Suite 101 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Attention: Jean-Paul Kress </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:15%; font-size:10pt; font-family:Times New Roman">with a copy (which
shall not constitute notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">New York, New
York 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Attention: Divakar Gupta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If to any
Investor, at its address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth on <U>Exhibit A</U>, or such address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;8.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <U>Consent to Electronic Notice</U>. Each Investor consents to the delivery of any stockholder notice pursuant to the DGCL, as amended or
superseded from time to time, by electronic mail pursuant to Section&nbsp;232 of the DGCL (or any successor thereto) at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth below the Investor&#146;s name on the signature page or
<U>Exhibit A</U>, as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected <FONT STYLE="white-space:nowrap">e-mail</FONT> address has
been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its <FONT STYLE="white-space:nowrap">e-mail</FONT> address, and that
failure to do so shall not affect the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <U>Severability</U>. If any part or provision of this Agreement is held
unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of
such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 <U>Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws
or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles of Delaware law may apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company and each of the Investors hereby irrevocably and unconditionally: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated
hereby, to the general jurisdiction of the any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in the State of New York; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to
the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified
mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in <U>Section</U><U></U><U>&nbsp;8.2</U> or at such other address of which the other party shall have been notified
pursuant thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by
law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i)&nbsp;are not available despite the intentions of the parties
hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of
any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) agrees that to the extent that such party has or hereafter may acquire any immunity
from jurisdiction of any court or from any legal process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <U>Waiver</U>. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more
instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <U>Expenses</U>. Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses, including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed
investment in the Securities and the consummation of the transactions contemplated thereby; provided, however, that the Company shall pay all Transfer Agent fees (including, without limitation, any fees required for
<FONT STYLE="white-space:nowrap">same-day</FONT> processing of any instruction letter delivered by the Company), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of any Securities to the
Investors. Notwithstanding the foregoing, the Company shall pay the fees and expenses of Covington&nbsp;&amp; Burling, LLP and Beijing Tian Yuan Law Firm, counsels for the Investors, as well as expenses incurred by the Investors in their evaluation
of the Company and the other parties to this Agreement, including, without limitation, expenses related to third-party services customarily engaged in connection with such evaluation. The aggregate amount of fees and expenses to be reimbursed
pursuant to the preceding sentence shall not exceed (a) with respect to fees and expenses of Covington &amp; Burling LLP, $150,000, exclusive of the amounts to be reimbursed pursuant to <U>Section</U><U></U><U>&nbsp;5.12(a)</U>, and (b) with respect
to fees of Beijing Tian Yuan Law Firm, $150,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <U>Assignment</U>. None of the parties may assign its rights or obligations under
this Agreement or designate another person (i)&nbsp;to perform all or part of its obligations under this Agreement or (ii)&nbsp;to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of
(x)&nbsp;the Company, in the case of an Investor, and (y)&nbsp;the Investors, in the case of the Company, provided that an Investor may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder to any of its
affiliates or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of such Investor (provided each such assignee agrees to be bound by the terms of this Agreement and makes the same
representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4</U> ). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement
by executing a writing agreeing to be bound by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an
assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <U>Confidential Information</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each Investor covenants that until such time as the transactions contemplated by this Agreement and any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information provided to such Investor are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction), other than to such Investor&#146;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or
required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The
Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate the eligibility of the Investor to acquire the Securities, and the Investor shall promptly provide such
information as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor confidential, except (i)&nbsp;as required by the federal securities laws, rules or
regulations and (ii)&nbsp;to the extent such disclosure is required by other laws, rules or regulations, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq. The Investor acknowledges that the Company may
file a copy of this Agreement and the Registration Rights Agreement with the SEC as exhibit to a periodic report or a registration statement of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10 [Reserved] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.11 <U>Third
Parties</U>. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no
Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a
derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby. Notwithstanding the foregoing, the Indemnified Persons are
intended third-party beneficiaries of <U>Section</U><U></U><U>&nbsp;5.9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.12 <U>Independent Nature of Investors</U><U>&#146;</U><U>
Obligations and Right</U><U>.</U> The obligations of each Investor under this Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance obligations of any
other Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such obligations or the
transactions contemplated by this Agreement. The Company acknowledges and each Investor confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each
Investor also acknowledges that Cooley LLP has not rendered legal advice to such Investor. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and
it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company has elected to provide all Investors with the same terms and Transaction Agreements for the convenience of the
Company and not because it was required or requested to do so by any Investor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.13 <U>Headings</U>. The titles, subtitles and headings in this Agreement are for
convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.14 <U>Counterparts</U>. This
Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that
a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and
effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.15 <U>Entire
Agreement; Amendments</U>. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto), together with any side letter agreements with any of the Investors, constitute the entire agreement between the
parties hereto respecting the subject matter of this Agreement and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter of this Agreement, whether written or oral. No amendment,
modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed by the Company and the Investors of at least a majority in interest of the
Securities then held by the Investors, provided that prior to the Closing the consent of all Investors shall be required. Notwithstanding the foregoing, this Agreement may not be amended and the observance of any term of this Agreement may not be
waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to all Investors in the same fashion. The Company, on the one hand, and each Investor, on the other hand, may by an instrument
signed in writing by such parties waive the performance, compliance or satisfaction by such Investor or the Company, respectively, with any term or provision of this Agreement or any condition hereto to be performed, complied with or satisfied by
such Investor or the Company, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.16 <U>Survival</U>. The covenants, representations and warranties made by each party hereto
contained in this Agreement shall survive the Closing and the delivery of the Securities in accordance with their respective terms. Each Investor shall be responsible only for its own representations, warranties, agreements and covenants hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.17 <U>Contract Interpretation</U><U>.</U> This Agreement is the joint product of each Investor and the Company and each provision of
this Agreement has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.18 <U>Arm</U><U>&#146;</U><U>s Length Negotiations</U>. For the avoidance of doubt, the parties acknowledge and confirm that the terms and
conditions of the Securities were determined as a result of <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Vor Biopharma Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[NAME]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: [&#149;]</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>d27026dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS REGISTRATION RIGHTS AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;), dated as of June 25, 2025, is entered into by and among Vor
Biopharma Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), and the several investors signatory hereto (individually as an &#147;<B>Investor</B>&#148; and collectively together with their respective permitted assigns, the
&#147;<B>Investors</B>&#148;).&nbsp;Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among certain of the parties hereto, dated as of the date
hereof (as amended, restated, supplemented or otherwise modified from time to time, the &#147;<B>Purchase Agreement</B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Upon the
terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to certain of the Investors, and such Investors have agreed to purchase, severally and not jointly, <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants (the &#147;<B><FONT STYLE="white-space:nowrap">Pre-funded</FONT></B> <B>Warrants</B>&#148;) to purchase up to an aggregate of 700,000,000 shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;<B>Common
Stock</B>&#148;) pursuant to the Purchase Agreement. Upon the terms and subject to the License Agreement dated June 25, 2025, by and between the Company and RemeGen Co., Ltd. (&#147;<B>RemeGen</B>&#148;) (the &#147;<B>License Agreement</B>&#148;),
the Company has agreed to issue Yantai Rongpu Investment Partnership (Limited Partnership), a subsidiary of RemeGen, warrants (the &#147;<B>RemeGen</B><B> Warrants</B>&#148; and together with the <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrants, the &#147;<B>Warrants</B>&#148;) to purchase up to an aggregate of 320,000,000 shares of Common Stock pursuant to the License Agreement. The shares of Common Stock issuable upon exercise of the Warrants, without giving effect to any
limitations on exercise of the Warrants, and assuming all of the Warrants are exercised for cash, are collectively referred to herein as the &#147;<B>Shares</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. To induce the Investors to enter into the Purchase Agreement or the License Agreement, as applicable, the Company has agreed to provide
certain registration rights under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &#147;<B>Securities Act</B>&#148;), and applicable state securities laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the promises and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>1.
DEFINITIONS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Person</B>&#148; means an individual, partnership, corporation, limited liability company, business trust, joint stock company,
trust, unincorporated association, joint venture or any other entity or organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Register</B>,&#148;
&#147;<B>Registered</B>,&#148; and &#147;<B>Registration</B>&#148; refer to a registration effected by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and providing for offering
securities on a continuous basis, and the declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Registrable Securities</B>&#148; means the Shares and any Common Stock issued or issuable with respect to the Shares as a result
of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be Registrable Securities upon the date on which the Investors shall have resold all the Registrable Securities
covered by the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Registration Expenses</B>&#148; means all registration and filing fee expenses
incurred by the Company in effecting any registration pursuant to this Agreement, including (i)&nbsp;all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated with filings required to be made
with the SEC, FINRA or any other regulatory authority, (ii)&nbsp;all fees and expenses in connection with compliance with or clearing the Registrable Securities for sale under any securities or &#147;Blue Sky&#148; laws, (iii)&nbsp;all printing,
duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv)&nbsp;all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of
any special audit and cold comfort letters required by or incident to such performance). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Registration Statement</B>&#148;
means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act, that Registers Registrable Securities, including the related prospectus, amendments and supplements to such registration statement,
including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws.
&#147;Registration Statement&#148; shall also include a New Registration Statement (as defined below), as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including any
information contained in a prospectus subsequently filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Selling Expenses</B>&#148; means all underwriting
discounts and selling commissions applicable to the sale of Registrable Securities and all similar fees and commissions relating to the Investors&#146; disposition of the Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2. REGISTRATION. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Mandatory Registration</U>.&nbsp;The Company shall, as promptly as reasonably practicable and in any event no later than thirty (30)&nbsp;days after Company Stockholder Approval (the &#147;<B>Filing Deadline</B>&#148;), prepare and file with the
SEC an initial Registration Statement (the &#147;<B>Initial Registration Statement</B>&#148;) covering the resale of all Registrable Securities. Before filing the Registration Statement, the Company shall furnish to the Investors a copy of the
Registration Statement. The Investors and their counsel shall have at least three Business Days prior to the anticipated filing date of a Registration Statement to review and comment upon such Registration Statement and any amendment or supplement
to such Registration Statement and any related prospectus, prior to its filing with the SEC; provided that, in connection with such review, the Company shall pay the reasonable fees and expenses of (i)&nbsp;outside counsel of the Investors
collectively in an amount not to exceed, in the aggregate, $15,000 and (ii)&nbsp;outside counsel of RemeGen, in an amount not to exceed, in the aggregate, $15,000 (the &#147;<B>Outside Counsel Registration Expenses</B>&#148;). Subject to any SEC
comments, such Registration Statement shall include the plan of distribution substantially in the form attached hereto as <U>Exhibit A</U>. The Company shall (a)&nbsp;use commercially reasonable efforts to address in each such document prior to
being so filed with the SEC such comments as the Investor or its counsel reasonably proposed by the Investor, and (b)&nbsp;not file any Registration Statement or related prospectus or any amendment or supplement thereto containing information
regarding the Investor to which Investor reasonably objects, unless such information is required to comply with any applicable law or regulation. The Investors shall furnish all information reasonably requested by the Company and as shall be
reasonably required in connection with any registration referred to in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Effectiveness.</U>&nbsp;The Company shall use its reasonable best efforts to have the
Initial Registration Statement and any amendment declared effective by the SEC at the earliest possible date but no later than the earlier of (a)&nbsp;the 75th calendar day following the initial filing date of the Initial Registration Statement if
the SEC notifies the Company that it will &#147;review&#148; the Initial Registration Statement and (b)&nbsp;the fifth Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Initial
Registration Statement will not be &#147;reviewed&#148; or will not be subject to further review (the &#147;<B>Effectiveness Deadline</B>&#148;); <U>p</U><U>rovided</U>,<U>&nbsp;further</U>, that if the SEC is closed for operations due to
a&nbsp;government shutdown&nbsp;or lapse in appropriations, the&nbsp;deadline shall be extended by the same amount of days that the SEC remains closed for operations. The Company shall notify the Investor by
<FONT STYLE="white-space:nowrap">e-mail</FONT> as promptly as practicable, and in any event, within 24 hours, after the Registration Statement is declared effective or is supplemented and shall provide the Investor with copies of any related
prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Company shall use reasonable best efforts to keep the Initial Registration Statement continuously effective pursuant to Rule 415
promulgated under the Securities Act and available for the resale by the Investors of all of the Registrable Securities covered thereby at all times until the earliest to occur of the following events: (i)&nbsp;the date on which the Investors shall
have resold all the Registrable Securities covered thereby; and (ii)&nbsp;the date on which the Registrable Securities may be resold by the Investors without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any
other rule of similar effect (the &#147;<B>Registration Period</B>&#148;). The Initial Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Sufficient Number of Shares Registered</U>.&nbsp;In the event the number of shares available under the Initial Registration Statement
at any time is insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration Statement or file a new registration statement (together with any prospectuses or prospectus
supplements thereunder, a &#147;<B>New Registration Statement</B>&#148;), so as to cover all of such Registrable Securities as soon as reasonably practicable, but in any event not later than ten Business Days after the necessity therefor arises (the
&#147;<B>New Registration Filing Deadline</B>&#148;).&nbsp;The Company shall use its reasonable best efforts to have such amendment and/or New Registration Statement become effective as soon as reasonably practicable following the filing thereof but
no later than the earlier of (a)&nbsp;the 75th calendar day following the initial filing date of the New Registration Statement if the SEC notifies the Company that it will &#147;review&#148; the New Registration Statement and (b)&nbsp;the fifth
Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the New Registration Statement will not be &#147;reviewed&#148; or will not be subject to further review (the earlier of such dates, the
&#147;<B>New Registration Effectiveness Deadline</B>&#148;). The provisions of <U>Section</U><U></U><U>&nbsp;2(a)</U> and <U>(b)</U>&nbsp;shall apply to the New Registration Statement, except as modified hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Liquidated Damages</U>.&nbsp;If (i)&nbsp;the Initial Registration Statement has not been filed by the Filing Deadline, (ii)&nbsp;the
Initial Registration Statement has not been declared effective by the Effectiveness Deadline, (iii)&nbsp;the New Registration Statement has not been filed by the New Registration Filing Deadline, (iv)&nbsp;the New Registration Statement has not been
declared effective by the New Registration Effectiveness Deadline or (v)&nbsp;after any Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to such Registration Statement for any reason (including without
limitation by reason of a stop order, or the Company&#146;s failure to update such Registration Statement), but excluding any Allowed Delay (as defined below) or, if the Registration Statement is on Form <FONT STYLE="white-space:nowrap">S-1,</FONT>
for a period of 20 days following the date on which the Company files a post-effective amendment to incorporate the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (a &#147;<B>Maintenance Failure</B>&#148;), then
the Company will make pro rata payments to each Investor then holding Registrable Securities, as liquidated damages and not as a penalty, in an amount equal to 1.0% of the aggregate amount paid pursuant to the Purchase Agreement by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Investor for such Registrable Securities then held by such Investor for each <FONT STYLE="white-space:nowrap">30-day</FONT> period or pro rata for any portion thereof during which the
failure continues (the &#147;<B>Blackout Period</B>&#148;). Such payments shall constitute the Investors&#146; exclusive monetary remedy for such events, but shall not affect the right of the Investors to seek injunctive relief. The amounts payable
as liquidated damages pursuant to this paragraph shall be paid in cash no later than five Business Days after each such <FONT STYLE="white-space:nowrap">30-day</FONT> period following the commencement of the Blackout Period until the termination of
the Blackout Period (the &#147;<B>Blackout Period Payment Date</B>&#148;). Interest shall accrue at the rate of 1.0% per month on any such liquidated damages payments that shall not be paid by the Blackout Period Payment Date until such amount is
paid in full. Notwithstanding the above, in no event shall the aggregate amount of liquidated damages (or interest thereon) paid under this Agreement to any Investor exceed, in the aggregate, 5.0% of the aggregate purchase price of the Shares
purchased by such Investor under the Purchase Agreement. Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;2(d)</U> to the contrary, during any periods that the Company is unable to meet its obligations hereunder with respect to the
registration of the Registrable Securities because any Investor fails to furnish information required to be provided pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> or <U>Section</U><U></U><U>&nbsp;4(a)</U> within three Business Days of the
Company&#146;s request, any liquidated damages that would otherwise accrue as to such Investor only shall be tolled until such information is delivered to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Allowable Delays.</U>&nbsp;On no more than two occasions and for not more than 30 consecutive days or for a total of not more than 60
days in any 12 month period, the Company may delay the effectiveness of the Initial Registration Statement or any other Registration Statement, or suspend the use of any prospectus included in any Registration Statement, in the event that the
Company determines in good faith that such delay or suspension is necessary to (A)&nbsp;delay the disclosure of material <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company, the disclosure of which at the time is
not, in the good faith opinion of the Company, in the best interests of the Company or (B)&nbsp;amend or supplement the affected Registration Statement or the related prospectus so that such Registration Statement or prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances under which they were made, not misleading
(an &#147;<B>Allowed Delay</B>&#148;); provided, that the Company shall promptly (a)&nbsp;notify each Investor in writing of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such
Investor any material <FONT STYLE="white-space:nowrap">non-public</FONT> information giving rise to an Allowed Delay, (b)&nbsp;advise the Investors in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and
(c)&nbsp;use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
<U>Rule</U><U></U><U>&nbsp;415; Cutback</U>. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in any Registration Statement is not eligible to be made on a delayed or continuous basis under the
provisions of Rule&nbsp;415 under the Securities Act (provided, however, the Company shall be obligated to use reasonable best efforts to advocate with the SEC for the registration of all of the Registrable Securities) or requires any Investor to be
named as an &#147;underwriter,&#148; the Company shall (i)&nbsp;promptly notify each holder of Registrable Securities thereof and (ii)&nbsp;make commercially reasonable efforts to persuade the SEC that the offering contemplated by such Registration
Statement is a valid secondary offering and not an offering &#147;by or on behalf of the issuer&#148; as defined in Rule&nbsp;415 and that none of the Investors is an &#147;underwriter.&#148; The Investors shall have the right to select one legal
counsel, at such Investor&#146;s expense, to review and oversee any registration or matters pursuant to this <U>Section</U><U></U><U>&nbsp;2(f)</U>, including participation in any meetings or discussions with the SEC regarding the SEC&#146;s
position and to comment on any written submission made to the SEC with respect thereto. No such written submission with respect to this matter shall be made to the SEC to which any Investor&#146;s counsel reasonably objects. In the event that,
despite the Company&#146;s reasonable best efforts and compliance with the terms of this <U>Section</U><U></U><U>&nbsp;2(f)</U>, the SEC refuses to alter its position, the Company shall (i)&nbsp;remove from such Registration Statement such portion
of the Registrable Securities (the &#147;<B>Cut Back Shares</B>&#148;) and/or (ii)&nbsp;agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require to assure the Company&#146;s compliance with the requirements of Rule&nbsp;415 (collectively, the &#147;<B>SEC Restrictions</B>&#148;); provided, however, that the Company shall not name
any Investor as an &#147;underwriter&#148; in such Registration Statement without the prior written consent of such Investor (provided that, in the event an Investor withholds such consent, the Company shall have no obligation hereunder to include
any Registrable Securities of such Investor in any Registration Statement covering the resale thereof until such time as the SEC no longer requires such Investor to be named as an &#147;underwriter&#148; in such Registration Statement or such
Investor otherwise consents in writing to being so named). Any <FONT STYLE="white-space:nowrap">cut-back</FONT> imposed on the Investors pursuant to this <U>Section</U><U></U><U>&nbsp;2(f)</U> shall be allocated among the Investors on a pro rata
basis and shall be applied first to any of the Registrable Securities of such Investor as such Investor shall designate, unless the SEC Restrictions otherwise require or provide or the Investors otherwise agree. No liquidated damages shall accrue as
to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions applicable to such Cut Back Shares (such date, the &#147;<B>Restriction Termination
Date</B>&#148;). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section&nbsp;2 (including the Company&#146;s obligations with respect to the filing of a Registration Statement and its
obligations to use reasonable best efforts to have such Registration Statement declared effective within the time periods set forth herein and the liquidated damages provisions relating thereto) shall again be applicable to such Cut Back Shares;
provided, however, that the date by which the Company is required to file the Registration Statement with respect to such Cut Back Shares shall be the tenth day following the Restriction Termination Date and the date by which the Company is required
to have the Registration Statement effective with respect to such Cut Back Shares shall be the 55<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day immediately after the Restriction Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>3. RELATED COMPANY OBLIGATIONS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Registration Statement and whenever any Registrable Securities are to be Registered pursuant to
<U>Section</U><U></U><U>&nbsp;2</U>, including on the Initial Registration Statement or on any New Registration Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable Securities in accordance with
the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Notifications</U>. The Company will promptly notify the Investors when any subsequent amendment to the Initial Registration Statement or any New Registration Statement, other than documents incorporated by reference, has been filed with the SEC
and/or has become effective or where a receipt has been issued therefor or any subsequent supplement to a prospectus has been filed and of any request by the SEC for any amendment or supplement to the Registration Statement, any New Registration
Statement or any prospectus or for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendments.</U> The Company will prepare and file with the SEC any
amendments, post-effective amendments or supplements to the Initial Registration Statement, any New Registration Statement or any related prospectus, as applicable, that, (a)&nbsp;as may be necessary to keep such Registration Statement effective for
the Registration Period and to comply with the provisions of the Securities Act and the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;) with respect to the distribution of all of the Registrable Securities covered
thereby, or (b)&nbsp;in the reasonable opinion of the Investors and the Company, as may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Investor Review</U>. The Company will not file any amendment or supplement to the Registration Statement, any New Registration
Statement or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A)&nbsp;the Investors and their counsel shall have been advised and
afforded the opportunity to review and comment thereon at least three (3)&nbsp;Business Days prior to filing with the SEC and (B)&nbsp;the Company shall have given reasonable due consideration to any comments thereon received from the Investors or
their counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Copies Available</U>. The Company will furnish to any Investor whose Registrable
Securities are included in any Registration Statement and its counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein), any prospectus supplement thereunder, any New
Registration Statement and all amendments to the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such
period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to
such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment) and such other documents as Investor may reasonably request in order to facilitate the disposition of the
Registrable Securities owned by Investor that are covered by such Registration Statement, in each case as soon as reasonably practicable upon such Investor&#146;s request and in such quantities as such Investor may from time to time reasonably
request; provided, however, that the Company shall not be required to furnish any document to the Investor to the extent such document is available on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Notification of Stop Orders; Material Changes</U>. The Company shall use commercially reasonable efforts to (i)&nbsp;prevent the
issuance of any stop order or other suspension of effectiveness and, (ii)&nbsp;if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Investors promptly (but in no event later than 24
hours) and shall confirm such advice in writing, in each case: (i)&nbsp;of the Company&#146;s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a supplement to the Registration
Statement or any prospectus or for any additional information; (ii)&nbsp;of the Company&#146;s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of the
Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration Statement, or of the Company&#146;s receipt of any notification of the suspension of qualification of the
Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii)&nbsp;of the Company becoming aware of the happening of any event, which makes any statement of
a material fact made in any Registration Statement or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any prospectus in order to state a material fact
required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend
any Registration Statement or any prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth in clause (i)&nbsp;to
(iii) of the immediately preceding sentence (each, a &#147;<B>Suspension Event</B>&#148;), but rather, shall only be required to disclose that the event has occurred. If at any time the SEC, or any other federal or state governmental authority shall
issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, the Company shall use its reasonable best efforts to obtain the withdrawal of such order
at the earliest practicable time. The Company shall furnish to the Investors, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental authority to the Company or its
representatives relating to the Initial Registration Statement, any New Registration Statement or any prospectus, or prospectus supplement as the case may be. In the event of a Suspension Event set forth in clause (iii)&nbsp;of the first sentence of
this <U>Section</U><U></U><U>&nbsp;3(e)</U>, the Company will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements
may resume; provided, however, that if the Company has a bona fide business purpose for not making such information public, the Company may suspend the use of all Registration Statements for up to 60 consecutive calendar days; provided, further,
that the Company may not suspend the use of all Registration Statements more than twice, or for more than 90 total calendar days, in each case during any twelve-month period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Confirmation of Effectiveness</U>. If reasonably requested by an Investor at any time
in respect of any Registration Statement, the Company shall deliver to such Investor a written confirmation from Company&#146;s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason
(including, without limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Listing</U>. The Company shall use best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on
the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Compliance</U>. The Company shall otherwise use best efforts to comply with all applicable rules
and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424
under the Securities Act, promptly inform the Investor in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a
prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its security holders, as
soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least 12 months, beginning after the effective date of each Registration Statement, which earnings statement
shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this <U>subsection 3(h)</U>, &#147;<B>Availability Date</B>&#148; means the 45<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day following the end of the fourth fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the
Company&#146;s fiscal year, &#147;<B>Availability Date</B>&#148; means the 90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day after the end of such fourth fiscal quarter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U><FONT STYLE="white-space:nowrap">Blue-Sky</FONT></U>. The Company shall register or qualify or cooperate with the Investor and their
counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by the Investor; provided, however, that the Company
shall not be required in connection therewith or as a condition thereto to (i)&nbsp;qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this <U>Section</U><U></U><U>&nbsp;3(</U><U>i</U><U>)</U>,
(ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this <U>Section</U><U></U><U>&nbsp;3(</U><U>i</U><U>)</U>, or (iii)&nbsp;file a general consent to service of process in any such
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Rule 144</U>. With a view to making available to the Investors the benefits of Rule&nbsp;144 (or its successor rule)
and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to: (i)&nbsp;make and keep adequate current public information
available, as those terms are understood and defined in Rule&nbsp;144, until the earlier of (A)&nbsp;six months after such date as all of the Registrable Securities may be sold without restriction by the holders thereof pursuant to Rule&nbsp;144 or
any other rule of similar effect or (B)&nbsp;such date as there are no longer Registrable Securities; and (ii)&nbsp;file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act;
(iii)&nbsp;furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A)&nbsp;a written statement by the Company that it has complied with the reporting requirements of the Exchange Act,
(B)&nbsp;a copy of or electronic access to the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and (C)&nbsp;such other
information as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Cooperation.</U>&nbsp;The Company shall cooperate with the holders of the Registrable
Securities to facilitate the timely preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and
representing such number of shares of Common Stock and registered in such names as the holders of the Registrable Securities may reasonably request to the extent permitted by such Registration Statement or Rule 144 to effect sales of Registrable
Securities ; for the avoidance of doubt, the Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company&#146;s Direct Registration System. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>4. OBLIGATIONS OF THE INVESTORS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Investor Information</U>. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as <U>Exhibit
B</U> in connection with the registration of the Registrable Securities. If the Company has not received such completed Investor Questionnaire from an Investor within three Business Days of the Company&#146;s request, the Company may file the
Registration Statement without including such Investor&#146;s Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Suspension of Sales</U>. Each Investor,
severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence of Suspension Event as set forth in <U>Section</U><U></U><U>&nbsp;3(e)</U>, the Investor will immediately discontinue
disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor&#146;s receipt of a notice from the Company confirming the resolution of such Suspension Event and that such
dispositions may again be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Investor Cooperation</U>. Each Investor, severally and not jointly with any other Investor, agrees
to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has
notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>5.
EXPENSES OF REGISTRATION. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be
borne by the Company. Pursuant to Section&nbsp;2(a), the Company shall also pay the Outside Counsel Registration Expenses. All Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors pro rata on
the basis of the number of Registrable Securities so registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>6. INDEMNIFICATION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investors, each Person,
if any, who controls the Investors, the members, the directors, officers, partners, employees, members, managers, agents, representatives and advisors of the Investors and each Person, if any, who controls the Investors within the meaning of the
Securities Act or the Exchange Act (each, an &#147;<B>Indemnified Person</B>&#148;), against any losses, obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs
and costs of preparation), reasonable and documented attorneys&#146; fees, amounts paid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in settlement or reasonable and documented expenses, (collectively, &#147;<B>Claims</B>&#148;) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry,
proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an Indemnified Person is or may be a
party thereto (&#147;<B>Indemnified Damages</B>&#148;), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i)&nbsp;any
untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, any preliminary prospectus or final prospectus, or any amendment or supplement thereof, or (ii)&nbsp;any
violation or alleged violation by the Company or any of its subsidiaries of the Securities Act, Exchange Act or any other state securities or other &#147;blue sky&#148; laws of any jurisdiction in which Registrable Securities are offered or any rule
or regulation promulgated thereunder applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses
(i)&nbsp;and (ii) being, collectively, &#147;<B>Violations</B>&#148;).&nbsp;The Company shall reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim.&nbsp;Notwithstanding anything to the contrary contained
herein, the indemnification agreement contained in this <U>Section</U><U></U><U>&nbsp;6(a)</U>: (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with
information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement or prospectus and was reviewed and approved in writing by such Investor or such Indemnified Person
expressly for use in connection with the preparation of any Registration Statement, any prospectus or any such amendment thereof or supplement thereto, if such in each case if the foregoing was timely made available by the Company; (B)&nbsp;with
respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any other Indemnified
Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not to use the
outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C)&nbsp;shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which
consent shall not be unreasonably withheld, conditioned or delayed.&nbsp;Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the
Registrable Securities by the Investor pursuant to <U>Section</U><U></U><U>&nbsp;8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with the Initial Registration
Statement, any New Registration Statement or any prospectus, the Investors, severally and not jointly, agree to indemnify, hold harmless and defend, the Company, each of its directors, each of its officers who signed<B> </B>the Initial Registration
Statement or signs any New Registration Statement, each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each, an &#147;<B>Indemnified Party</B>&#148;), against any losses, claims, damages,
liabilities and expense (including reasonable attorney fees) resulting from any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with information about an Investor furnished
in writing by such Investor to the Company and reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement, any
prospectus or any such amendment thereof or supplement thereto. In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim
relating to this <U>Section</U><U></U><U>&nbsp;6</U> and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable Securities
included in such Registration Statement giving rise to such indemnification obligation. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the
transfer of the Registrable Securities by any Investor pursuant to <U>Section</U><U></U><U>&nbsp;8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an Indemnified Person or Indemnified Party under this
<U>Section</U><U></U><U>&nbsp;6</U> of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is
to be made against any indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U>, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the
Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the
Indemnified Party in connection with the defense thereof; provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented without conflict by one
counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of
the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such
proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all
information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim.&nbsp;The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense
or any settlement negotiations with respect thereto.&nbsp;No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not
unreasonably withhold, delay or condition its consent.&nbsp;No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless
such judgment or settlement (i)&nbsp;imposes no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all
liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on
behalf of, the Indemnified Party or Indemnified Person.&nbsp;Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third
parties, firms or corporations relating to the matter for which indemnification has been made.&nbsp;The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve
such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this <U>Section</U><U></U><U>&nbsp;6</U>, except to the extent that the indemnifying party is prejudiced in its ability to defend such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The indemnification required by this <U>Section</U><U></U><U>&nbsp;6</U> shall be made by periodic payments of the amount thereof during
the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.&nbsp;Any Person receiving a payment pursuant to this <U>Section</U><U></U><U>&nbsp;6</U> which person is later determined to not be
entitled to such payment shall return such payment (including reimbursement of expenses) to the person making it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The indemnity
agreements contained herein shall be in addition to (i)&nbsp;any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii)&nbsp;any liabilities the indemnifying party may be
subject to pursuant to the law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7. CONTRIBUTION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum
contribution with respect to any amounts for which it would otherwise be liable under <U>Section</U><U></U><U>&nbsp;6</U> to the fullest extent permitted by law; provided, however, that: (i)&nbsp;no seller of Registrable Securities guilty of
fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii)&nbsp;contribution
by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses paid by such holder in connection with any claim relating to this <U>Section</U><U></U><U>&nbsp;7</U> and the amount of any damages
such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8. ASSIGNMENT OF REGISTRATION RIGHTS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the
prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Warrants then outstanding have been exercised without regard to any limitations on the exercise of such Warrants);
provided, however, that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of
another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#147;Company&#148; shall be deemed to refer to
such Person and the term &#147;Registrable Securities&#148; shall be deemed to include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable by the Investor after giving
effect to such transaction, and the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Warrants then outstanding have been exercised without regard to any limitations
on the exercise of such Warrants) shall not be required for such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">An Investor may transfer or assign its rights hereunder, in
whole or from time to time in part, to one or more Persons in connection with the transfer of not fewer than 500,000 Registrable Securities (including Registrable Securities issuable upon exercise of Warrants), with such number to be adjusted for
any stock split or reverse stock split, by such Investor to such Person,&nbsp;provided&nbsp;that such Investor complies with all laws applicable thereto, and the provisions of the Purchase Agreement (to the extent such Investor is a party thereto)
or the License Agreement (to the extent such Investor is a party thereto), as applicable, and provides written notice of assignment to the Company promptly after such assignment is effected, and such Person agrees in writing to be bound by all of
the provisions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this Agreement shall be binding upon and inure to the benefit of the Investor and its
successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>9. AMENDMENTS AND WAIVERS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a
written instrument executed by (i)&nbsp;the Company and (ii)&nbsp;the holders of a majority of the then outstanding Registrable Securities (determined as if all of the Warrants then outstanding have been exercised without regard to any limitations
on the exercise of such Warrants), provided that any party may give a waiver as to itself and provided further that any amendment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
modification, supplement or waiver that disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other
Investors shall require the prior written consent of such adversely affected Investor or each Investor, as applicable. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates
exclusively to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors may be given by Investors holding all of the Registrable Securities to which such waiver or consent relates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>10. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notices</U>. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to
be given (a)&nbsp;when delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on
the earlier of (x)&nbsp;confirmation of receipt or (y)&nbsp;the opening of business on the recipient&#146;s next Business Day, (c)&nbsp;three days after having been sent by certified or registered mail, return-receipt requested and postage prepaid,
or (d)&nbsp;one Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. If to the Company, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Vor Biopharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">100
Cambridgepark Drive, Suite 101 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Attention: Jean-Paul Kress </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:15%; font-size:10pt; font-family:Times New Roman">with a copy (which
shall not constitute notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">New York, New
York 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Attention: Divakar Gupta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. If to any
Investor, at its <FONT STYLE="white-space:nowrap">e-mail</FONT> address or address set forth on its signature page to the Purchase Agreement or the License Agreement, as applicable, or to such <FONT STYLE="white-space:nowrap">e-mail</FONT> address,
or address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Person may change the
address to which notices and communications to it are to be addressed by notification as provided for herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Consent to
Electronic Notice.</U> Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the &#147;<B>DGCL</B>&#148;), as amended or superseded from time to time, by electronic mail pursuant to
Section&nbsp;232 of the DGCL (or any successor thereto) at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth below the Investor&#146;s name on the signature page, as updated from time to time by notice to the Company. To the
extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected <FONT STYLE="white-space:nowrap">e-mail</FONT> address has been
provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its <FONT STYLE="white-space:nowrap">e-mail</FONT> address, and that
failure to do so shall not affect the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Waiver.</U> No waiver of any term, provision or condition of this Agreement, whether
by conduct or otherwise, in any one or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Governing Law</U>. The provisions of <U>Section</U><U></U><U>&nbsp;8.5</U> of the Purchase Agreement are incorporated by reference
herein <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Headings</U>. The titles, subtitles and headings in this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Counterparts</U>. This Agreement may be
executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the
signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Further Assurances</U>. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
<U>Contract Interpretation</U>. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or
against any party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>No Third Party Beneficiaries</U>. Nothing in this Agreement, express or implied, is intended to confer
on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any
partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a
third party beneficiary with respect to this Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Severability</U>. If any part or
provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent
possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U><FONT STYLE="white-space:nowrap">Non-Recourse</FONT></U>. Notwithstanding anything that may be expressed or implied in this Agreement,
the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, stockholder,
general or limited partner or member of the Investors or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law,
it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, as such for any
obligation of the Investors under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Specific Performance.</U> In addition to any and all other remedies that may be available at law in the event of any breach of this
Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunction or other equitable relief as may be granted by a court of competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <U>Cumulative Remedies</U>. The remedies provided herein are cumulative and not exclusive of any remedies provided by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have caused this Registration Rights Agreement to be
duly executed as of date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Vor Biopharma Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have caused this Registration Rights Agreement to be
duly executed as of date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[NAME]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>d27026dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING AND SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Voting and Support Agreement (this &#147;<U>Agreement</U>&#148;) is entered into as of June&nbsp;25, 2025 by and among Vor Biopharma
Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the stockholder of the Company named on the signature page hereto (the &#147;<U>Stockholder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Concurrently with
the execution and delivery of this Agreement, the Company is entering into a Securities Purchase Agreement (as the same may be amended or supplemented, the &#147;<U>Purchase Agreement</U>&#148;) with certain investors party thereto, which provides,
among other things, for the sale and issuance of warrants (the &#147;<U>PIPE Warrants</U>&#148;) to purchase 700,000,000 shares of the Company&#146;s common stock (the &#147;<U>Common Stock</U>&#148;) by the Company to such investors in a private
investment in public equity financing (the &#147;<U>PIPE</U>&#148;). Capitalized terms used herein that are not defined shall have the meanings set forth in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Following the closing of the PIPE, the Company intends to duly call, give notice of, convene and hold a meeting of the Company&#146;s
stockholders (including any adjournment, recess, reconvening or postponement thereof, the &#147;<U>Company Stockholders Meeting</U>&#148;) for the purpose of obtaining the approval of the Company&#146;s stockholders for (i)&nbsp;the issuance of
700,000,000 shares of Common Stock issuable upon exercise of the PIPE Warrants and the issuance of 320,000,000 shares of Common Stock issuable upon exercise of warrants to purchase Common Stock issued pursuant to that certain License Agreement by
and between the Company and RemeGen Co., Ltd., dated as of June&nbsp;25, 2025 (the &#147;<U>RemeGen Warrant</U>&#148; and together with the PIPE Warrants, the &#147;<U>Warrants</U>&#148;) in accordance with Nasdaq Stock Market Rule 5635(d) (the
&#147;<U>Warrant Shares Proposal</U>&#148;) and (ii)&nbsp;an amendment to the Company&#146;s certificate of incorporation that has the effect of increasing the number of authorized and unreserved shares of Common Stock, whether through an increase
of the number of authorized shares of Common Stock or through effecting a reverse stock split, in each case as approved by the Company&#146;s Board of Directors, such that the total number of authorized and unreserved shares of Common Stock is
sufficient for the Warrants to be exercised for the maximum number of shares of Common Stock issuable in accordance with the terms of the Warrants (the &#147;<U>Certificate Amendment Proposal</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. The Stockholder is the record and/or beneficial owner of the number of shares of Common Stock and warrants to purchase shares of Common
Stock set forth on <U>Exhibit A</U> hereto (such securities, as they may be adjusted by stock dividend, stock split, recapitalization, combination or exchange of shares, merger, consolidation, reorganization or other change or transaction of or by
the Company are collectively referred to herein as the &#147;<U>Securities</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AGREEMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the recitals and the representations, warranties, covenants and agreements contained herein, and intending to be legally
bound hereby, the parties hereto agree as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Covenants of the Stockholder</U>. The Stockholder agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Stockholder shall not, directly or indirectly Transfer any Securities. For purposes of this Agreement, &#147;Transfer&#148; shall mean
to (i)&nbsp;sell, transfer, pledge, assign or otherwise encumber or dispose of, or enter into any agreement, option or other arrangement (including any profit sharing arrangement) or understanding with respect to any of the Securities to any person
other than the Company, (ii)&nbsp;deposit any Securities into a voting trust or enter into any voting arrangement, whether by proxy, voting agreement, voting trust,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">power-of-attorney,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> agent or otherwise, with respect to the Securities,
except as contemplated by this Agreement, or (iii)&nbsp;take any other action that would in any way make any representation or warranty of the Stockholder herein untrue or incorrect in any material respect. Notwithstanding the foregoing,
(i)&nbsp;the Stockholder may (A)&nbsp;make Transfers or dispositions of the Securities to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder, (B)&nbsp;make Transfers or dispositions of the
Securities by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder, (C)&nbsp;make Transfers of the Securities to its stockholders, direct or
indirect affiliates (within the meaning set forth in Rule 405 under the Securities Act of 1933, as amended), current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such
stockholders, affiliates, partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder, (D)&nbsp;make
Transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement, (E)&nbsp;make Transfers or dispositions not involving a change in beneficial ownership, (F)&nbsp;if the Stockholder
is a trust, make Transfers or dispositions to any beneficiary of the Stockholder or the estate of any such beneficiary, (G)&nbsp;exercise an option or warrant (including a net or cashless exercise of such option or warrant) to purchase Securities,
and (H)&nbsp;Transfer Securities to the Company to cover tax withholding obligations of the Stockholder in connection with any option or warrant exercise or the vesting of any restricted stock or restricted stock unit award, provided that the
underlying Securities shall continue to be subject to the restrictions on transfer set forth in this Agreement; provided that, with respect to clauses (A)&nbsp;through (F) above, the transferee agrees in writing to be bound by the terms and
conditions of this Agreement and either the Stockholder or the transferee provides the Company with a copy of such agreement promptly upon consummation of any such Transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Company Stockholders Meeting or in any other circumstances upon which a vote, consent or other approval (including by written
consent) is sought with respect to the Warrant Shares Proposal or the Certificate Amendment Proposal, the Stockholder shall vote (or cause to be voted) all of the Common Stock held by it as set forth on Exhibit A hereto as well as any shares of
Common Stock issued to the Stockholder upon the exercise of any warrants set forth on Exhibit A hereto: (i)&nbsp;in favor of the Warrant Shares Proposal; (ii)&nbsp;in favor of the Certificate Amendment Proposal; and (iii)&nbsp;against any action,
proposal, transaction or agreement which would reasonably be expected to impede, interfere with, delay, postpone, discourage or adversely affect the approval of the Warrant Shares Proposal or the Certificate Amendment Proposal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Stockholder shall use reasonable efforts to take, or cause to be taken, all reasonable actions, and to do, or cause to be done, all
things reasonably necessary to fulfill the Stockholder&#146;s obligations under this agreement, including, without limitation, attending, if applicable, the Company Stockholders Meeting or any adjournment, postponement or recess thereof (or
executing valid and effective proxies to any other attending participant of the Company Stockholders Meeting in lieu of attending such Company Stockholders Meeting or any adjournment, postponement or recess thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Stockholder authorizes and hereby agrees to permit the Company to: (i)&nbsp;publish
and disclose in any proxy statement, prospectus, current report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;or</FONT> any other document or schedule required to be filed with the Securities and Exchange Commission (the &#147;SEC&#148;) or
any other regulatory authority in connection with the Purchase Agreement and the transactions contemplated thereby such Stockholder&#146;s identity, and the nature of such Stockholder&#146;s obligations under this Agreement, only to the extent
required by applicable rules and regulations, provided that the Company informs the Stockholder in advance; and (ii)&nbsp;file this Agreement as an exhibit to any proxy statement, prospectus, current report on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;or</FONT> any other document or schedule required to be filed with the SEC or any other regulatory authority in connection with the Purchase Agreement and the transactions contemplated thereby,
only to the extent required by applicable rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Grant of Irrevocable Proxy Coupled with an Interest; Appointment
of Proxy</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Stockholder hereby irrevocably (i)&nbsp;grants to the Company and any designee of the Company, alone or together,
the Stockholder&#146;s proxy, and (ii)&nbsp;appoints the Company and any designee of the Company as the Stockholder&#146;s proxy, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent (with full
power of substitution and resubstitution), alone or together, in each case, for and in the name, place and stead of the Stockholder, to vote the Securities, or grant a consent or approval in respect of the Securities, in accordance with
<U>Section</U><U></U><U>&nbsp;1</U> above at any Company Stockholders Meeting or in any other circumstances upon which their vote, consent or other approval is sought in favor of the approval of the Warrant Shares Proposal or the Certificate
Amendment Proposal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) THE STOCKHOLDER HEREBY AFFIRMS THAT THE PROXY SET FORTH IN THIS <U>SECTION</U><U></U><U>&nbsp;2</U> IS COUPLED
WITH AN INTEREST AND IS IRREVOCABLE UNTIL SUCH TIME AS THIS AGREEMENT TERMINATES IN ACCORDANCE WITH ITS TERMS. The Stockholder hereby further affirms that the irrevocable proxy is given in connection with the execution of the Purchase Agreement, and
that such irrevocable proxy is given to secure the performance of the duties of the Stockholder under this Agreement. The Stockholder hereby ratifies and confirms all that such irrevocable proxy may lawfully do or cause to be done by virtue hereof.
Such irrevocable proxy shall be valid until the termination of this Agreement in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and
Warranties of the Stockholder</U>. The Stockholder hereby represents and warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Stockholder has all
requisite power and authority to execute and deliver this Agreement and to perform the Stockholder&#146;s obligations under this Agreement. The execution, delivery and performance of this Agreement have been duly authorized by the Stockholder. This
Agreement has been duly executed and delivered by the Stockholder and, assuming this Agreement constitutes a valid and binding obligation of the Company, constitutes a valid and binding obligation of the Stockholder enforceable against the
Stockholder in accordance with its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii)&nbsp;rules of law governing specific performance, injunctive relief
and other equitable remedies. The failure of the spouse, if any, of the Stockholder to be a party or signatory to this Agreement shall not (x)&nbsp;prevent the Stockholder from performing the Stockholder&#146;s obligations contemplated hereunder or
(y)&nbsp;prevent this Agreement from constituting the legal, valid and binding obligation of the Stockholder in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Securities and the certificates (or any book-entry notations used to represent any uncertificated shares of Common Stock) representing
the Securities are now, and at all times during the term hereof will be, held by the Stockholder, or by a nominee or custodian for the benefit of the Stockholder, and the Stockholder has valid title to the Securities, free and clear of any
encumbrances (including voting trusts and voting commitments), except as would not limit the Stockholder&#146;s ability to vote the Securities in the manner provided herein and except as provided by this Agreement. As of the date of this Agreement,
the Stockholder does not own of record or beneficially any shares of Common Stock, other than the shares of Common Stock set forth on <U>Exhibit A</U> hereto. The Stockholder has full power to vote the Securities as provided herein. Neither the
Stockholder nor any of the Securities is subject to any voting trust, proxy or other agreement, arrangement or restriction with respect to the voting or disposition of the Securities, except as would not limit the Stockholder&#146;s ability to vote
the Securities in the manner provided herein and except as otherwise contemplated by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;(i) No filing with, and no
permit, authorization, consent or approval of any state, federal or foreign governmental authority is necessary on the part of the Stockholder for the execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder
of the Stockholder&#146;s obligations under this Agreement and (ii)&nbsp;neither the execution and delivery of this Agreement by the Stockholder nor the performance by the Stockholder of the Stockholder&#146;s obligations under this Agreement nor
compliance by the Stockholder with any of the provisions hereof shall (x)&nbsp;result in the creation of an encumbrance on any of the Securities or (y)&nbsp;violate any order, writ, injunction, decree, statute, rule or regulation applicable to the
Stockholder or any of the Securities, except in the case of (x)&nbsp;or (y) for violations, breaches or defaults that would not in the aggregate materially impair the ability of the Stockholder to perform its obligations hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As of the date hereof, there is no legal proceeding pending or, to the knowledge of the Stockholder, threatened against or affecting the
Stockholder&#146;s and/or any of its Affiliates before or by any governmental body that would reasonably be expected to impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby
in a timely manner. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Stockholder understands and acknowledges that the Company is entering into the Purchase Agreement in reliance
upon the Stockholder&#146;s execution and delivery of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Assignment; Binding Effect</U>. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties. Subject to the preceding sentence, this Agreement shall be binding
upon, inure solely to the benefit of, and be enforceable by, the parties hereto and their respective permitted successors and assigns. Notwithstanding anything contained in this Agreement to the contrary, nothing in this Agreement, expressed or
implied, is intended to or shall confer on any person other than the parties hereto or their respective heirs, successors, executors, administrators and assigns any rights, benefits, remedies, obligations or liabilities of any nature whatsoever
under or by reason of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Termination</U>. This Agreement, and all rights and obligations of the parties hereunder,
shall terminate upon the first to occur of (a)&nbsp;the date of the Company Stockholders Meeting at which the Warrant Shares Proposal and Certificate Amendment Proposal are approved, (b)&nbsp;the date on which no Warrants remain outstanding, and (c)
180 days from the date of this Agreement. In the event of termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>, this Agreement will become null and void and of no effect with no liability on the part of any party
hereto; <I>provided</I>, <I>however</I>, this <U>Section</U><U></U><U>&nbsp;5</U> and <U>Section</U><U></U><U>&nbsp;8</U> shall survive the termination of this Agreement and shall remain in full force and effect. For the avoidance of doubt, the
representations and warranties herein shall not survive the termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Stockholder Capacity</U>.
Notwithstanding anything to the contrary in this Agreement, the parties acknowledge that (a)&nbsp;the Stockholder is entering into this Agreement solely in the Stockholder&#146;s capacity as a record and/or beneficial owner of the Securities and not
in such Stockholder&#146;s capacity as a director, officer or employee of the Company (as applicable) and (b)&nbsp;nothing in this Agreement is intended to limit or restrict the Stockholder from taking any action or inaction or voting in the
Stockholder&#146;s sole discretion on any matter in his or her capacity as a director of the Company, and none of such actions or inactions in such capacity shall be deemed to constitute a breach of this Agreement. The Company shall not assert any
claim that any action taken by Stockholder in his or her capacity as a director of the Company violates any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Ownership Interest</U>.&nbsp;Nothing contained in this Agreement shall be deemed to vest in the Company any direct or indirect
ownership or incidence of ownership of or with respect to any Securities. All rights, ownership and economic benefits of and relating to the Securities shall remain vested in and belong to the Stockholder, and the Company shall have no power or
authority to direct the Stockholder in the voting of any of the Securities, except as otherwise provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>General
Provisions</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise set forth in the Transaction Agreements, all costs and expenses incurred in connection with this
Agreement and the transactions contemplated hereby shall be paid by the party incurring such expense, whether or not the transactions contemplated hereby are consummated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in a writing that refers to this
Agreement and signed, in the case of an amendment, by each of the parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by any party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given
(a)&nbsp;when delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then the earlier
of (x)&nbsp;confirmation of receipt or (y)&nbsp;on the open of business on the recipient&#146;s next business day, (c)&nbsp;three (3) days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or
(d)&nbsp;one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company, addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vor
Biopharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">100 Cambridgepark Drive, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jean-Paul Kress </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not
constitute notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New
York 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Divakar Gupta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Stockholder, at its address or
<FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth on <U>Exhibit A</U>. Any party may change the address to which notices and communications to it are to be addressed by notification as provided for herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated.
The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and
the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by PDF shall be sufficient to bind the parties to the terms and conditions of this Agreement; provided that a facsimile or pdf signature including any
electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original,
not a facsimile or pdf (or other electronic reproduction of a) signature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) This Agreement, the Purchase Agreement and the other Transaction Agreements constitute
the entire agreement and supersede all prior agreements and understandings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) This Agreement shall be governed and construed in accordance with the laws of the State of Delaware, regardless of the laws that might
otherwise govern under applicable principles of conflicts of laws thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;(i) each of the parties irrevocably and
unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware and any state appellate court therefrom or, if such court lacks subject matter jurisdiction, the United States District Court
sitting in New Castle County in the State of Delaware (it being agreed that the consents to jurisdiction and venue set forth in this Section&nbsp;8(h) shall not constitute general consents to service of process in the State of Delaware and shall
have no effect for any purpose except as provided in this paragraph and shall not be deemed to confer rights on any Person other than the parties hereto); and (ii)&nbsp;each of the parties irrevocably consents to service of process by first class
certified mail, return receipt requested, postage prepaid, to the address at which such party is to receive notice in accordance with Section&nbsp;8(c). The parties hereto agree that a final judgment in any such action or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable law; <I>provided, however,</I> that nothing in the foregoing shall restrict any party&#146;s rights to seek any post-judgment
relief regarding, or any appeal from, such final trial court judgment. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES HERETO ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) If any provision of this Agreement or the application thereof to any party or set of
circumstances shall, in any jurisdiction and to any extent, be finally held invalid or unenforceable by any rule of law or public policy, such term or provision shall only be ineffective as to such jurisdiction, and only to the extent of such
invalidity or unenforceability, without invalidating or rendering unenforceable any other terms or provisions of this Agreement or under any other circumstances, and the parties shall negotiate in good faith a substitute provision which comes as
close as possible to the invalidated or unenforceable term or provision, and which puts each party in a position as nearly comparable as possible to the position it would have been in but for the finding of invalidity or unenforceability, while
remaining valid and enforceable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Each of the parties acknowledges that irreparable damage would occur in the event any provision of
this Agreement was not performed in accordance with the terms hereof and agrees that the parties&#146; respective remedies at law for a breach or threatened breach of any of the provisions of this Agreement would be inadequate and, in recognition of
that fact, each agrees that, in the event of a breach or threatened breach by any party of the provisions of this Agreement, in addition to any remedies at law or damages, each party, respectively, without posting any bond, shall be entitled to
obtain equitable relief in the form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy which may then be available in order to enforce the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature pages follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Vor Biopharma Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STOCKHOLDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>d27026dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;25, 2025 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Robert Ang </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Via Email </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transition Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Robert: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter sets forth the substance of the
separation agreement (hereinafter, &#147;<B><I>Agreement</I></B>&#148;) which <B>Vor Biopharma Inc.</B> (hereinafter, &#147;<B><I>the Company</I></B>&#148;) is offering to you to aid in your employment transition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Transition Period.</B> You have tendered, and the Company hereby accepts, your resignation from your role as Chief Executive Officer
(&#147;<B><I>CEO</I></B>&#148;) effective as of the date of this letter (the &#147;<B><I>CEO Resignation Effective Date</I></B>&#148;). Notwithstanding your resignation as CEO, as part of this Agreement, your employment will continue for a
transition period (the &#147;<B><I>Transition Period</I></B>&#148;) through October&nbsp;14, 2025. During the Transition Period, you will not be expected, required, or permitted to perform your regular job duties as CEO, but will be expected to
provide such transition services as may be requested by the Company&#146;s Board to Directors (the &#147;<B><I>Board</I></B>&#148;), the Company&#146;s new CEO, and/or his designee. As part of this Agreement, the Company agrees that it will not
terminate your employment before the end of the Transition Period, unless you engage in Cause as defined under the Severance Plan (as defined below) in which case you will not be eligible for any Severance Benefits (as defined below). The date your
employment ends is the &#147;<B><I>Separation Date</I></B>&#148;. During the Transition Period, you will continue to receive your current salary and benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Payment. </B>On the next regular payroll date following the Separation Date, or earlier if otherwise required by applicable law, the Company will
make a payment to you for all wages earned for time worked through the Separation Date, subject to standard payroll deductions and withholdings. You will receive this payment regardless of whether or not you sign this Agreement. You acknowledge and
agree that the Company maintains an unlimited, <FONT STYLE="white-space:nowrap">non-accrual</FONT> vacation policy and, as a result, you have no accrued but unused vacation time that the Company is obligated to pay to you upon your separation from
employment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>Unemployment</B>. You may be eligible for unemployment insurance (&#147;<B><I>UI</I></B>&#148;) benefits after the Separation
Date as a result of your termination from the Company. Your state&#146;s applicable unemployment insurance agency, not the Company, will determine your eligibility for UI benefits. You acknowledge and agree that you have been provided any UI notice
required by applicable law and that the Company shall have no liability for the outcome of any unemployment claim that you may file. Furthermore, you acknowledge and agree that this Agreement shall remain in full force and effect notwithstanding the
outcome of any claim for UI benefits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Severance Benefits.</B> If you<B> </B>(a)&nbsp;timely execute and return this Agreement within seven
(7)&nbsp;days of receipt, and abide by its terms; and (b)&nbsp;execute the Updated Release of Claims attached to this Agreement as <B>Exhibit A</B> and made a part of this Agreement (the &#147;<B><I>Updated Release</I></B>&#148;) on or before the
date that is three (3)&nbsp;days after the Separation Date (but no earlier than the Separation Date) and allow it to become effective, then the Company will provide you with the following &#147;<B><I>Severance Benefits</I></B>&#148;, in lieu of any
benefits you may have been <B></B>eligible to receive under the Vor Biopharma Inc. Executive Severance and Change in Control Benefits Plan in which you are a participant (the &#147;<B><I>Severance Plan</I></B>&#148;): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Severance.</B> The Company will pay you, as severance, an amount equivalent to
your base salary in effect on the Separation Date for eighteen (18)&nbsp;months (the &#147;<B><I>Severance</I></B>&#148;). The Severance will be subject to standard payroll deductions and withholdings and will be paid in a lump sum on the
Company&#146;s first ordinary payroll date following the Updated Release Effective Date (as defined therein), so long as the Company receives your executed Updated Release by 12:00 p.m. on the day before payday. If the Company receives your executed
Updated Release after 12:00 p.m. on the day before payday, the Company will make its first payment to you on the following payday. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>COBRA Severance.</B> If you are eligible for and timely elect to continue your health insurance coverage under the Consolidated
Omnibus Budget Reconciliation Act of 1985 (&#147;<B><I>COBRA</I></B>&#148;) or the state equivalent, the Company will reimburse you for the cost of COBRA premiums for you and your eligible dependents, if any, until the earlier of (A)&nbsp;eighteen
(18) months from Separation Date, (B)&nbsp;the expiration of your eligibility for the continuation coverage under COBRA, or (C)&nbsp;such time as you become employed by another employer or self-employed through which you are eligible for health
insurance (thereafter, you will be responsible for the cost of all COBRA premium payments, if any). To receive this reimbursement, you will be required to remit timely payment to the Company&#146;s COBRA provider and present proof of payment within
ten (10)&nbsp;days, and the Company will process the reimbursement to you in accordance with its ordinary expense reimbursement practices. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA
Premiums without a substantial risk of violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), the Company instead shall pay you, on the first day of each calendar month, a fully taxable cash
payment equal to the applicable COBRA Premiums for that month (including premiums for any dependents), subject to applicable tax withholdings (such amount the &#147;<B><I>Special Cash Payment</I></B>&#148;), for the remainder of the COBRA Premium
Period. You may, but are not obligated to, use such Special Cash Payment toward the cost of COBRA Premiums. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Bonus Severance.
</B>The Company will pay you an amount equal to 1.5x your 2025 target annual bonus (the &#147;<B><I>Bonus Severance</I></B>&#148;). The Bonus Severance will be subject to standard payroll deductions and withholdings and will be paid in a lump sum on
the Company&#146;s first ordinary payroll date following the Updated Release Effective Date (as defined therein), so long as the Company receives your executed Updated Release by 12:00 p.m. on the day before payday. If the Company receives your
executed Updated Release after 12:00 p.m. on the day before payday, the Company will make its first payment to you on the following payday. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Accelerated Vesting and PTEP Extension. </B>You were granted certain equity awards in respect of shares of the Company&#146;s
common stock (the &#147;<B><I>Awards</I></B>&#148;), pursuant to either Vor&#146;s 2015 Stock Incentive Plan or Vor&#146;s 2021 Equity Incentive Plan (as applicable, the &#147;<B><I>Plan</I></B>&#148;). Notwithstanding anything to the contrary in
the Plan and/or your applicable award document (the &#147;<B><I>Award Documents</I></B>&#148;), and subject to Board approval, all of your outstanding and unvested awards that are subject to time-based vesting shall be deemed vested as of the
Separation Date. The Company will also extend the period of time during which you may exercise any vested, outstanding and unexercised stock options (&#147;<B><I>Options</I></B>&#148;) until the earlier of (i)&nbsp;the date that is twelve
(12)&nbsp;months following the Separation Date and (ii)&nbsp;the applicable expiration date (as defined in the Plans and/or Award Documents. Except as provided in this Agreement, all terms, conditions and limitations applicable to the Options
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will remain in full force and effect pursuant to the applicable terms of the Plans and/or Equity Award Documents. The Company makes no representations or guarantees regarding the status of any
Options granted to you as incentive stock options (&#147;<B><I>ISOs</I></B>&#148;). You understand and agree that to the extent any Option granted as an ISO is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;in-the-money&#148;</FONT></FONT> (the fair market value of the underlying shares of common stock is greater than the exercise price of the Option) at the time the exercise
period is extended (as contemplated above), such Option will be treated as a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options (&#147;<B><I>NSOs</I></B>&#148;) for federal tax purposes. Additionally, if any Option will retain its
status as ISOs, but is exercised with respect to any vested shares later than the date that is three (3)&nbsp;months following the Separation Date, such Option will also be treated as an NSO, and you will be obligated to satisfy your tax obligations
that arise when you exercise the Option. No shares of the Company common stock will be issued to you in respect of any Option treated as an NSO unless and until you satisfy such tax obligations. You acknowledge that the Company is not providing tax
advice to you and that you have been advised by the Company to seek independent tax advice with respect to the exercise and modification of the Options. You also understand that because the Separation Date will be prior to February&nbsp;3, 2026,
your Options will not be subject to the option repricing that occurred on February&nbsp;2, 2025. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Waiver of <FONT
STYLE="white-space:nowrap">Non-Solicit.</FONT></B> As described in Section&nbsp;10 below, effective on the date of this Agreement, the Company will waive and elect not to enforce the <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
restrictions set forth in your Employee Confidentiality, Assignment and <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement, attached hereto as <B>Exhibit B</B>(the &#147;<B><I>Confidentiality Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Retention of Laptop Computer.</B> As an additional Severance Benefit, the Company will permit you to retain the Company-issued
laptop computer provided to you during your employment; provided, however, that you agree to reasonably cooperate with the Company to confirm all files stored on the computer are intact and all Company confidential information and trade secrets have
been deleted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Letter of Reference</B>. As an additional Severance Benefit, upon your request, the Company will provide you
with a signed letter of reference. This letter of reference will be provided to you after you send a written request for the letter to Tania Philipp, provided you have returned this executed Agreement to the Company by the date of such request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is offering severance to you in reliance on Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9)</FONT> and the
short-term deferral exemption in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4).</FONT> Any payments made in reliance on Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> will
be made not later than March&nbsp;15, 2026. For purposes of Code Section&nbsp;409A, your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive
a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Benefit Plans. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> If you are currently participating in the Company&#146;s group health insurance plans, your participation as an employee will end on
the last day of the month in which you separate. Thereafter,<B> </B>to the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#146;s current group health insurance policies, you will be eligible to
continue your participation in your current group health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurance plan at your own expense. Later, you may be able to convert to an individual policy through the provider of the Company&#146;s health insurance, if you wish. Human Resources will
discuss the details of COBRA continuation coverage, your eligibility for same, and premium payments with you. Eligibility for COBRA continuation coverage is determined by the Company&#146;s group insurance plan, not the Company. The Company makes no
representation or warranty regarding your eligibility for COBRA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Your participation in employer-sponsored Group Life Insurance
and Short- and Long-Term Disability Insurance will cease as of the Separation Date. Human Resources will provide you with information concerning options for converting these benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If applicable, deductions for the 401(k) Plan will end with your last regular paycheck. You will receive information by mail
concerning 401(k) plan rollover procedures should you be a participant in this program. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> If you are currently participating in
the Health Savings Account (&#147;<B><I>HSA</I></B>&#148;) program, you may take any remaining HSA balance with you when you leave the company. If applicable, deductions for the HSA Plan will end with your last regular paycheck. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>No Amounts Owing.</B> You acknowledge and agree that, other than the amounts stated in Section&nbsp;2 of this Agreement, and any amounts that may
be owed to you under Section&nbsp;4, there are no amounts otherwise due or owing to you under any employment agreement or policy or practice of the Company, including (without limitation) the Severance Plan, and that the contemplated Severance
Benefits to be provided to you subject to the conditions of this Agreement are not intended to, and shall not constitute, a severance plan, and shall confer no benefit on anyone other than you. You further acknowledge and agree that you have been
paid and provided all wages, bonuses, vacation pay, holiday pay and any other form of compensation that may be due to you now or which would have become due in the future in connection with your employment with or separation of employment from the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Expense Reimbursements.</B> You agree that, within ten (10)&nbsp;days of the Separation Date, you will submit your final documented
expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for reasonable business expenses pursuant to its regular business
practice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Return of Company Property.</B> By the Separation Date, you agree to return to the Company all Company electronic and hard copy
documents (and all copies thereof) and other Company property that you have had in your possession at any time, including, but not limited to, Company files, notes, drawings, records, business plans and forecasts, financial information,
specifications, computer-recorded information, tangible property (including, but not limited to, computers, tablets, and smartphones), credit cards, entry cards, identification badges and keys; and, any materials of any kind that contain or embody
any proprietary or confidential information of the Company (and all reproductions thereof); <I>provided, however</I>, you may be permitted to retain certain Company property after the Separation Date as described in Section&nbsp;4(d) above. Please
coordinate return of Company property with Tania Philipp<B>. </B>Receipt of the Severance Benefits described in Section&nbsp;4 of this Agreement is expressly conditioned upon return of all Company property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Confidential Information and Post-Termination Obligations.</B> You acknowledge your continuing
obligations under your Confidentiality Agreement (attached as <B>Exhibit B</B>) both during and after employment. As part of this Agreement, and as described in Section&nbsp;4(e) above, the Company hereby waives the
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> restriction contained in the Confidentiality Agreement. Notwithstanding the foregoing, you and the Company agree that all other provisions in the Confidentiality Agreement shall remain in full
force and effect. If you have any doubts as to the scope of the restrictions in your agreement, you should contact Tania Philipp<B> </B>immediately to assess your compliance. Please familiarize yourself with the enclosed agreement which you signed
as the Company intends to enforce its contract rights.<B> </B>Confidential information that is also a &#147;trade secret,&#148; as defined by law, may only be disclosed (A)&nbsp;if it is made (i)&nbsp;in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other
proceeding, if such filing is made under seal. In addition, in the event that you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and use the trade secret
information in the court proceeding, <I>if</I> you: (A)&nbsp;file any document containing the trade secret under seal; and (B)&nbsp;do not disclose the trade secret, except pursuant to court order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Confidentiality.</B> In addition to your ongoing obligations under <B>Exhibit B </B>to maintain the utmost confidentiality of the Company&#146;s
trade secrets and other confidential information, the provisions of this Agreement will be held in strictest confidence by you and will not be publicized or disclosed in any manner whatsoever; <I>provided, however,</I> that: (a)&nbsp;you may
disclose this Agreement to your immediate family; (b)&nbsp;you may disclose this Agreement in confidence to your attorney, accountant, auditor, tax preparer, and financial advisor; and (c)&nbsp;you may disclose this Agreement insofar as such
disclosure may be required by law. Notwithstanding the foregoing, nothing in this Agreement shall limit your right to voluntarily communicate with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor
Relations Board, the Securities and Exchange Commission, other federal government agency or similar state or local agency or to discuss the terms and conditions of your employment with others to the extent expressly permitted by Section&nbsp;7 of
the National Labor Relations Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><FONT STYLE="white-space:nowrap">Non-Disparagement.</FONT></B> Both you and the Company agree not to
disparage the other party, and the other party&#146;s officers, attorneys, directors, managers, partners, employees, shareholders, agents and affiliates, in any manner likely to be harmful to them or their business, business reputation or personal
reputation; <I>provided, however</I>, that you may respond accurately and fully to any question, inquiry or request for information when required by legal process. The Company&#146;s obligations under this section are limited to Company
representatives with knowledge of this provision. Notwithstanding the foregoing, nothing in this Agreement shall limit your right to voluntarily communicate with the Equal Employment Opportunity Commission, United States Department of Labor, the
National Labor Relations Board, the Securities and Exchange Commission, other federal government agency or similar state or local agency or to discuss the terms and conditions of your employment with others to the extent expressly permitted by
Section&nbsp;7 of the National Labor Relations Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Cooperation After Termination. </B>You agree to cooperate fully with the Company in all
matters relating to the transition of your work and responsibilities on behalf of the Company, including, but not limited to, any present, prior or subsequent relationships and the orderly transfer of any such work and institutional knowledge to
such other persons as may be designated by the Company, by making yourself reasonably available during regular business hours without additional costs to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>General Release. </B>In exchange for the payments and other consideration under this Agreement,
to which you would not otherwise be entitled, and except as otherwise set forth in this Agreement, you, on behalf of yourself and, to the extent permitted by law, on behalf of your spouse, heirs, executors, administrators, assigns, insurers,
attorneys and other persons or entities, acting or purporting to act on your behalf (collectively, the &#147;<B><I>Employee Parties</I></B>&#148;), hereby generally and completely release, acquit and forever discharge the Company, its parents and
subsidiaries, and its and their officers, directors, managers, partners, agents, representatives, employees, attorneys, shareholders, predecessors, successors, assigns, insurers and affiliates (the &#147;<B><I>Company Parties</I></B>&#148;) of and
from any and all claims, liabilities, demands, contentions, actions, causes of action, suits, costs, expenses, attorneys&#146; fees, damages, indemnities, debts, judgments, levies, executions and obligations of every kind and nature, in law, equity,
or otherwise, both known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the execution date of this Agreement,
including but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with your employment with the Company or the termination of that employment; claims or demands related to salary, bonuses,
commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law, statute,
or cause of action; common law; tort law; or contract law (individually a &#147;<B><I>Claim</I></B>&#148; and collectively &#147;<B><I>Claims</I></B>&#148;). The Claims you are releasing and waiving in this Agreement include, but are not limited to,
any and all Claims that any of the Company Parties: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has violated its personnel policies, handbooks, contracts of employment, or covenants of good faith and fair
dealing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has discriminated against you on the basis of age, race, color, sex (including sexual harassment), pregnancy,
national origin, ancestry, disability, religion, sexual orientation, gender identity or expression, marital status, parental status, military service or veteran status, source of income, entitlement to benefits, need for leave or accommodation, any
union activities or other protected category, retaliated against you in violation of any local, state or federal law, constitution, ordinance, or regulation, or has violated any other employment statutes, including but not limited to: the Employee
Retirement Income Security Act of 1974 (ERISA); the Fair Labor Standards Act of 1938; the National Labor Relations Act; the Family and Medical Leave Act of 1993; Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1866 (42 U.S.C.
1981); the Fair Credit Reporting Act; the Employee Polygraph Protection Act; the Civil Rights Act of 1991; the Genetic Information Nondiscrimination Act; Executive Order 11246, which prohibit discrimination based on race, color, national origin,
religion, or sex; the Americans with Disabilities Act and Sections 503 and 504 of the Rehabilitation Act of 1973, which prohibit discrimination against&nbsp;the disabled; the Age Discrimination in Employment Act, which prohibits discrimination based
on age; the Older Workers Benefit Protection Act; the National Labor Relations Act, the Lily Ledbetter Fair Pay Act; the Uniformed Services Employment and Reemployment Rights Act;&nbsp;the anti-retaliation provisions of the Sarbanes-Oxley Act, or
any other federal or state law regarding whistleblower retaliation; the Massachusetts Fair Employment Practices Act (M.G.L. c. 151B); the Massachusetts Parental Leave Act; the Massachusetts Paid Family and Medical Leave Law (M.G.L. c. 175M, section
9); the Massachusetts Payment of Wages Act (M.G.L. c. 149 sections 148 and 150); the Massachusetts Overtime regulations (M.G.L. c. 151 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
sections 1A and 1B); the Massachusetts Meal Break regulations (M.G.L. c. 149 sections 100 and 101); the Massachusetts Earned Sick Time Law; the Massachusetts Equal Rights Act; the Massachusetts
Equal Pay Act; the Massachusetts Privacy Statute; the Massachusetts Civil Rights Act; the Massachusetts Pregnant Workers Fairness Act, and any and all other federal, state or local laws, rules, regulations, constitutions, ordinances or public
policies, whether known or unknown, prohibiting employment discrimination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has violated any other laws, such as federal, state, or local laws providing workers&#146; compensation benefits,
restricting an employer&#146;s right to terminate employees, or otherwise regulating employment; any federal, state or local law enforcing express or implied employment contracts or requiring an employer to deal with employees fairly or in good
faith; any other federal, state or local statutory or common law providing recourse for alleged wrongful discharge, retaliatory discharge, negligent hiring, retention, or supervision, physical or personal injury, emotional distress, assault,
battery, false imprisonment, fraud, negligent misrepresentation, defamation, intentional or negligent infliction of emotional distress and/or mental anguish, intentional interference with contract, negligence, detrimental reliance, loss of
consortium to you or any member of your family, whistleblowing, and similar or related claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You expressly release any and all
claims, whether known or unknown, arising under any state or federal statute regarding the payment of wages and other compensation, including but not limited to the Massachusetts Payment of Wages Act and the Massachusetts minimum wage and overtime
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You acknowledge that you have been advised that you have the right to consult an attorney regarding this Agreement and that you were given a
reasonable time period of not less than five business days in which to do so. You further acknowledge and agree that, in the event you sign this Agreement prior to the end of the reasonable time period provided by the Company, your decision to
accept such shortening of time is knowing and voluntary and is not induced by the Company through fraud, misrepresentation, or a threat to withdraw or alter the offer prior to the expiration of the reasonable time period, or by providing different
terms to employees who sign such an agreement prior to the expiration of the time period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing general release, other than
events expressly contemplated by this Agreement you do not waive or release rights or Claims that may arise from events that occur after the date this waiver is executed or your right to enforce this Agreement. Also excluded from this Agreement are
any Claims which cannot be waived by law, including, without limitation, any rights you may have under applicable workers&#146; compensation laws and your right, if applicable, to file or participate in an investigative proceeding of any federal,
state or local governmental agency. Nothing in this Agreement has prevented, currently prevents or shall prevent you from filing, cooperating with, or participating in any proceeding or investigation before the Equal Employment Opportunity
Commission, United States Department of Labor, United States Department of Justice, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal government agency,
or similar state or local agency (&#147;<B><I>Government Agencies</I></B>&#148;), or exercising any rights pursuant to Section&nbsp;7 of the National Labor Relations Act. You further understand this Agreement does not limit your ability to
voluntarily communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, you are otherwise waiving, to
the fullest extent permitted by law, any and all rights you may have to individual relief based on any Claims that you have released and any rights you have waived by signing this Agreement. If any Claim is not subject to release, to the greatest
extent permitted by law, you waive any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on such a Claim in which
the Company is a party. This Agreement does not abrogate your existing rights under any Company benefit plan or any plan or agreement related to equity ownership in the Company; however, it does waive, release and forever discharge Claims existing
as of the date you execute this Agreement pursuant to any such plan or agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Your Acknowledgments and Affirmations. </B>You acknowledge
and agree that (i)&nbsp;the consideration given to you in exchange for the waiver and release in this Agreement is in addition to anything of value to which you were already entitled; (ii)&nbsp;that you have been paid for all time worked, have
received all the leave, leaves of absence and leave benefits and protections for which you are eligible, and have not suffered any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on-the-job</FONT></FONT> injury for which you have
not already filed a Claim; (iii)&nbsp;you have been given sufficient time to consider this Agreement and to consult an attorney or advisor of your choosing; and (iv)&nbsp;you are knowingly and voluntarily executing this Agreement waiving and
releasing any Claims you may have as of the date you execute it. You affirm that all of the decisions of the Company Parties regarding your pay and benefits through the date of your execution of this Agreement were not discriminatory based on age,
disability, race, color, sex, religion, national origin or any other classification protected by law. You agree that you will not voluntarily (except in response to legal compulsion or as permitted in Section&nbsp;13 above) assist any person in
bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against any of the Company Parties. You further affirm that you have no known workplace injuries or occupational diseases. You
acknowledge and affirm that you have not been retaliated against for reporting any allegation of corporate fraud or other wrongdoing by any of the Company Parties, or for exercising any rights protected by law, including any rights protected by the
Fair Labor Standards Act, the Family Medical Leave Act, or any related statute or local leave or disability accommodation laws, or any applicable state workers&#146; compensation law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>No Admission. </B>This Agreement does not constitute an admission by the Company of any wrongful action or violation of any federal, state, or
local statute, or common law rights, including those relating to the provisions of any law or statute concerning employment actions, or of any other possible or claimed violation of law or rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Breach.</B> You agree that upon any breach of this Agreement you will forfeit all amounts paid or owing to you under this Agreement. Further, you
acknowledge that it may be impossible to assess the damages caused by your violation of the terms of Sections 8, 9, 10, 11, and 12 of this Agreement and further agree that any threatened or actual violation or breach of those Sections of this
Agreement will constitute immediate and irreparable injury to the Company. You therefore agree that any such breach of this Agreement is a material breach of this Agreement, and, in addition to any and all other damages and remedies available to the
Company upon your breach of this Agreement, the Company shall be entitled to an injunction to prevent you from violating or breaching this Agreement. You agree that if the Company is successful in whole or part in any legal or equitable action
against you under this Agreement, you agree to pay all of the costs, including reasonable attorneys&#146; fees, incurred by the Company in enforcing the terms of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Miscellaneous.</B> This Agreement, including Exhibits, constitutes the complete, final and
exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it
supersedes any other such promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal
representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole
or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable. This Agreement will be deemed to have been entered into and will be
construed and enforced in accordance with the laws of state or commonwealth in which you worked for the Company without regard to conflict of laws principles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Agreement to Arbitrate.</B> You and the Company agree that any and all disputes, claims, or controversies of any nature whatsoever arising from,
or relating to, this Agreement or its interpretation, enforcement, breach, performance or execution, your employment or the termination of such employment (including, but not limited to, any statutory claims), shall be resolved, pursuant to the
Federal Arbitration Act, 9 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1-16,</FONT> and to the fullest extent permitted by law, by final, binding and confidential arbitration in the state or commonwealth in which you worked for the Company (or
another mutually acceptable location) conducted before a single neutral arbitrator by JAMS, Inc. (&#147;<B><I>JAMS</I></B>&#148;) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at
<U>http://www.jamsadr.com/rules-employment-arbitration/</U>). <B>By agreeing to this arbitration procedure, both you and the Company waive the right to have any claim resolved through a trial by jury or judge.</B> You will have the right to be
represented by legal counsel at any arbitration proceeding, at your own expense. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, to the extent such claims are not permitted by
applicable law to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#147;<B><I>Excluded Claims</I></B>&#148;). In the event you intend to bring
multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration. The arbitrator shall have sole authority for determining
if a claim is subject to arbitration, and any other procedural questions related to the dispute and bearing on the final disposition. In addition, the arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of
the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b)&nbsp;issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded
as to each claim, the reasons for the award, and the arbitrator&#146;s essential findings and conclusions on which the award is based. The Company shall pay all JAMS arbitration fees. Nothing in this Agreement shall prevent you or the Company from
obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Agreement is acceptable to you, please sign below within seven (7)&nbsp;days following receipt and return the original to me. The
Company&#146;s offer contained herein will automatically expire if we do not receive the fully signed Agreement within this timeframe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I wish you good luck in your future endeavors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signatures to follow on next page</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g27026dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vor Biopharma Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Matthew Patterson,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chairman of the Board</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attachments: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit A
&#150; </B>Updated Release </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit B - </B>Employee Confidentiality, Assignment, and <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreed to and accepted this 25th day of June, 2025: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Ang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Robert Ang</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Print Name</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | <B>vorbio.com</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g27026dsp62.jpg" ALT="LOGO">
</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>8
<FILENAME>d27026dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL> </B>(the &#147;<B><I>Agreement</I></B>&#148;) is entered into on June&nbsp;25, 2025
by and between Jean-Paul Kress (the &#147;<B><I>Executive</I></B>&#148;) and Vor Biopharma Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive&#146;s personal services to the
Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive wishes to be employed by the Company and provide personal services and certain covenants to the Company in return
for certain compensation and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, in consideration of the mutual promises and covenants contained herein, the parties
agree to the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>1. <U>E<SMALL>MPLOYMENT</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL></U><SMALL></SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1 </B><B><U>Position</U></B><B>. </B>Subject to the terms set forth herein, the
Company agrees to employ Executive initially in the position of Chief Executive Officer, and Executive hereby accepts such employment. The Company expects that concurrent with Executive being named as Chief Executive Officer, he will also be
appointed to the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) and be appointed as Chair. The Company agrees to take all reasonable and necessary measures to advance his candidacy as such with the Nominating&nbsp;&amp; Corporate
Governance Committee of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2 </B><B><U>Start Date</U></B><B>. </B>Executive&#146;s employment with the Company shall commence
on upon the closing of the transactions contemplated under the Securities Purchase Agreement dated June&nbsp;25, 2025, by and between the Company and the investors identified therein (the &#147;<B><I>Transaction</I></B>&#148;), or such other later
date mutually agreed to in writing by Executive and the Company. The date Executive actually commences working for the Company is referred to as Executive&#146;s &#147;<B><I>Start Date</I></B>.&#148; Prior to the Start Date or in the event that
(i)&nbsp;the Transaction does not close or (ii)&nbsp;Executive otherwise does not commence employment with the Company under this Agreement, the Company shall have no obligation to provide Executive with compensation and benefits (including, but not
limited to, the &#147;Severance Benefits&#148; stated in Section&nbsp;6.1, 6.2 or 6.3). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.3 </B><B><U>Duties</U></B><B>. </B>Executive
will report to the Board, performing such duties as are normally associated with Executive&#146;s position, subject to the oversight and direction of the Board or the Board&#146;s designee. During the term of Executive&#146;s employment with the
Company, Executive will devote Executive&#146;s best efforts and substantially all of Executive&#146;s business time and attention to the business of the Company. Executive shall perform Executive&#146;s duties under this Agreement principally out
of Cambridge, MA or such other location as is the headquarters of the Company. In addition, Executive shall make such business trips to such places as may be necessary or advisable for the efficient operations of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.4 </B><B><U>Company Policies and Benefits</U></B><B>. </B>The employment relationship between the parties shall be subject to the
Company&#146;s personnel policies and procedures as they may be established, interpreted, adopted, revised or deleted from time to time in the Company&#146;s sole discretion. Executive will remain eligible to participate on the same basis as
similarly-situated Executives in the Company&#146;s benefit plans in effect from time to time during Executive&#146;s </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment. The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement
differ from or are in conflict with the Company&#146;s general employment policies or practices, this Agreement shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2.
<U>C<SMALL>OMPENSATION</SMALL></U><SMALL></SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1 </B><B><U>Salary</U></B><B>. </B>Executive shall receive for
Executive&#146;s services to be rendered under this Agreement an initial base salary of $700,000 on an annualized basis, subject to review and adjustment by the Company in its sole discretion, and payable subject to standard federal and state
payroll withholding requirements in accordance with the Company&#146;s standard payroll practices (&#147;<B><I>Base Salary</I></B>&#148;). Executive&#146;s Base Salary shall be subject to annual review by the Board or a committee thereof and may be
increased (but not decreased) at the Board&#146;s discretion. After any such increase in Base Salary, the term &#147;Base Salary&#148; shall refer to the increased amount. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2 </B><B><U>Annual Discretionary Bonus</U></B><B>. </B>Executive will be eligible to be awarded a discretionary annual cash bonus with a
target of sixty percent (60%) of Executive&#146;s then-current Base Salary, subject to review and adjustment from time to time by the Company in its sole discretion, payable subject to standard payroll withholding requirements (&#147;<B><I>Target
Bonus</I></B>&#148;). Whether or not Executive is awarded any bonus will be dependent upon (a)&nbsp;the achievement of the applicable performance goals, as determined by the Board in its sole discretion, and (b)&nbsp;Executive&#146;s continuous
performance of services to the Company through the last date of the applicable performance period. The bonus may be greater or lesser than the Target Bonus and may be zero. The bonus, if any, will be paid on or before March&nbsp;15 of the year
following the applicable performance period. In the event Executive&#146;s Base Salary is increased during an applicable bonus year, any bonus Executive is eligible to receive for that year (as a percentage of Executive&#146;s Base Salary) will be
calculated such that the modified Base Salary rate only applies to the period of time from the effective date of the Base Salary adjustment through the end of the applicable bonus year (and the prior Base Salary rate applies to the period before the
Base Salary adjustment). The Board will determine in its sole discretion the extent to which Executive has achieved the performance goals upon which the bonus is based and the amount of the bonus, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3 </B><B><U>Signing Bonus</U></B><B>. </B>Subject to Executive commencing work on the Start Date, the Company will pay Executive a lump
sum cash signing bonus of $400,000 (the &#147;<B><I>Signing Bonus</I></B>&#148;), subject to applicable tax withholdings, to be paid as an advance on the first payroll date after the Start Date. The Signing Bonus will be earned upon Executive&#146;s
continuous employment for the <U>twelve</U> (12)&nbsp;months following the Start Date. If Executive is terminated for Cause (as defined herein) or if Executive resigns without Good Reason (as defined herein) within the first twelve (12)&nbsp;months
after the Start Date, the bonus is not earned and therefore Executive will be required to repay the <FONT STYLE="white-space:nowrap">after-tax</FONT> value of the signing bonus. In this instance, Executive must repay the signing bonus within thirty
(30)&nbsp;days of Executive&#146;s last day of employment. If Executive fails to timely and fully repay the Signing Bonus, the Company will be entitled to its reasonable attorneys&#146; fees and costs incurred to recover such amount. For the
avoidance of doubt, the foregoing repayment obligation will not apply in the event Executive&#146;s employment is terminated by reason of Executive&#146;s death or Disability (as defined herein). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4 </B><B><U>Stock Option</U></B><B>. </B>As soon as practicable following the Start
Date and subject to approval of the Board, Executive will be issued an option to purchase 83,296,638 shares of the Company&#146;s common stock (the &#147;<B><I>Option</I></B>&#148;). The Option shall have an exercise price per share equal to the
fair market value per share of the Company&#146;s common stock as of the date of grant and shall be governed in all aspects by the Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan, as amended and restated from time to time
(&#147;<B><I>Equity Incentive Plan</I></B>&#148;) and the Company&#146;s standard form of Stock Option Agreement between Executive and the Company. The Option shall be an incentive stock option to the extent permissible under Section&nbsp;422 of the
Internal Revenue Code. The Option shall vest according to the following schedule: 25% of the shares will vest as of one year from the date of grant, and the remaining 75% of the shares will then vest in substantially equal installments each month
thereafter over the following 36 months, subject to continuous employment with the Company through each such date. Notwithstanding anything herein to the contrary, effective as of the consummation of a Change in Control transaction in which the
Company equity awards have not been continued, assumed or substituted for by the Company and/or the acquiror (or any affiliate of the acquiror) in connection with such Change in Control transaction, the vesting and exercisability of all equity
awards that are held by Executive which are scheduled to vest solely based on the passage of time (the &#147;<B><I>Time-Based Equity Awards</I></B>&#148;) and all other outstanding unvested Company equity awards that are subject to performance-based
vesting conditions (the &#147;<B><I>Performance-Based Equity Awards</I></B>&#148;, together with the Time-Based Equity Awards, the &#147;<B><I>Equity Awards</I></B>&#148;) in each case, that are held by Executive as of immediately prior to the
consummation of the Change in Control (x)&nbsp;shall be deemed, in the case of Time-Based Equity Awards, vested and exercisable, and in the case of Performance-Based Equity Awards, deemed vested and exercisable at &#147;maximum&#148; levels of
achievement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.5 </B><B><U>Expense Reimbursement</U></B><B>. </B>The Company will reimburse Executive for reasonable business expenses
in accordance with the Company&#146;s standard expense reimbursement policy, as the same may be modified by the Board from time to time. The Company shall reimburse Executive for all customary and appropriate business-related expenses actually
incurred and documented in accordance with Company policy, as in effect from time to time. For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section&nbsp;409A of the Internal
Revenue Code of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;): (a) any such reimbursements will be paid no later than December&nbsp;31 of the year following the year in which the expense was incurred, (b)&nbsp;the amount of expenses
reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (c)&nbsp;the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.6 </B><B><U>Legal Fees</U></B><B>. </B>Following the Start Date, the Company shall pay (as soon as reasonably practicable following the
Company&#146;s receipt of an invoice from Executive), to the extent permitted by law, all reasonable legal fees and expenses up to $15,000 for advice and representation that Executive reasonably incurred as a result of evaluating and negotiating the
terms of this Agreement (and the other documents referenced herein). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><U>C<SMALL>ONFIDENTIAL</SMALL>
I<SMALL>NFORMATION</SMALL>, I<SMALL>NVENTIONS</SMALL>, N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-C</FONT><SMALL>OMPETITION</SMALL> <SMALL>AND</SMALL> N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-S</FONT><SMALL>OLICITATION</SMALL>
O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>. </B>As a condition of employment, Executive agrees to execute and abide by the Employee Confidential Information and Invention Assignment Agreement attached as Exhibit A
(&#147;<B><I>Confidential Information Agreement</I></B>&#148;), which may be amended by the parties from time to time without regard to this Agreement. The Confidential Information Agreement contains provisions that are intended by the parties to
survive and do survive termination of this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. </B><B><U>O<SMALL>UTSIDE</SMALL> A<SMALL>CTIVITIES</SMALL> D<SMALL>URING</SMALL>
E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>. </B>Except with the prior written consent of the Company, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation or
business enterprise that would interfere with Executive&#146;s responsibilities and the performance of Executive&#146;s duties hereunder, except for (i)&nbsp;reasonable time devoted to volunteer services for or on behalf of such religious,
educational, <FONT STYLE="white-space:nowrap">non-profit</FONT> and/or other charitable organization as Executive may wish to serve, (ii)&nbsp;reasonable time devoted to activities in the <FONT STYLE="white-space:nowrap">non-profit</FONT> and
business communities consistent with Executive&#146;s duties, and (iii)&nbsp;such other activities as may be specifically approved in writing by the Company. This restriction shall not, however, preclude Executive (i)&nbsp;from owning less than one
percent (1%) of the total outstanding shares of a publicly-traded company, (ii)&nbsp;from employment or service in any capacity with a subsidiary of the Company, or (iii)&nbsp;from serving on the board of directors of any company, including, without
limitation, Sanofi S.A. or its affiliates, provided such service does not interfere with Executive&#146;s duties under this Agreement. Executive agrees to promptly disclose to the Board his involvement in any activities contemplated by this
Section&nbsp;4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><U>N<SMALL>O</SMALL> C<SMALL>ONFLICT</SMALL> <SMALL>WITH</SMALL> E<SMALL>XISTING</SMALL>
O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>. </B>Executive represents that Executive&#146;s performance of all the terms of this Agreement and service as an executive of the Company do not and will not breach any
agreement or obligation of any kind made prior to Executive&#146;s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services. Executive has not
entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. </B><B><U>T<SMALL>ERMINATION</SMALL> O<SMALL>F</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL></B><SMALL><B></B></SMALL><B>. </B>The
parties acknowledge that Executive&#146;s employment relationship with the Company will remain <FONT STYLE="white-space:nowrap">at-will.</FONT> Either Executive or the Company may terminate the employment relationship for any reason whatsoever at
any time, with or without cause or advance notice. The provisions in this Section govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this
<FONT STYLE="white-space:nowrap">at-will</FONT> status. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.1 <U>Termination by the Company without Cause (not in connection with a
Change in Control)</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall have the right to terminate Executive&#146;s employment with the Company pursuant to
this Section&nbsp;6.1 at any time without &#147;Cause&#148; (as defined below) by giving notice as described in Section&nbsp;7.1 of this Agreement. A termination pursuant to Sections 6.5 or 6.6 below is not a termination without Cause for purposes
of receiving the benefits described in this Section&nbsp;6.1. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If the Company terminates Executive&#146;s employment at any time without Cause, then
Executive shall be entitled to receive the Accrued Obligations (as defined below) and subject to Executive&#146;s compliance with the obligations in Section&nbsp;6.1(c) below, Executive shall also be eligible to receive the following severance
benefits (the &#147;<B><I>Severance Benefits</I></B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The Company will pay Executive an amount equal to Executive&#146;s then
current Base Salary for eighteen (18)&nbsp;months (the &#147;<B><I>Severance Period</I></B>&#148;), less all applicable withholdings and deductions, and paid in equal installments beginning on the Company&#146;s first regularly-scheduled payroll
date following the Release Effective Date (as defined below), with the remaining installments occurring on the Company&#146;s regularly-scheduled payroll dates thereafter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) The Company will pay Executive a prorated Target Bonus for the year in which Executive&#146;s employment terminates (calculated based on
actual performance for the year), which Target Bonus is multiplied by a fraction the numerator of which is equal to the number of days Executive worked in the year in which Executive&#146;s employment terminates and the denominator of which is equal
to 365). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) The Executive will have the right to exercise any outstanding options under the Equity Incentive Plan until the earlier of
(A)&nbsp;one (1) year following the Separation from Service and (B)&nbsp;the applicable expiration date of the options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) If Executive
timely elects continued coverage under COBRA for Executive and Executive&#146;s dependents under the Company&#146;s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executive&#146;s
and his/her covered dependents&#146; health insurance coverage in effect for Executive (and Executive&#146;s covered dependents) on the termination date until the earliest of: (i)&nbsp;the termination of the Severance Period; (ii)&nbsp;the date when
Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii)&nbsp;the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including
plan termination (such period from the termination date through the earlier of (i)-(iii), (the &#147;<B><I>COBRA Payment Period</I></B>&#148;). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums
on Executive&#146;s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act) or subject the Company
or Executive to any additional taxes or tax penalties, then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment
equal to the COBRA premium for such month, subject to applicable tax withholding, for the remainder of the COBRA Payment Period. Nothing in this Agreement shall deprive Executive of his/her rights under COBRA or ERISA for benefits under plans and
policies arising under his/her employment by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Executive will be paid the Accrued Obligations on the Company&#146;s first
payroll date after Executive&#146;s date of termination from employment or earlier if required by law. Executive shall receive the Severance Benefits pursuant to Section&nbsp;6.1(b) of this Agreement if: (i)&nbsp;by the sixtieth (60th) day following
the Executive&#146;s termination date, Executive has signed and delivered to the Company a separation agreement in the form attached </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as Exhibit A (the &#147;<B><I>Release</I></B>&#148;) and which cannot be revoked in whole or part by such date (the date that the Release can no longer be revoked is referred to as the
&#147;<B><I>Release Effective Date</I></B>&#148;); (ii) Executive holds any other positions with the Company or any affiliate, including a position on the Board, Executive resigns such position(s) to be effective no later than the date of
Executive&#146;s termination date (or such other date as requested by the Board); (iii) Executive returns all Company property; (iv)&nbsp;Executive is in compliance in all material respects with his/her post-termination obligations under this
Agreement and the Confidential Information Agreement when any such Severance Benefits are due and payable; and (v)&nbsp;Executive complies with the terms of the Release, including without limitation any mutual
<FONT STYLE="white-space:nowrap">non-disparagement</FONT> and confidentiality provisions contained in the Release. To the extent that any of the Severance Benefits are deferred compensation under Section&nbsp;409A of the Code, and are not otherwise
exempt from the application of Section&nbsp;409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the payment of the Severance Benefits will not be made or begin until the later calendar year.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this Agreement, &#147;<B><I>Accrued Obligations</I></B>&#148; are (i)&nbsp;Executive&#146;s accrued but unpaid salary
through the date of termination, (ii)&nbsp;any unreimbursed business expenses incurred by Executive payable in accordance with the Company&#146;s standard expense reimbursement policies, and (iii)&nbsp;benefits owed to Executive under any qualified
retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Severance Benefits provided to Executive pursuant to this Section&nbsp;6.1 are in lieu of, and not in addition to, any benefits to
which Executive may otherwise be entitled under any Company severance plan, policy or program. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) For purposes of this Agreement, the
term &#147;<B><I>Change in Control</I></B>&#148; shall have the meaning provided in the Equity Incentive Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2 <U>Resignation by
Executive for Good Reason (not in connection with a</U> <U>Change in Control).</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Provided Executive has not previously been
notified of the Company&#146;s intention to terminate Executive&#146;s employment, Executive may resign from employment with the Company for Good Reason (as defined in Section&nbsp;6.2(b) below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Good Reason</I></B>&#148; for purposes of this Agreement shall mean the occurrence of any of the following conditions without
Executive&#146;s consent, after Executive&#146;s provision of written notice to the Company of the existence of such condition (which notice must be provided as described in Section&nbsp;7.1 within thirty (30)&nbsp;days of the initial existence of
the condition and must specify the particular condition in reasonable detail), provided that the Company has not first provided notice to Executive of its intent to terminate Executive&#146;s employment: (i)&nbsp;a material reduction in
Executive&#146;s Base Salary or Target Bonus opportunity; (ii)&nbsp;a material diminution in Executive&#146;s authority, duties or responsibilities; (iii)&nbsp;a material breach by the Company of a term of an agreement between Executive and the
Company concerning the terms and conditions of such Executive&#146;s employment with the Company; or (iv)&nbsp;a material change in the geographic location at which the employee must perform services to the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company (it being understood that any change of thirty (30)&nbsp;or more miles would be material). Notwithstanding the foregoing, Good Reason shall only exist if the Company is provided a thirty
(30)&nbsp;day period to cure the event or condition giving rise to Good Reason, and it fails to do so within that cure period (and, additionally, Executive must resign for such Good Reason condition by giving notice as described in Section&nbsp;7.1
within thirty (30)&nbsp;days after the period for curing the violation or condition has ended). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) In the event Executive resigns from
Executive&#146;s employment, then Executive shall be entitled to the Accrued Obligations and, provided Executive complies with the obligations in Section&nbsp;6.1(c) of this Agreement (including the requirement to provide an effective Release),
Executive shall also be eligible to receive the same Severance Benefits as described in Section&nbsp;6.1 and on the same conditions as if Executive had been terminated by the Company without Cause. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.3 <U>Termination by the Company without Cause or Resignation by Executive for Good Reason in Connection with a Change in Control</U>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In the event that the Company terminates Executive&#146;s employment without Cause (as defined below) or Executive resigns for
Good Reason either three (3)&nbsp;months prior to or within twelve (12)&nbsp;months following the effective date of a Change in Control (&#147;<B><I>Change in Control Termination Date</I></B>&#148;), then Executive shall be entitled to the Accrued
Obligations and, subject to Executive&#146;s compliance with Section&nbsp;6.1(c), including but not limited to the Release requirement and Executive&#146;s continued compliance with Executive&#146;s obligations to the Company under Executive&#146;s
Confidential Information Agreement, then Executive will be eligible for the following &#147;<B><I>Change in Control Severance Benefits</I></B>:&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The Company will provide Executive the Severance Benefits as described in and subject to conditions in Section&nbsp;6.1(b)(i), but payable
in lump sum, and Section&nbsp;6.1(b)(iv) above, provided that, in each case, the references to &#147;18 months&#148; shall instead refer to &#147;24 months.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) The Company will pay Executive 150% of the Target Bonus for the year in which Executive&#146;s employment terminates, payable in lump
sum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) Effective as of Executive&#146;s Change in Control Termination Date, all Equity Awards that are held by Executive as of
immediately prior to the Change in Control Termination Date and that were not previously vested pursuant to Section&nbsp;2.4 of this Agreement (x)&nbsp;shall be deemed, in the case of Time-Based Equity Awards, vested and exercisable, and in the case
of Performance-Based Equity Awards, deemed vested and exercisable at &#147;maximum&#148; levels of achievement, in each case, as of the later of (A)&nbsp;the Executive&#146;s Change in Control Termination Date and (B)&nbsp;the effective date of the
Release (the &#147;<B><I>CIC</I></B> <B><I>Accelerated Vesting Date</I></B>&#148;), provided that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive&#146;s Equity Awards that would
otherwise be forfeited on the Executive&#146;s Change in Control Termination Date will be delayed until the earlier of (A)&nbsp;the Release Effective Date (at which time acceleration will occur), or (B)&nbsp;the date that the Release can no longer
become fully effective (at which time the unvested portion of the Executive&#146;s Equity Awards will be forfeited) and (y)&nbsp;shall be exercisable until the earlier of (C) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one (1)&nbsp;year following the Change in Control Termination Date and (D)&nbsp;the original expiration date of such options (and, for clarity, if any unvested equity award is in the form of
restricted stock where the unvested shares are subject to a share reacquisition or repurchase right on behalf of the Company upon Executive&#146;s termination from employment or service (<I>e.g.</I>, at the lower of the stock&#146;s fair market
value or the original purchase price), such unvested share reacquisition or repurchase right will lapse as to the shares of stock that otherwise are scheduled or are eligible to vest following the Change in Control Termination Date). Notwithstanding
the foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Change in Control Termination Date and the CIC Accelerated Vesting Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.4 <U>Termination by the Company for Cause</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall have the right to terminate Executive&#146;s employment with the Company at any time for Cause by giving notice as
described in Section&nbsp;7.1 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Cause</I></B>&#148; shall mean that Executive has engaged in any of the
following: (i)&nbsp;a material breach of any covenant or condition under this Agreement or any other written agreement (including but not limited to restrictive covenants) between the Company and Executive; (ii)&nbsp;any commission of, or
Executive&#146;s plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony or crime involving moral turpitude under the laws of the United States or any other jurisdiction; (iii)&nbsp;material failure to comply with the Company&#146;s
written policies applicable to all senior executives of the Company which are provided to Executive prior to the date of such failure; or (iv)&nbsp;failure to cooperate in good faith with a governmental or internal investigation of the Company or
its directors, officers or employees, if the Company has requested such cooperation; <I>provided, however</I>, that &#147;Cause&#148; shall not be deemed to have occurred pursuant to subsection (i), (iii), or (iv)&nbsp;hereof unless Executive has
first received written notice from the Company specifying in reasonable detail the particulars of such grounds and that the Company intends to terminate Executive&#146;s employment for such grounds, and, if curable, Executive has failed to
reasonably cure such grounds within a period of thirty (30)&nbsp;days from the date of such notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) In the event Executive&#146;s
employment is terminated at any time for Cause, Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the
Company shall provide to Executive the Accrued Obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.5 <U>Resignation by Executive (other than for Good Reason)</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Executive may resign from Executive&#146;s employment with the Company at any time by giving notice as described in Section&nbsp;7.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In the event Executive resigns from Executive&#146;s employment with the Company (other than for Good Reason), Executive will not receive
Severance Benefits, Change in Control Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.6 <U>Termination by Virtue of Death or Disability of Executive</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In the event of Executive&#146;s death while employed pursuant to this Agreement, (i)&nbsp;all obligations of the parties hereunder shall
terminate immediately, (ii)&nbsp;the Company shall, pursuant to the Company&#146;s standard payroll policies, provide to Executive&#146;s legal representatives all Accrued Obligations, and (iii)&nbsp;the vesting and exercisability of all Equity
Awards that are held by Executive as of immediately prior to the Executive&#146;s death (x)&nbsp;shall be deemed, in the case of Time-Based Equity Awards, vested and exercisable, and in the case of Performance-Based Equity Awards, deemed vested and
exercisable at &#147;target&#148; levels of achievement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to applicable state and federal law, the Company shall at all times
have the right, upon written notice to Executive, to terminate this Agreement based on Executive&#146;s Disability. Termination by the Company of Executive&#146;s employment based on &#147;<B><I>Disability</I></B>&#148; shall mean termination
because Executive is unable due to a physical or mental condition to perform the essential functions of Executive&#146;s position with or without reasonable accommodation for six (6)&nbsp;months in the aggregate during any twelve (12)&nbsp;month
period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family
and Medical Leave Act, and other applicable law. In the event Executive&#146;s employment is terminated based on Executive&#146;s Disability, Executive will not receive the Severance Benefits, Change in Control Severance Benefits, or any other
severance compensation or benefit, except that, (i)&nbsp;pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations, and (ii)&nbsp;the vesting and exercisability of all Equity Awards that
are held by Executive as of immediately prior to the Executive&#146;s termination for Disability (x)&nbsp;shall be deemed, in the case of Time-Based Equity Awards, vested and exercisable, and in the case of Performance-Based Equity Awards, deemed
vested and exercisable at &#147;target&#148; levels of achievement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.7 </B><B><U>Termination Due to Discontinuance of
Business</U></B><B>. </B>Anything in this Agreement to the contrary notwithstanding, in the event the Company&#146;s business is discontinued because rendered impracticable by substantial financial losses, lack of funding, legal decisions,
administrative rulings, declaration of war, dissolution, national or local economic depression or crisis or any reasons beyond the control of the Company, then this Agreement shall terminate as of the day the Company determines to cease operation
with the same force and effect as if such day of the month were originally set as the termination date hereof. In the event this Agreement is terminated pursuant to this Section&nbsp;6.7, Executive will not receive the Severance Benefits, Change in
Control Severance Benefits, or any other compensation or benefit, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.8 </B><B><U>Application of Section</U></B><B><U></U></B><B><U>&nbsp;409A</U></B><B>. </B>The parties intend that all compensation and
benefits payable under this Agreement either satisfy, to the greatest extent possible, the exemptions from the application of Section&nbsp;409A of the Code and the regulations and other guidance thereunder and any state law of similar effect
(collectively, &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;) provided under Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.409A-1(b)(4)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT>
or comply with the requirements of Section&nbsp;409A. To the extent that any payment or benefit described in this Agreement constitutes <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A
of the Code, and such payment or benefit is payable upon Executive&#146;s termination of employment, then such payments or benefits </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with
the presumptions set forth in Treasury Regulation Section&nbsp;1.409A 1(h). For purposes of Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> Executive&#146;s right to receive any installment payments under this Agreement (whether severance payments or otherwise) shall be treated as a right to receive a series of
separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding anything to the contrary contained herein, if at the time of Executive&#146;s separation from
service within the meaning of Section&nbsp;409A, the Company determines at the time of Executive&#146;s separation from service that any payment or benefit to provided under this Agreement constitutes &#147;deferred compensation&#148; under
Section&nbsp;409A and if Executive is a &#147;specified Executive&#148; of the Company at such time, as such term is defined in Section&nbsp;409A(a)(2)(B)(i) of the Code at the time of Executive&#146;s separation from service, then, solely to the
extent necessary to avoid the incurrence of the adverse personal tax consequences under Section&nbsp;409A, the timing of the Severance will be delayed until the earlier to occur of (a)&nbsp;the date that is six months and one day after
Executive&#146;s separation from service, and (b)&nbsp;the date of Executive&#146;s death (such earlier date, the &#147;<B><I>Delayed Initial Payment Date</I></B>&#148; and such delayed payments and benefits the &#147;<B><I>Delayed
Payments</I></B><I>&#148;</I>), and the Company will (i)&nbsp;pay to Executive a lump sum amount equal to the sum of Delayed Payments that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the
Delayed Payments had not been delayed pursuant to this Section&nbsp;6.8 and (ii)&nbsp;commence paying the balance of the Delayed Payments in accordance with the applicable payment schedule set forth in Section&nbsp;6.1. No interest shall be due on
any amounts deferred pursuant to this Section&nbsp;6.8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.9 <U>Notice; Effective Date of Termination</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Termination of Executive&#146;s employment pursuant to this Agreement shall be effective on the earliest of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) immediately after the Company gives notice to Executive of Executive&#146;s termination, with or without Cause, unless pursuant to
Section&nbsp;6.4(b)(vi) in which case ten (10)&nbsp;days after notice if not cured or unless the Company specifies a later date, in which case, termination shall be effective as of such later date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) immediately upon Executive&#146;s death; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) thirty (30)&nbsp;days after the Company gives notice to Executive of Executive&#146;s termination on account of Executive&#146;s
Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, <I>provided </I>that Executive has not returned to the full-time performance of Executive&#146;s duties prior to such date;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) ten (10)&nbsp;days after Executive gives written notice to the Company of Executive&#146;s resignation, <I>provided </I>that the
Company may set a termination date at any time between the date of notice and the date of resignation, in which case Executive&#146;s resignation shall be effective as of such other date. Executive will receive compensation through any required
notice period; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) for a termination for Good Reason, immediately upon Executive&#146;s full satisfaction
of the requirements of Section&nbsp;6.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In the event notice of a termination under subsections (a)(i) and (iii)&nbsp;is given
orally, at the other party&#146;s request, the party giving notice must provide written confirmation of such notice within five (5)&nbsp;business days of the request in compliance with the requirement of Section&nbsp;7.1 below. In the event of a
termination for Cause, written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.10 </B><B><U>Cooperation With Company After Termination of Employment</U></B><B>. </B>Following termination of Executive&#146;s employment
for any reason, during the period Executive is receiving Severance Benefits, Executive shall reasonably cooperate with the Company in matters relating to the winding up of Executive&#146;s pending work including, but not limited to, any litigation
in which the Company is involved, and the orderly transfer of any such pending work to such other executives as may be designated by the Company. The Company will reimburse Executive for reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses Executive incurs in connection with any such cooperation (excluding forgone wages, salary, or other compensation) and will make reasonable efforts to accommodate Executive&#146;s
scheduling needs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.11 <U>Excise Tax Adjustment</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If any payment or benefit Executive will or may receive from the Company or otherwise (a &#147;<B><I>280G Payment</I></B>&#148;) would
(i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this Section, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<B><I>Excise
Tax</I></B>&#148;), then any such 280G Payment provided pursuant to this Agreement (a &#147;<B><I>Payment</I></B>&#148;) shall be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; shall be either (x)&nbsp;the largest portion
of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax, or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause
(x)&nbsp;or by clause (y)), after taking into account all applicable federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#146;s receipt, on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence
and the Reduced Amount is determined pursuant to clause (x)&nbsp;of the preceding sentence, the reduction shall occur in the manner (the &#147;<B><I>Reduction Method</I></B>&#148;) that results in the greatest economic benefit for Executive. If more
than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#147;<B><I>Pro Rata Reduction Method</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding any provision of this Section&nbsp;6.11 to the contrary, the Company shall cooperate in good faith with Executive to
mitigate the 280G Payment such that any such payments or benefits or a portion thereof will not be deemed an &#147;excess parachute payment&#148; within the meaning of Section&nbsp;280G of the Code. Notwithstanding any provision of this
Section&nbsp;6.11 to the contrary,&nbsp;if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A that would not otherwise be subject to taxes pursuant to
Section&nbsp;409A, then the Reduction Method </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A)&nbsp;as a first priority, the
modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis; (B)&nbsp;as a second priority, Payments that are contingent on
future events (<I>e.g.</I>, being terminated without Cause) shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&nbsp;as a third priority, Payments that are &#147;deferred compensation&#148; within the
meaning of Section&nbsp;409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Unless Executive and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for
general tax compliance purposes as of the day prior to the effective date of the Change in Control transaction shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the
individual, entity, or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting or law firm or consultant to make the determinations required by this Section&nbsp;6.11. The Company shall bear
all expenses with respect to the determinations by such accounting or law firm or consultant to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting or law firm or consultant engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15)&nbsp;calendar days after the date on which Executive&#146;s right to a 280G Payment becomes
reasonably likely to occur (if requested at that time by Executive or the Company) or such other time as requested by Executive or the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) If Executive receives a Payment for which the Reduced Amount was determined pursuant to clause (x)&nbsp;of Section&nbsp;6.11(a) and the
Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x)&nbsp;of
Section&nbsp;6.11(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y)&nbsp;of Section&nbsp;6.11(a), Executive shall have no obligation
to return any portion of the Payment pursuant to the preceding sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>7. <U>G<SMALL>ENERAL</SMALL>
P<SMALL>ROVISIONS</SMALL></U><SMALL></SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1 </B><B><U>Notices</U></B><B>. </B>Any notices required hereunder to be in
writing shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by electronic mail if sent during normal business hours of the recipient, and if not, then on the next business day,
(c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying
<FONT STYLE="white-space:nowrap">next-day</FONT> delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to Executive at Executive&#146;s address as listed on the Company
payroll or to Executive&#146;s Company-issued email address or Executive&#146;s email address as listed in Company records, or at such other address as the Company or Executive may designate by ten (10)&nbsp;days&#146; advance written notice to the
other. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2 </B><B><U>Severability</U></B><B>. </B>Whenever possible, each provision of this
Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any
jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or
unenforceable provisions had never been contained herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3 </B><B><U>Survival</U></B><B>. </B>Provisions of this Agreement which by
their terms must survive the termination of this Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive&#146;s employment, or otherwise, for such
period as may be appropriate under the circumstances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4 </B><B><U>Waiver</U></B><B>. </B>If either party should waive any breach of
any provisions of this Agreement, it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5 </B><B><U>Complete Agreement</U></B><B>. </B>This Agreement constitutes the entire agreement between Executive and the Company with
regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements. This
Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company. The parties
will enter into a separate Confidential Information Agreement and may enter into separate agreements related to equity. These separate agreements govern other aspects of the relationship between the parties, have or may have provisions that survive
termination of Executive&#146;s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.6 </B><B><U>Counterparts</U></B><B>. </B>This Agreement may be executed in separate counterparts, any one of which need not contain
signatures of more than one party, but all of which taken together will constitute one and the same Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.7
</B><B><U>Headings</U></B><B>. </B>The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.8 </B><B><U>Successors and Assigns</U></B><B>. </B>The Company shall assign this Agreement and its rights and obligations hereunder in
whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or substantially all of its assets, if in any such case said Company or other entity
shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may not otherwise assign this Agreement or its rights and obligations hereunder.
Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executive&#146;s estate upon Executive&#146;s death. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.9 </B><B><U>Choice of Law</U></B><B>. </B>All questions concerning the construction,
validity and interpretation of this Agreement will be governed by the laws of the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.10
</B><B><U>Resolution of Disputes</U></B><B>. </B>The parties recognize that litigation in federal or state courts or before federal or state administrative agencies of disputes arising out of Executive&#146;s employment with the Company or out of
this Agreement, or Executive&#146;s termination of employment or termination of this Agreement, may not be in the best interests of either Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The
parties agree that any dispute between the parties arising out of or relating to the negotiation, execution, performance or termination of this Agreement or Executive&#146;s employment, including, but not limited to, any claim arising out of this
Agreement, claims under Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section&nbsp;1981 of the Civil Rights Act of
1966, as amended, the Family Medical Leave Act, the Executive Retirement Income Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall
be settled by binding arbitration in accordance with the Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association; <I>provided however, </I>that this dispute resolution provision shall not apply to any separate
agreements between the parties that do not themselves specify arbitration as an exclusive remedy. The location for the arbitration shall be the Boston area. Any award made by such panel shall be final, binding and conclusive on the parties for all
purposes, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitrators&#146; fees and expenses and all administrative fees and expenses associated with the filing of the arbitration
shall be borne by the Company; <I>provided however</I>, that at Executive&#146;s option, Executive may voluntarily pay up to <FONT STYLE="white-space:nowrap">one-half</FONT> the costs and fees. The parties acknowledge and agree that their
obligations to arbitrate under this Section survive the termination of this Agreement and continue after the termination of the employment relationship between Executive and the Company. The parties each further agree that the arbitration provisions
of this Agreement shall provide each party with its <B>exclusive remedy</B>, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Agreement. By election
arbitration as the means for final settlement of all claims, <B>the parties hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with respect to such claims, but may seek to
enforce in court an arbitration award rendered pursuant to this Agreement. The parties specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by jury</B>.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the parties have
executed this Employment Agreement on the day and year first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VOR BIOPHARMA INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matt Patterson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matt Patterson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman, Board of Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Executive:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jean-Paul Kress</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Jean-Paul Kress</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>9
<FILENAME>d27026dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27026g0625222229020.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-<I>Vor Bio receives <FONT STYLE="white-space:nowrap">ex-Greater</FONT> China rights to develop and commercialize telitacicept, a novel, dual-target
recombinant fusion protein</I> <I>in global Phase 3 development for generalized myasthenia gravis</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>-RemeGen receives initial payment of
$125&nbsp;million consisting of an upfront payment of $45&nbsp;million plus $80&nbsp;million of warrants, potential regulatory and commercial milestones exceeding $4&nbsp;billion, as well as tiered royalties </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>-Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical
development, commercialization, and strategic growth </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA June&nbsp;25, 2025 (GLOBE NEWSWIRE) &#150;Vor Bio, Inc. (Nasdaq: VOR) and RemeGen
Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein
approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125&nbsp;million consisting of an upfront
payment of $45&nbsp;million as well as $80&nbsp;million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4&nbsp;billion, in
addition to tiered royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telitacicept is a novel, investigational fusion protein that targets key immune pathways involved in autoimmune disease. By
selectively inhibiting BlyS (also known as BAFF) and APRIL&#151;cytokines critical to B cell survival&#151;telitacicept reduces autoreactive B cells and autoantibody production. RemeGen is conducting a global Phase 3 clinical trial which is now
enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio also announced that its Board
of Directors (the &#147;Board&#148;) has appointed Jean-Paul Kress, M.D., as Chief Executive Officer and Chairman of the Board, effective today. This follows Dr.&nbsp;Robert Ang&#146;s resignation from the positions of Chief Executive Officer and
director earlier today. Dr.&nbsp;Ang will continue with Vor Bio as a strategic advisor to assist in the transition through October 2025. Dr.&nbsp;Kress&#146;s strategic vision and track record of transformative leadership position him to guide the
company into its next phase of growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in
autoimmune disease treatment,&#148; said Dr.&nbsp;Kress, Chairman and Chief Executive Officer, Vor Bio. &#147;Targeting BAFF/APRIL signaling with telitacicept represents a significant advancement in addressing autoantibody driven diseases, which is
highly differentiated from other modalities in this space. With a clinically advanced asset, we are uniquely positioned to develop this innovative therapy, with the goal of making a meaningful impact for patients living with autoimmune diseases
around the world.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27026g0625091326078.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Kress brings decades of executive leadership experience in the pharmaceutical and biotech
industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (tafasitamab), and advanced the
company&#146;s pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys&#146; position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that,
he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A. and has held senior roles across leading biopharma companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Today marks a transformative milestone for RemeGen and the global development of telitacicept,&#148; said Dr.&nbsp;Jianmin Fang, CEO of RemeGen.
&#147;The strategic <FONT STYLE="white-space:nowrap">out-licensing</FONT> of telitacicept&#146;s <FONT STYLE="white-space:nowrap">ex-China</FONT> rights accelerates our mission to deliver this innovative therapy to patients worldwide and will help
maximize telitacicept&#146;s clinical and commercial potential on the global scale.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Telitacicept </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and
APRIL&#151;two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia
gravis in China, telitacicept demonstrated a <FONT STYLE="white-space:nowrap">4.8-point</FONT> improvement in <FONT STYLE="white-space:nowrap">MG-ADL</FONT> (Myasthenia Gravis Activities of Daily Living scale) vs. placebo at 24 weeks, the primary
endpoint of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia
gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, and South America to support potential approval in the United States and Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vor Bio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio is a clinical-stage biotechnology
company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious
autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About RemeGen Co. Ltd. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Founded in 2008, RemeGen is a leading biopharmaceutical company in&nbsp;China&nbsp;committed to providing solutions to the unmet clinical needs of patients
suffering from life-threatening illnesses. RemeGen has research laboratories and offices in&nbsp;China&nbsp;and&nbsp;the&nbsp;United States. The company is committed to discovering, developing, and commercializing innovative and differentiated
biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27026g0625091326078.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words &#147;aim,&#148;
&#147;anticipate,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;enable,&#148; &#147;expect,&#148; &#147;initiate,&#148; &#147;intend,&#148; &#147;may,&#148;
<FONT STYLE="white-space:nowrap">&#147;on-track,&#148;</FONT> &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;should,&#148; &#147;target,&#148; &#147;update,&#148; &#147;will,&#148; &#147;would,&#148; and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio&#146;s statements regarding its plans for development and
commercialization of telitacicept, the potential of telitacicept in various indications, the timing and pace of patient enrollment and dosing in clinical trials and the availability of data therefrom, the expected safety profile of telitacicept, the
market opportunities for telitacicept and the ability of telitacicept to transform patient lives. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties
inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio&#146;s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim
results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to conduct trials or to market products; and availability of funding sufficient for its
foreseeable and unforeseeable operating expenses and capital expenditure requirements and Vor Bio&#146;s ability to continue as a going concern. These and other risks are described in greater detail under the caption &#147;Risk Factors&#148;
included in Vor Bio&#146;s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date
hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors&nbsp;&amp; Media </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah Spencer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">857-242-6076</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>sspencer@vorbio.com </U></P>
<P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>10
<FILENAME>d27026dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27026g0625091326078.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vor Bio Announces $175 Million Private Placement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., June&nbsp;25, 2025 (GLOBE NEWSWIRE) &#151; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of
autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the &#147;PIPE&#148;) that is expected to result in gross proceeds of approximately $175&nbsp;million,
before deducting expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio will issue prefunded warrants (the &#147;Warrants&#148;) to
purchase an aggregate of 700,000,000 shares of common stock at a purchase price of $0.25 per Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PIPE included a syndicate of world-class
investors including Vor Bio&#146;s existing stockholder RA Capital Management, as well as Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners and NEXTBio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio intends to use the net proceeds from the PIPE to advance development of its clinical pipeline and for general corporate purposes. The PIPE is expected
to close on June&nbsp;27, 2025, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants have an exercise price of $0.0001 per share and
will become exercisable upon approval by Vor Bio stockholders of the issuance of the shares underlying the Warrants. Vor Bio intends to hold a special stockholder meeting to approve, among other things, the issuance of the underlying shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities being issued and sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;).&nbsp;Accordingly, these securities may not be offered or sold in&nbsp;the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities
Act.&nbsp;Concurrently with the execution of the securities purchase agreement, Vor Bio and the investors named therein entered into a registration rights agreement pursuant to which Vor Bio has agreed to file a registration statement with the
Securities and Exchange Commission registering the resale of the shares of common stock issuable upon the exercise of the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or other jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vor Bio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept,
a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words &#147;aim,&#148; &#147;anticipate,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148;
&#147;enable,&#148; &#147;expect,&#148; &#147;initiate,&#148; &#147;intend,&#148; &#147;may,&#148; <FONT STYLE="white-space:nowrap">&#147;on-track,&#148;</FONT> &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;should,&#148;
&#147;target,&#148; &#147;update,&#148; &#147;will,&#148; &#147;would,&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking
statements in this press </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27026g0625091326078.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">release include Vor Bio&#146;s statements regarding the PIPE, including expected proceeds, expected use of
proceeds and expected closing, expectations and timing with respect to a special stockholder meeting and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these
forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a
result of various factors. These and other risks are described in greater detail under the caption &#147;Risk Factors&#148; included in Vor Bio&#146;s most recent annual or quarterly report and in other reports it has filed or may file with the
Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new
information, future events or otherwise, except as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors&nbsp;&amp; Media </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah Spencer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-242-6076</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>sspencer@vorbio.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>vor-20250625.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/26/2025 4:40:31 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:vor="http://www.vor.com/20250625"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.vor.com/20250625"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vor-20250625_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vor-20250625_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>vor-20250625_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/26/2025 4:40:31 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>vor-20250625_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/26/2025 4:40:31 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vor-20250625.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g27026dsp61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27026dsp61.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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'% !10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g27026dsp62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27026dsp62.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MZ("+[9;?\]/_ !R3_P")H%W;D@"3J<#*N![<E<"JY9+IL!9HJ=O*P!10 44
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M ** (9ID@7+'G^%1U)']/>L669YFW.>GW5'"J/0"M(*VOW M"*BK&%% !10
M44 %% !10 44 %% !1T]L?AC% &E:WF,1RGCHKGMCH&/]?S]M.LI+E?ET%L%
M%2 44 %% !10 44 %5I[E(!C[TF/E7T]"WH*:5VEL!C.[2,6<DG\L8[ =A3*
MV2MIV'M\@HH ** "B@ HH ** "B@ HH ** "B@ J];79BQ')DQC@'J4Q_P"R
M^W_ZJ35U;:VP&L"" 5((/((Y%+6.WR$%% !10 44 %% %.YNA#\B8:3]$],^
M_M_DX[,6)8G))R2:U@K+L"T$HJAA10 44 %% !10 44 %% !10 44 %% !10
M!:M[EH/EQN0GE>A'J5_PK91E=0R'*D9&/\]16<E;46PZBH ** "B@ K/N;L)
MF.(_-T9QT3'&%_VO?M]>E15WY(#*HK7;RL,** "B@ HH ** "B@ HH ** "B
M@ HH ** "B@ J:"=H&R.5_B3. 0/ZCUH:TL&WR-N*5)5W(>!U'0J1V([5)6%
MK:;6$%% !1T]@/PQB@#*N;S<#'%PO0OR"<=0!V'O6?6T5RH-@HIC"B@ HH *
M* "B@ HH ** "B@ HH ** "B@ HH ** )(I7A8,AQCJ.Q'H16U!.DR\?*R_>
M3N/IZCWJ)KKV%^A/168#'D2%2[G:%_,GL /6L6XN&F;NJ+]U,^G=L=_Y5<%U
M[ M/D5Z*T&%% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !2@E2""
M5(Y!'!&.F"* -6VNPX$<IVOT#= WIGT:K]8M<K\N@MC)OR?,09. F0.P.3SC
MUX%4*UCI%=!A13 ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B
:@ Z>V/PQBN@A),49)).Q>3R>GK43V7D(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g27026g0625091326078.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27026g0625091326078.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P (8# 2(  A$! Q$!_\0
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M&8LV.!6FQP'JFE0^1I%I$>JPKGZXYHU738-8TNXL+D9BF3:3CE3V(]P<&K8
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M\^*[8?\ 3HG_ *&]3WWPR2V\.2:K%JF7CM_/,;Q8!&W)&<]:@^+/_(UV^/\
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;N8(IK.3YU19AE7]?Q'\A17?44IU.=\S0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g27026g0625222229020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27026g0625222229020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U )(# 2(  A$! Q$!_\0
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MPCGVY_'VK,\9:TTMV+"W<A(3F0@]6]/P_P :ZK7-372=+DGX\P_+$/\ :_\
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001817229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 25,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vor Biopharma Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1591163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cambridgepark Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-6580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d27026d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d27026d8k.htm">d27026d8k.htm</File>
    <File>vor-20250625.xsd</File>
    <File>vor-20250625_lab.xml</File>
    <File>vor-20250625_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>25
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d27026d8k.htm": {
   "nsprefix": "vor",
   "nsuri": "http://www.vor.com/20250625",
   "dts": {
    "inline": {
     "local": [
      "d27026d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "vor-20250625.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "vor-20250625_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vor-20250625_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-06-25_to_2025-06-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d27026d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-06-25_to_2025-06-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d27026d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.vor.com//20250625/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001193125-25-147339-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-147339-xbrl.zip
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M58'3^SX?J).;LZS!6C_W48;588( 0/TB5T H,$R?2)87;E$0WGJ HXA/#/<
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M^TRUDT,$6JZ$AS7>0: :^<F -E/Q9C2T@,;BT)^++UZ$9@X9&@1L:W#["$#
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M:5%$]$(&MIZ[6/!T.OA<S<Q:>,RI^Z$P<<DMGKGO!LENM\+57FYV<,82ZIP
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MWJ?4FE -]?';Q?')1?/HVY<OA^>7)WOZC]FF3)FS!WCV+B;>@_7NM2W-M,;
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MZ/>BK%>J^O''7#U5U1R9*!4/F8A+V2=]OS$(W0E\'J5C_^#_ 5!+ P04
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M<"N7^!\<I@/KL8,8<D2WUXU"\(]G,_5:R0<4O@G"&/VJ5A#%>'Y1\GM2C%,
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MH[.]]R"_X/%\RHO/T2$^@B+^7;>/N_=Q=Y+3TD&',E1M_>+2C&T::\W::Q\
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M8K-;E1<TGHF;Q18Y-G'U>@^".B#^6CBOG]OV+]#''9RM6XAMHT?>5%"GG0/
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M[ZKIUJM<&*47CJ#=@H14INO0E'?BTE7HFYV;*Z[R$P39DJ-&+WVWH]4"/[Q
MYA"*4B327X4Z6[*V S1LS9GX(_*7+HD@[)1BK*)!+1.MQW:D:'@I4B"OD>IN
MLX^UHQRD>FP\Z^5\3B483<"-90BQZ77J>*!U(6L7Z%I7&X!)M[SMH)(B,#!?
MK9=3T$GV$ [22"D(EB87V*ZI*.0AXPU*:::CD/>+R$[EUQV?JY^,XLZBLG4=
M6&33D8S?@'+HX4PEY$YS4RL26"D*OI +U+0M5D\8(,U^<34E.]R;T$E1!3KC
M6M!.58N?92A1",.LQ 1OKE9FKZZ^X^T-8ZW7W@D()%T9\8 '8P6^[M:E6.=<
M27A>:<<P75N% C"Y5,$ 4\F/J(M15,") X0V\Y%RT>)=B8N]U8Y"Y61L8;AU
M8YG+,Z:!VOR@-1W-]G.PY@@)H.GXXB_E"-3+RA/Z28X2I1NG&9>R705^TEMK
MU6B:@GALGE=#>D_;%M,I%302A:VSXIJUC, [LP5Z.=)[1:*Q5-)I4!G@:#$8
MJ&[,<\:WNID=%AC:EVB.FMF@N:QC&;V0(&T<";YW/G)&N W<BID-[.<""5R(
M75S(OA6W.P,*@N6148LHTTG"M5<4@C;T6.-F1Z8W2;O7_DL$-_R^95&F36?I
MZ7]3PTM \V8*N<QF7,92D<#6(4N3^$YH'C)W,0RZY+$RQ6C".$OR9;FZ&5 -
M:[ZLZ8]?=-M> -+0U%IFMTX[ME*#GRJ:Z:ZT?MI!I_$H/#X<X+R10CA1CN5$
MGS_NFF8\6!V>:=0F!5$Y8Z+EM&)TI*!_KR&ZUR4ZNL8J7M"&I#8WT*E.8";1
M%1-5:S^OZ6!#]Q87T@;JEM@5"03.9H4RX:W1\\76I>5G6$@\RR\1N2@T5]TL
MZO7N&,'M(KF'PI4)J9'MH?:H1@X;T#+V P;ER%LC&-5566M[<74O@QP#5SY?
MTATYC#0Q'YS41<R%FDYPRK)3N_2:/9=3,)<)"G?M<PS!:)E\;? FLRWFS^7J
MR5UG\W9>Z3:RA[E*7BZZ=WLZ7@8O=4&K@U;'EC*5JJ[69>I7)H2;EGH?7MXI
M(>]A/!M+:05!V"[UEG#?;M[.DY OJ"<GN)TE>)S5)KE)H%P_1%/GE=6=IJ1P
MCT6WT\.1^!JHE]\-9=\022Z9PMFN;T%&D[0ZKLNTY&)OB8G>R(9<J]\;47&-
MTE8-M-6$\!E35:.E[Y(M^2S!YR$1H%M^F6,)_1A(06=MRHQ?SH=,]]1 %RM7
MJ?I'( >0YLI94ZQ<^[-:(4*EN)MT:$-2&I+%[&]&D'<]_.KU 4,5<N.,,N]:
M@6H&DA\:XPV1]#CU)8M+A?A# @!+->KRBI6Z%.M?@!P^8V(;HQ:NRK"$O ;;
M4B*;$&P+#MO'$G+-V/.V/8SAY!>W%C%9.U4'Y0M=L<O:#^I<^ 4N[X-J7P47
M\M!&7/>NW:U$V_4&.6R>*<@(U1(85:J@;R\ZO!XY+Y'H*[U07M%+O,=^I/P&
M\>_D4:5TMZDJ4F4=1RN]162U664(L_:O"Y"OT[BX[>CBM+8R <?)<\D&$*>)
M;I?&3'^K;)"H9R;SQ8R+PJ/UCZM2E-J&YDI1&/M;F^K(6D_#<M@\-EO"&P4%
MIU.!<(+9+/UM:?T+Z"UD\6:YL 1F"M2N9LCKD*B5470]F@9-"E&F&LBQ5E4E
M7/6HI3]Z3IH755G<H,0]6G6+-)[Q#K&&U6()>L?8=&.S34A<3X&:'MZL0L5F
MZ<;4HNV1UC%188U*JL)B)46"D8N^,IV-BEK6C8L4,O9;]D(GTBP)W?Y!IJ%K
M:AK$G\#PUWG5DCJO5KZZ.K2J,NT57S208&R;)+@/:7%O"W&C.8);G#-V874R
M+J$C!V\(CH!0U[ZEX^<[.+'1-#PI58<A-SF)TE^/4QLTA/L62+4C\@WI'N0(
MG!;X9Y -G31H&Z;$T&YSV(0MFIM3FV>N>CFE(LDI5RUR]$2\2W)6A _-)93J
M[;P4I-L:VS?AB-Z.D1/&+KF&.&C;<FURM= Y6U"+]BE'W?QJ2^06^Q@;MK2G
M.T%1=-T=^=Z]TW8WG'1B6I^^P\*QU]&I;716WEP:HDIK73]/AQ2Z+R:T;6NR
M1/?IX\B17,!M'LZU?6NUI);*%PABH5D 'A%) L;-Q,7*50<KC'K##-.&)-!U
MX+ABNS-7G9A*&IV*9M/3H/F+* T:N4Q]HHXJ7D4ALFP- M'8KW=8ZR(@Y5I:
MVO\YL<MY352-8NN-4>O[:E/9EU3(V'],E3E,C8PSET_K*SBN4D9HF8&M<..(
MFA5?,(?+'Q>WH:&S/?*1JZ[<-C2H6C3;>DQCV7BUN5N%:1"_\\M ZXK7_AU:
MZ9Q)I4"7C1/PJET2RPX0VVMB\'0GWMUY8?M8^7U+.SIR.#:X5+Y<I>+\N&&[
MZJ_"G']&OT2?ULN/_[73?7BP^ZC[WX:3W_>ZR8=__^!C+/VG.&&H1%6Y&LN\
MRNL>=O[\+[*;3_7=<!NVUCV%)-7XX7P9@22/BX3</G*;)S]_MR;^P:?9K9]F
M>SFSUB0[\>@G7G$S73/,%\^QIGQCHTRN!=;.'O]$-#^H Z;&C%!K=0X/5=/3
M"!1AYUQ6ZDQQ"Z]3SQ=)!7?:UQNVR6 E=3K#.W76IAKR*4GD7(,(<PDP$JE"
MPRU91<>?@1W,DLDEY8C+7AO*:;%RNH:%>W:"!DW4Q7K8)"JO6)M3MDS?DX5I
MTUHT+:QM"BG'AXJ^R0QKJL]DLW9>]9&<]%_KHJ!2Q$T*N2^ET!Y6R2!/E31!
MCEQ1[PHK"QKC*UOQ5N+.;J#>L^>PK0^]:5;=T(B^?EP=HT%AD%9,X80NX *U
MP6!=[4EBHEDJHC\G(C%C3[@A^4K&JZ%&YTL*H7$ @U6*&YI9.Z1DV[>=V(6N
M!%JK0W4.;3>Z#W5M:'!?W$42]"A-[=KXW;T8:PF5<MVTB,+'L(D47" XZ!(4
M0VMIM%6L UY+&^&X!,R(&W].N.90WG2+UHRU!SL@^V5X7ILUJ5LO<.Y<+&^!
MP!MQDWK12?_C-=CPA(MOG.31&RF]!3>9P;S;(7)N'<Y<J/]J12;E!7N99E(/
M$=#F?I2[?5W_\-@+O[*X=,]]3EK5R4![K*F73=6&5,Q7>#X4$-1<8E:Z.BJ%
M+SQ/-;H9LC9>X@WG-/S@4EZ@D(\A1]AC(L?V$1><=<:]7(C$L[(GR;^NLU8\
MD=1&*F\Z0>)33P)M#*_(BS!XTQ(PO6\<4'>QQ5\:TK$Z*O<1LPIN.**0[>OA
M3Q%5][!*[#HBN/\4TT $H#VC5'?'KC!= >))Z<DFE>HLR>6&I?/-B[T7+WX(
M@@DE>8P"\21[3%?6:8X*L3EL3@<+RSVVP'<O"L4K&\6!?:B;TE*G%(3#$*/<
M:4DYP'4UI+ZE#'R3O4Z9<J9UC0O'L4I8:W0QQ7Y*$\WP$$,I:E,\$9,*AT0&
M"NZ?MHQH,5M*K^VULZ_.RRN267*-],#0A38--BPFF!I.2-$WF*S(D.%:61M"
MA@?W\- MU3J*@S6C>(9V5[*P+S/'U<T6[@1O$_O: &2_6+-;12'!]*4BE'H=
M><$]DR7>7I%45_G,#Z759+]M]:!XFN73=?1;^H;KO]VHU)O.&@0Z3&'GZBM;
M\\TXOR7Y-:SGZZ7U9AYT"LU>5(PE[EB]%7)"G\:X*'JRYYIPS_U]VZ^E+1E^
MLX.6ADQ)LR!7][D9I=ZU]KA(+!$40OHM& 0'LZSC$'5Z'):L\&BO?S'7EZO%
MQ(H6&0)%Z )!DH<]/#:H@AMCGMATQK9D#)#?=W'C-NW+.!_F><E>.9@5=CM?
M+S;O/W[X#^MMW?B5_[2O'%*0614-$KR_N,/-!OGIX3]4+I9$IY"+)L(6J)B]
M^=W0]^4%X"Q7##*N[;5Q1HB.B>"E"CRL[G5<S8&84]L$J>2(XBS+@7:S]:">
M$+GSU+QL";FX(NO/UEUHDO#F^A;[87L;<4Q]L79L;X(&X:V40OV>I,C(#$^?
MJB>YRP]'1GL)*&^$M[ U1.<HN^I!-DB. J& _#9'1C:YI? H)<=5VU+)Z0DW
M#4>3QG4IQ^*)%QQ 395&BCR#$YM3=-\*WU9KERQ<M&Y2-@I" :P/-VP6L>'X
M%$>*.]](HD.K0]DFM3".7PD^%V&!"V-'"A5$V$J*O4"OO=(-1I7S<Y>B%OGF
M+EP;ZS-2C &<G<E#P 3MYO#X"QBG8OVXUM##F"Y#\32LIF\B-<K&0:BY@(H;
M0$NAI-A+Z(>TL+T3XP(&2*8ZTX!R>VOMM6I2[*UXBQ1DZLFD&M^G7X;.$?7S
M;5"FB6;4^J>0!.X*C4AKY*N@PD^@3/.E;D!F?KQ9*NL$VO,=PR.4S <OL&K8
MHD;ZSODET"0%:4NHIV0]GBS'R8K6&.RJ-%&>D^TMO>I&B.XTGAH6.G:1QS9J
ME!HATQ)J]'HBW9H;FFIXVHGJ+:<::JHV<TTH*,6BPZ#D6T<+%I)F8YO7VX[+
MYH:&2^0X*0J#-;;D.]TNY9UP80*4&221W\889FUI3;J&'[(0!)ZJ<'A?4O8U
M0Y&]M[<:588T&ZLB;F$9M;44 50JJI- 3S7Y-$)W1=C11RUT=70])VF7?H&B
M-6:Q[2UE%\.E.U=1R)ILASAKF.FHF@$M!IX:5=L ,79\NL'>N\WTJ-T0#TNO
M22\KU71XVG383/3:&+BA><X^U:B3,L4JVP#C&_9Z;/:KW_W0A1>87VWTUX5M
M3)8HJZQS&)I::2)VK-2/7:/2BEQY-QR71T'$$L=LI%N!OUL[E79:39]4406-
M]K6A2 HB>W'3WC>F<G2QV\E<%%"Y8#<'MU;N%?D_3.Q=J3/7NQ[9UI J6[$-
M1R1.5%1+][WTJW6VXGTV%J,I+YVFSJE&,:ZP:!?:[;ER.931[\[9L S3?9A,
MM-9'RG&*^,J/^\!Q)[%73L>$_)8FLC,)$V 4\N+8&5XE+F 1N\1W"F6/9X[F
MN9@T+_N2*< ]-: 8;2+,J$1&J25'=4CO8CV-VPU<EHR+I8:#FAOT"R]1P!)9
M)NM<I2)@J,:R,?;RQ)V N=[FIE?D]1@EB:PUHK?TPYA1Y]BPUT%P$1N\&+,8
M:P1*A8XUQG1?;&W+V/.N8\L]JM'RW!1>7&>[WMY: 5\3#2X[5#+/--CW-W16
MX8'[P_WX58XOLV2*W]D@I7?_Q_@A*@@[^[NV'_U)+E0AS50BA"4=WGE]M\Q]
MN65N1;,C53/'U4,R1F,30Y;.5/+/RC(/H8LJ*&)::WIEZR#2%&UU)+#S4M@;
MB;. "F-?2['<-%(E$]<%6\\2W5^'A%YDLTS&T9:5PUJJV[;<WHT8A*_&>\W2
MQWE1<&R !R)S^8/H  5#XATF!H83M(0YI)DJ VJ7;:+AFL7:1J/0AD%+^Z;J
M#N53?$Z$;7/1]N5"0%ZJ?9.05$HE< RAI[@Q()*7N 6G( 8E9_GDW6<V5_EK
M=1!"V(AX<Q/#N%JNMO5$8E7;Y:I1X+N?*)DG.DK&"P "^FF+AICL!]N:#\ZT
M%M LQ3QL6%;8>-VS%]0VWW?=F/%!-5%I"D'92 1WC90O.%3=5@61N^YO.97N
MC28HV_#M :$7@ IXG]L&WBU):B8APQGCJ$81?H5YK*8-+Y?<V+G@(B.2,E.+
M)][U2M[5]__UPND7X<=3'S]0*E<8T14Y7,12_%&+?//Y,I/J=27?16ZSC<J9
ME00V<#]O;P56,Z78*A.HI\Z*D(07/:-?G.HA9Y#$!6 <>R"\6E2F<QVIJ=9'
M%*0=Y\$&?5U%?!/PUUH_8/(0/1-&"!&#S@8B3/#>9%*@^.ATN,#19!6>YR^?
M/H[.]M[O=>BL/^7%Y^B0A!WRUZ#LK-TL8053NAS:#>/4\6\ M^LT)F+[#8#W
M[4!'()G09><6LY20[,?U%Q'J&9+\N &(_:;GG-NOP:P'=^%5&LJX!:X'-*7X
M EPUBS*D!F!R^&4&-QUH#L V(U?0. ?%C()*BFLJP41;OL6AZ5QM?5+<K9P*
M=NO3#2+)B"CN$)/5)P"39',*!LKGH28?I&73S<3HTBF^?L6A$#SC_;#"9YK4
M&>[11?^KWRH[R)GCJOD <00J&7AO3!D6\MTV%2C#JB';6Y)LR@;!P#YDK:]J
M0A0T0*#(4QP;#NS&GXG)L<F&YWI\8=5/75JB-H"IP$:UC&V)#3T@FXA)-T3+
ME"F!ZVHOKYEO>\N?T'5")5/-;=.<=]N",2V&!>M5U617+P $]I(J.!&+-65D
MY7*4[C:H93HI;MTI6V9&#&RZ+(@IQF,Y)VF+VCR:R!>V2!!YV5PN<\J5BO%5
ML74$0,BYVE6*UMP=N%U 3F&CW#4(O^Y@A@49%:A,4#K9#:R>C6T[9I@A;:@E
M^I&N4&H2;FIV/9!@^WN25Y[K2_P^+=&DS2[F>X[U9O%:"HY24=RAR\WG; R7
M'^ $W'IFAU<?UI )J9%IV\40(3;G-HZ!^Z5<&!;8:[/ZT5'6Q: *H['<&RN<
M;33,%D+K\[E255VE#K'M+>L[XP.;$^;/F%B*AI3J8.>^NLT5.*;&N]4.%%-^
MM DJ"O,;XN.ML<$4^9F:8M\:E#7B9*,O$'X=5CES]@U1 1;<@ZF6H6B>+6-B
MZZUS^()7 EQ2M?.I:3;6V.*=?B)Y2E>DYU+UL+%Y/+N,Y[91;G8MA6]S9:C8
M[=AC=_1GGB3(!,I.,TI(U:,%LPS;:<H-VO%+VE@WCD^#_,P"JV<ZM[@IN"UY
ML@IEJ7JV7^%XLFS/60E*=F"YVM48V&3V*='JPUH=!\VP&8FLX%[YD"KWRT#I
M1AZK/;3>P1":E35,] *H.C: 7BP<;DU4&ZXL.?*X'I0&WXQ!5DNKO%:/Z7LY
MPV_>@/R-2 ==N D%7H72YPBN_)OKG22V)@["*MG6B(S?B[YH2Q2ZN.42,K8-
MUVH5?)ZPQYW$)U6E#E$0BT7-V$& !D$GN)'/0?(6&RB8=0+GID!Q)^R=82B5
M5T5,*)]J&:?=3>BB-BY/5X;,[)-Z=G./QX2"(_@+A%%^@7*?H7^+I*#:).)<
M5CR@T7_3<4V8T"^**7)TTEX11]PEB$;&B36&5TGS0FCGW.Q#VD]0E\5L8IZL
MXL\2X66?L>6(2VN:]:R>5.L'B*R4$H0/E4D,<TS,R'I-^:.VE.0E4$!<-& 0
MZN1(+#]J%#%J*0B>21%KT[PJ6:N1D* $$I&-:7,^9#+HZR*U^'R8G(I5UI7#
M$:WQ7-N7/$(H61 1]?//V@OO:@>VG;L#4K-1QM'0',#=@3UJA;ISE*JL9ZO&
M40TS"5J=)9>DHC!B8T'[6XXPH,S-]88@K"*&%ZBD!D[&JA& S?+!]F1DBA,;
M&RV_E#SO0MR*-AB#[.: *V12S2^XJ)&%C]2N8IL?9DHD\X6U_PFA*IWV*-'4
M@"B8$8']*R[R"5H#KBD _E>XV.4DM;T5J 9;$_#149<9+'#QM[FYR$$YG>:R
MX0?2<).OFZ./7O:1Z^*&5:Y42= PLR$X $3,YB(?0?<M]%2S'U175F@BY*N!
M+V%N!OR5J3.OSZ'BVFV=1IBN.R24$O()&7/IN**FT[J_;L%#HULS+076"DS>
ME$!W.4E4]RIU"3>J4H5B++/XAD+D@_B<"Y*A8-S0X[Y'41W;6_IAT:S"%W2+
M+:2J^)V)&3(J@A\C;_*/ K?2QL$1O+BZ,'LA!3GS3+B/%&S$48/>F6&S)3\2
M,BVHC^I"[.VE?Q(,@-([!7;EUM.EC"B^@0 .HY"*)>J4Z:)5V9)T*]=]RV28
M+LUO2Y!\J, FLLJ.9-+3Q2%##,)6U[+SJ AG[?RI1?^Y=UP7A30B1;BYCR@=
MBEUAU(2V<W;24JT)Y4-IQDT?7!T)UTD+=;2<@F;/MLF688+(&I/8J9(]\5I'
M=Z66&KQWE5ZDU+P452"0.C1IEQ?,TX&969[B/:551W8<I%+B.B]$V5M[ >^#
MIG%CARZU*4-BQ2<[<%7U? N)YY@T!?YL[=O8#L-"UD35DN3:G;ZTBT_ ZZP?
ME]H;;I(P_W2<YUX!;]FU 7A['-_\'/U=,2!I'7!\'/WG>6\XZI^>#*/#TY/#
MWN"D?_(V&KWKX<?A:'!^B#]VH@^@.A[U1Y\Z4>_DS>G@L/<>=,BH>W*TO=5'
M9?)LT!MU\='H] V\WA]&'[N#01<]3>]PFH->]/;T PS?.XH./N&+9@+X C_)
ML$=1_R3J'AZ>#HZZL!Q07T?O:#G'W8]#'KL'<.R.>OCAI/<Q^G0Z^ <]=GH^
MB@:]M]W!430ZI>?.!OV3P_[9<8_>A/G>'/</1_0!AL-'!KW3-W =NX?OS-B'
MI^_/NB>\0OS\[O3XJ#>(\%%8=W\PZ'TX/>P>''\"J?/\X'T?AI/9>O\\/#X?
M]C_THK^?#_K#HSZ![KLYX"N"H;SSQA-YTX/#Z![#*9T/ /+#_FB$^ HX0V<'
M"*K1HA,=G Y.S]_2X;[OGKSKCD9=0&; -'J^>_3W<S@FB[=X[D?]X=DYS(8'
M?GZ"1P\/P_B /2<]/E'\B? 2?J%_\;T1(/NPRP_ LZ/>^[-C6#7<#T$=>!C&
M/CP?#@')\3L8= ?P\QB6 %N@@0:]X1E,8C%*7359GD!$SW9T>GB.CPQW.P2C
M.JK"702T'/+/W;>#'ER(DU.:I@O+&8SHTL'HP_/^")[B<6'!9X/3PUX/U]>A
MWP^/N_WWL( NO '_YU'.>H/AZ0E<<GS_X.]N_=M;WD60'0S/X;+1^7WAQ9/=
MV'DCV,&'_B$1!%KP<&CI"X(%5V.^/^@AK/$%H31F0>T[1W+UOML_QC^[,.C9
M)T,XH@_]+E*<_A"N#XQW.MC> @HZZK_IPR=\!T<BJM=_^VX4'?6.8>&#3]$.
M'7;O0_^H=\+K-C_MXF)I0;R[""#-F'HTP/7#DGMOWB"($8<!^K!OVF!_I ^7
M3HCW);!A*DPDMS]"_'Y[>LJ$=WC^YDW_L(\XU@)(GL:12_C\#J&!:-[MGQ@<
MA[596G_4 ZPE.GS<?]^W^/6Q^XG^'1 \<*MX$G8R>0INZ@F</$  7ATQPP!Z
M?1=T$13!U=!<!*,N7)L^X O\#HCYZ3X$%>[/\BZA\(72"*#8>8F_,6(:VI^G
M)H,T2[E-2X9MGB8YJ4I:7B'O<$W*\3, O#IU9)JBL&>5#5 /&=4ZZI\JOG#3
MC"$6R9=H4UN0S>0M2$M'TRDS#!@ON?[',DLP<G2<:/,!.L1F&%9J@S+]@LXE
M>_,N;4,E,;5I!;XCP9QDJ>)*)7JFV@J5E[Q(%K,8TR19H5:[D$2$,2O=Y17E
MG3?VJN?I33-XYXHW4>JY1!7).K:WW"04<,O+IK@OM6H.PW5I35P?IKWJ%?]N
M%6-K1%N87&PRGZS"GR?/OH&<8,28,0DNY.C^KT$/R"]R;Y(ASKIO>Q&*J2=(
MWHE3'??>C**#X^[)/_Z;7>+?I;1O%&< 1!S8VPG2\X_,,3HU;9(L!1,?IZ0=
MQ7)V*ZT+C%**RK,I^H]U!*?IF.WR0K$HY(MC.! 3QUP[!@WA-=13&T'*%8"B
M!HD'$EN-HQ"DY2C(\D$G\6H$$@DPH][Q\?"L>PA<\9<'CQ_0YS/@V>:SG.<S
M/$X020$OZ6M9%7_S$'#@N'LV[+TT?ZP$='@J>,J,K*/!:_GCR$S\MQ_@6CP:
M';D?/LA6>+,.X\R#_OLOGICOX3\#-9/9@D+ZE%*97K+OZ(Y;"!8'!P.P/$70
MGN!MP:O] <CJ09HOKN)B'D?];+S'U]>LS5^7FD"-_ZZ',@'L]D=_M^I[-^V3
M!ZVC_W&[?GUP^U*O+#PN68 @T\.#T]'H]#WL\7=J;C&)_O*8_N<0N#X4 =?'
MP(V&^7/AL ((:_;V^B2>)R__=RUYA"$:+_5%@W^0PKQFSA1]9U'?1D 8'K[K
M'9T#Y=Y_A<5CJ8*LDP+N4DC\*Q<":MQ[5&EZ_^P-#OO#GE&VS&K^R/+>Q_%$
M"MEL;[V%)5&&T,LO**9^-^E^?Y=4'BX&S@;U- PR,T+!"8J/YZ__^I>?]E\\
M_YD+\58VMU^>,NG\K@A!G4E@*OE1 M(]Q=VY.(SM+36>JC-%E9L..3Z/Y ZV
M]9+88G2TC+-,G0E_DDQUEQ/7W=YY>^9)G)&B5ZN-]S6)3G<[@"=T *8<.Y\
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MZO;0;.90B/'EM5HM0&F:P$S"0&%ZS$F#FZLYNH\-\.;MK\DE;H)7;\]/>1O
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M! -)Y7!1F!)*T4-*3*&&EAE95A).9+./D%EHDL'_IJKG-*!@+;*:XHM)"&+
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M&&'#M/M+C(GYD_GFZ.0HY<L):2(D,<9A)TPZ/_OHA.ZL,1L'^Z6'J%%N5K5
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MP1/6!O0(2F(FY3G#E"!\##.<Y<J:#>Z1GNWH29$&TSY=F<$-[DPF%,TUH9I
MVQ(%W=]3[!SYYT@'JD1V&,C3-IS;"1M(N)]3O1F:Z$)H1 =M4K>\HJNYGC<#
M:I@5]P@+8_%-%PKW,B"-4 AO[.9:80:@0!-@W>#<[.\9L1G+2B-'?33*O9+_
MG:N>EOBD6##HL4M:FI(\G$;A2A.^@X:Z?!_NS._)1;.M+,-G2;DY?GS7[L'U
MUD-)"%4(3^VR20TD/"6.*.=A\9G:' =T.0YCIZAH0VE#UR7(0UM,_/AQFAP_
MP8YAF\<4A9<S&U1N41F-<"_B3O';CZ*6(PD5C+@=<&=II8DSG[V0G!V='#W&
M5G9C7KEX\-C!T$Z<PDJ2&D?NYE;G $8.DW" REXQ=PG>G*F.1W_&LY:IZ JV
M]/  Z9XHXZP2!O!2(Z"BYP8PRQT*088X+Q(?&(>6M0S64*M\R'\7\GA(8-DI
MNIR)>)T+Y(XZ@DJO1^\-]4TS$CAWBO(,O/ FSX7K+^8ID3Q9%JV8.>(2CIZ)
M=JNXA5K/7..1"/0WJ7@5-/(A]TY#0VG'$7ZX_=5K@\.UA-ZJASI!+'. 8C&E
MNV!9-(N<- /R]V&Q24KY" !@5<V5A3$(1<7/N0^<YRDG#!Z>SP>35 .HYV60
ME:9HFP^PL8DR)5R7 ,%>RQR(EX$T,-A^5Q7V$)Y$+^Q-D=]^JH7V$;)MPK+-
M9].:A8K<!D*T, C2/U"6AIM\L8[ /$Z4PU$>(-(\%+KOW6&:&$KHR&@.C]16
M_XOV.EQJC?=R)H$0P[5>+,$/1;8<6%*HEE$:E+NC,@A]*= C5I+<3!ZRI0X*
M#M)TB84[/ESU'5-]<Z*R=HNCW#GQTH28Y<:#EGWPQA##D]GGR>')"9$U(/P6
MU6WC[HP5%1IPQU63B*A-HMWH!=^B$NP^/(M.5^+G,RMGH[,C=7D.7>Y3UIA"
MK&5E1$^JT'OK;>G*K)L5X=39"QJ#:>@E;F7A/H(NS6TF[H#T$[59UN W=X$,
M%H+PL["&2:]:'%?CD-X&\U>B!;^0#8W%#'#^MG87[_L'<%NZP*2G.3GDTZ0V
M <6[&]K/9!<D0F:$'OF-.R$YZ$J,J4M.?G]U#C<"D(=T/+G0=KW% Z6,V#U*
MJO8PDQ"K*9M@_6RFKJ_S9IAX7$55W:4AZ2Q[WVOV#8GCT5=R,%-(1V&5-<A#
M@+X3O,K@,>9YB[6-(:E;&T>F&0$-SUW#?#GB>9$;N<[G"Y9$&V:7[MR\()</
M'A9_9]$UNXM_%(T5-%EFNQ1+V&:N?77P?#X;Z@<">,/](V'-%UPV@8VFYT)*
M^Q*TM.4DKR49]9CH9I^X2\*>-.-U3 >I+NG,^2RK( >K*A?K\9-C$JI*D14^
M'P8U.'<I!I%2FGS:X/W<[BA+-D)?]B*^HQ0L^WO*[.OFI&BF'=&LPO$I\ZNJ
M+<S%&7200$LJ_=KJ\!DZX(+QB+)/Z)RU^5CH]2CLXFGJ<)"#C@@7HW$!(^/1
MY7@=F_<NCF>"7 [R:N?3)3 T/M-F4PX(TP0X]YFNH?FU*5)PXZB\A/S Q?)<
M8J9[^V>1+,\<6 8$5G6+9$0IO\+HZ/M[GGK4.UF()H_'NVQRL!K0W\T2,UO0
MCVNQC">.L*RM#$9/5:[P94G_75QNAS:SZ$78L'*AT9."4_.S&SG7T_$I,$5R
MME?#HQIK/WZB]7%G[@!.!]"R3@;.Y]!^?)1A;JOEVI9+,O5A5A5>CT19Q@\6
M4W*CFA"KX=R0C1QHJF%%C:N\N@+]"0X5>03C5&(]A"+W&E/-J9_984XL'@LX
M3W@BD5ZO0C8'-U+OD7[VJ>ZMCU@$6 5%3KH9=H@%/+62"LB3;F;38O25RRVI
M=4H=LP=]XOB\M9J/T]^#:8L*S=YQWK[HWBW"W4N+'F]ALL0ZA#!P;DU_'Y'U
M@KFO01A>=M<?LKF^Z"3='"9@AK37?^] V&$V!EHO4ZR3BX"[!JRD94&Y?W69
MS2JB%5Q48&NDR;*;-0MD\<)S7^<&*4FI^K ?8<099@LBXT>>L4YK]N85%UB"
M.9KE(!10C*\*^B=Y#P5L?)UG"]#70>K75XQ2ILP^:HV]YLOLMQSC$E*L;+L$
M45+5@47SV/-_YE6#12LUW$>W'?%@R@=.WM(L5F'UNH9<)'K$)6$:*R+I]WTZ
MQCA ,LNGL"X>2.2[XM:(\R@9!48*IJGPQWK%$FVFK&8VA;RNJQJ,LR1KVPS)
MYOZ'"NH;$#B1(DESS&"D>2M!]6%KF?6U>^@S=+H0%E%23_/%/ V57PW\11H]
M>H_SG%-^5]UDP6SR?C\NV)>VRE"%Q7IN2X6EULS72D"%%94+13:%K"XIUN?D
MB%,7K'4PEZ/,/@^DHQ>*: )$;9YCL-M1]W7\%TV+=!!NDZ$?7;QM@9_[JJ!*
M%0IE#(A$)+G"LS?'>J8\,*A+8@;;-F5RDP89NCJ95X@[-SP095SRSJ" V,7#
MM X?H(S1^2/R;Q(/]Y)*<?PP,IQ?0U^NP@QI8A9 0RX3G&+3%6UJ$D-@&NM)
MT6I5.!AJL4RE3I?#EC(O;LK^;J1(YMV,'ITUHI(U8I%&!'@#H8;V&DPC6!9T
M= WD\VQ ^-W!T?.9C#%T,M4:!*D9JRP!^/V]V[I@MY1B0!L/#6T8)C4E]L$@
MJ#.*!#48+0^_S2BQQZ9*N;28'2;,)_9_'J?7_MX;L2=M!TKIP5>/V,=#GMRR
MK7G+R2ERQZ8'7Z<*'9)<3?<"IUR/X&5M\UH(&!923LX"/;YP(BG.WACYVHO\
MK34#',1#M2#9G['$V-^#!V*PO*LL*1:] I-1_1I$'MG4N6@8S)?BQD$CXU>3
M5Z[6J/<<),.4GIAU[?H.+=Z+ #]FE&D(57B=W3[#8MG+0H$CFX[="!8Z(K>A
M-<>5)1KO&XDR*'X.(P+NZ2:.)Z>*B6\<KK\QF/XFE;!EB.K7'1/@4!%]FMY-
M^KDH!^HWMI-W<?L+ HM30SX++=EEWQ(.UX ;4$H2U/0D6P)-8EY<B[>Q!3HB
MT%<<HO8Q1SNU 4%*$*0FQ "K/T*8#P*'N?38Y%O8A1B&#F-^ R8!ZR,$(Z;[
M!6]'-F*0P:;/ZN#"M2J;O*<]B@0/S2+ZZ5WCSF,?$=BQBNKXZU85I3::'[(M
MMV&ZG/]7]TBA0:N/P--O/J]&AO7.(ZH4*(@/=M*DJAHK7$CB$:<):WT"L".T
M/@IZ%)W!LJQFGK--TSIP9XS/3;K[22OF V"1KIQG-]!5A#^ 1D1I7B0Q!.,R
M9\6&M;8==!2;N+,M.O<E13D1R&'A#3JJ6-GKG62SQ'16QLC8F:JJNN6,6YPD
MGS]OD^-5NM""2PH2@U@EFW6%6C<)G6JU5NHJ]V]J VLG<-6"68X^T\:5;TCD
M3_J*"'X%@ZO?TT=!F0QXI0%D#R%5[>5L\@=0XR. T:$K_[1#3C-:+"6KX1P;
MP)/RX+JZE3^IYXHH:% UMY5F*. $$D==+Y@46.!>8)I^7Z;F('8"T:Q2?3B8
MK'73YDL-8$WS6:=X<>*19IF03Z_+:E%=B<2S.\;E/_'R[._UQ:G(0.=!(F]/
M0P Q_6*SF TAV!OY2S=!H[2YD1WO;I]GP<L'G^X= P9..@Q:(YX). -]0AL0
MU(.?#V2N6\@2I;"GCL//!0%D5\.5URTGM:@W0@&VS:XU.+X1DCWG)!F:C_T]
MG9!G.[UMRZ06(B@B"@VB'IPTG+KPS!P Y:G>+)."U._(]RB9."RF5]G:(C'K
M:ITM4)F[XB0?]\W^GDLBY5.#_DWID@TR&SI^D19^9M=C*0L;9\CF /?\(V)9
MU%XZ.!X-1&#U_!WCEAJ#DL3E00 TD(&8 N>\:QHR^7P'E_3_.8*MZ&9=%@UE
MF(& R[B(\PR4I58N8'\=B79M:AR-228R\/!WM"5VG<;]O<\WCU-,%LAI@/0<
M[74V%P)6%.@)W'&<R.NNGI1D1MU<%RN"V3;._1[-^>C&N;G_$4?"01:&(<UR
M1+8-X\9QV6T1-V45'#=B6V2M1&:1$\WMRWW :$0^,<YB7N0+<K#C(C!7$7)&
M@1;1T+6C>DTL@0-Z2T;,X7,F)\0G"XZ*W& NS";F*E%YSN@X4#<S]7B"%923
MCNB +U7L=-G?X[C@EBD-#'29C*\NM(]WH<5H9#W1&$;0?P?5OWCY4M'@+-MR
MYO%53JM$;!(,1GP5[ON=J':HTEA;L%]>(*UQ$Z#S;&X$0=53J>DVT$J)@<JA
M$8C9Z>@(;O#"@4%)X%)<@4P.OL38$N_]>L-^]U8W@V[UB/G]S' RK^_H@=)S
M8!8"S97A][B'J<#5TB%48P?GU"3_<C0)YA!I:_BEG&E&;<QZ#=#!'])IB,J=
M&G.F:*Y%\VA<(-A;W&8%8:*]HC)L-G# RT,#9SG1%3DCA!).N/2DI%C.\ZL.
MB]CRG2^_W"+$0N+)H/JS5P#R>*]P)K_K-T4<3,HTH>5NBM%9<AE%;F[]0)7/
MBKRSKE&X%4WHO(\L&;XP'(AL]$900XNSNPV;9YV/YA,^2R*R^HII9__E^.G#
M9SQLERUNV1CF#NZ&OAMV/RS6O2Y%3A-7%LQX33[>!WGBK7K&BK(D"ZQNX^>_
MFQ&6[&Z#83]']1FG!Z2&K51XHE94_=T7+_?55Y]M5X\"@\MMN5FNZ*7$WOXZ
M36AC]&=IM[<Y*PX9KNAH*5-_,.,,,^^=BJ+FB 12:L!8*TZE-N=0NA#"<]Y)
M9^'12_7*)&\IV!,1-[^_>'?YUKI]!VRB7F=]R:S(EJ/Z*GIM<M0\RJ/S^T4[
MCAT0LX;RW02/,O 4N^$YT9O.%"9WNM+.;"(2@D;6:F HSG-IAL..&VR/R+F#
M"RI31R,%3$HU%WJY<X2@D,WBXZ="AQ<_S'[E<$(CAHE/EQD#CM9/3EOXDHY1
M8OD_%04@><[,4SV.?Y\H']+8+(H/,D<[.'XE^57>D;Q;@&V@U\;^'J:U*1B'
MKHH9XDL:19*/\XAJHE:<4TRKXI/['(L9;;C3\[.+$W74S,1E \>YP W]CI4'
MU0Q.YG-\,S;R L_=":NOCQX>/Z24+\D=M@@_\UZ.S VF#E*<*J2-[8=8ZF'^
M/^^_Q9>$M9:I)0X=;7B["4K8DKTFGL?2A2(W#6.$*)_2!9:B& QOAEU.B!P%
M.)P;0W@.';/()HC8*)H5X9-05_[ ' 85"-P&S@=:5&.(E=Z<WLG.-X@8EHF(
MC"*'Y!P[Z+::3SU!-;X8J$^G<XN<6JZRT]9!]6-==Y[G?S*10Q4CI'XX,3?!
M7C:5Z;=&'M?^LIM0Y#M@.O#Y/EYSR?@-Q":*U9K0D=HA>P%B.[#VAKY9\D6\
MT\VWQHRL>,Q]&<"95-I;96L\AJEY'/E>=<%_](Y97X*^<=M5VENM\FS1)(-<
M1R"\EBN,E2H>CRM"P>&DRW8F)0REI1E,#XH!X<RU;2I$E53=(9+;X71HGU2;
MAGF$=V5!^_B[\0W<_ICY2NC+3)D8N3^Q&[@'DF"7EU-#LR4.C'8:;XN=@MUU
M;HK!$"]+!>-J)/)G]TG=LEWKPC\(T4<HC;"%80*L3^FFN:!9ICW3Y"W1W(KM
M/ZNSVS(B(A"*7Z=$TR1+=E8P$JQ$"E(6-E%+!Y'S1?$_*\DPBLQ%R;!2]KB.
M!?\$B\&BBX62<[.XCB#>%>^/+HX<A(@KUF,Q=81AXQ0T=X?)^.Y$6C>5JG<N
M;ZD['W2(S2K.^=#BSYBY"#=]$O"=?/_#=P?3PX-'AW"4:[7,!:+KLY&+<ORG
MQX<')X=X'KXFG7[62X*(R$_+FZ*N%/CP&G29?FVAP;/JY6VL/L'EJP:*W@Q6
MC^(2?.EFA6I DPIQ;"NO0,*VN^Z6J.ER0HBZCUJQ6G,_1)8C_P"=K.KX+JI^
M+Z8T, %"4WY"0P"O5;58=&TF5C.E^Z-,Q+\][4$P?_M[/(&F9I"7XR2_/-H%
M71>,@C)*[2:$3I0_;J:TOX8"-Z>H&IO>0=JNB5AM4'Z]ZF^21"QFAON?N@@F
M.2,=DV._Q&99E?%[^EU/+9))ILN/W0''#-K#&P3T9OK(M"$J=<0QWQ^6&5+4
MOF_97\3DL_T#;^(R5I.W"G*WM?@&^H^L[$"1$](I2A9_F@8@*\_8S!.(##M=
MJ:Z$ W.AVB#I84K*-?V"@'79")NO;_@=C(UO0K1J,/ZKV.S8DQW"PPKEA>AO
M3WBPMW42HF"ZF]LLS()PY>16M4M\=G:(B+6!H%:OY_J%Z;:XX\88<@;'(SMJ
MWF%]VRTU:W67.R_")R [HQDD:+,9MM&U<0899$@ZJ[GAF;]1R$"<)H$<853$
M=:8BM4:$3>Q0/8Q_M\-O!O;/IYT*!9&%Q\+>0YZM^5;X_*2?&:<^T1S$//0[
MG9UTE\-#6\!,/\\9A:05'/4Q9PM'+MSTLY&-:2>!Q:;.1+^(0<CR8@%((39^
M\$WW8CQ368)++(0A/KI^ >8QQ'/#1B.[\C'EFBG=L2V'0J3UM.JU"RD4K0,
M>'20R+,14$PZ@O,2>)>%<;&[7:(#D9-V5C$MF[S5)4TJLJ3SQ#?!4LOO!GPU
M7:/5Z272H3YPK5K?:R\\*'#Z^FZE(>98L+\HNFMGE/*%NF+!ANHU BQXDW$!
MZ;[@&$H@,#\3')G'C?7!I]AP8X(,/,&,^_3I==X\'IL\H:"Z\^R%0]X^PN&I
MM%H_YG0SK.VVE BZF>-[.9G?,<2XZ6I?-<EV&6N42N6#H@FJV= 1$L\[!T"D
M$<UT=@X+5@Q!*+O@5ETT'QH]F?M[GFYX3O<1O+JF:[8IVHZ$)GU6:FURK#2C
M[J((Q*JZ7,RIXX]<T8HQ+E0X@>@@,RRZ>Z24059>%>1@X@(0O%]%CM&@_ 2L
M"%?ADF8&@\3XSQZ_PUTJ-7O%>[P#05%//\M;$29;'\C+V8-J_H#>LQ;HB")(
M\+IW?*]\*;N>80D2W% (\MND/O2ON78HS6A,TPXS%S(.2^-]7C4-+J+1M^*2
M*!+'"](9W I$,[P.W8IU/N\:?A&<QX)+TI+@I=V?79$!@]Y-U[I"'S'-Z3=O
M? <O9?B?O]+C3GSUX7Q6B4CLRP-E?KULO%MI^PSM'*WEC?:VP:F$-,:/D!]K
MB+A861"1'3Z?A2SP;-!(?__"+!\7.4(QI-^FPD"S7DZJA<3W__KVG%TJH< ?
MICIF!:CILXQ"=^7=0<&= *5A897R\&MIBRLG/WGZ\"!#KV2Z#2U^9%B2-Q A
MNA@< V@53FN LWS2?3[Z1X?7!L)W^WN@+,A Y78B:DQ?4XA2'\C:N2XFS"ND
MA9H8KQ#5 0@VU Y+SI!5+-HH)>1[C?A-87=:OP ZAVX<)#GB5AU@QW/Z]BQ'
M<*/H"L'@ B+]H1&.=>Z+5VPY)AK!BZR>($G/@[>_+_(U=L7) DMA(\E+H[>:
MR8*^RST?.7L'R][U.LBA_H>/6'287P_&U#%0URTXST+T7#QS=)!H+>Y#-7U$
M3!0O%D5)_#HOLS:CCI][*C.?Y2QD^-O4%E@Q7I)5G3^82M-2?Z'M9@4&=WWA
M2GT U#1<E\9C"#9F2A!0R3!!CJWN2"P3W?#5M%J0<>&)R/&K5R]/U.\@/O]^
M*C1"-&M,B:3HDFC2N?6##$00AN(#SUB&\U!7SJ>[=8[;CYKC1*;8S]MDO1OY
M!U:!SJ^SQ7R J(!HJ!7%WV=_I@V.B>R>)1X6A2C(+5LYUV5J%=8*>RYOQT]M
MF)TVA'W;.H5T7^XXB6@PA7.8!F-4-EOKB9@R935,[=\[O (K29'3WP3;NT=S
MN54W#_U^$NJI<7XJE ;(*Z2$\["C4[N?-70UD$6^X_[6 W(FS$#,EG5.C/+)
M\PKASXC=AEMKVA"DDHX8O5%9T.@U+&>=[]64481SV2"1$OW;NQ_$Y1NF0YO%
MP9#O3@<(M_G'KGU\?D9/!SF#@N,Q'.N._1Q!T*2-2R4*90BZR02<QZPUPBK2
M$!/)#F?:!&5,ZT@;()%#';77X:AU(@CAX324_9UZ G=B) &]#?;YP6.QV(B=
M1$#$E"!$B#A>7RFL,<LG&3%?TYXEN.ZT6 4I-@&*H*J=;);@Z90Q&$BD25E<
M'%EU0T"+,*O1CU"GEIB6RFL&VU_(D7I,2I9XR1G$NIE%;V,ZR>G.B? T;-:G
M[7:O:DVDDK]@O]T4]'.E(:JI2H!/CY!)\K%3Q/+>O1^B%#XZINE^<816S+??
M/4L>/WZ:)=9KY.+A>*O=B^(RR,#R,V\&PF(.8@+2^*")K U/F#E*>MC8J:3G
M+>4KJR0SD1U,?NLGX<[W *!8)8V+3,2]3PZ(IRS7&EN')E$$SA,7KX6SN"QX
M1>5.VE2*@JX"_ <=IY>&&F2NK\=?_DRGYX(I AK%K5=8NI<F"0<MA7G$C43.
M!J[D\$N.E2!J45#^-5NNGLEGQ<RUR3^3AO%7+XJ;8B'EN[P2$?;P/[H&+[L
MB3H0H3>[_W-CS\ &BZ*.KZK:(9F&#&6'N.CO385;2 $MA",Q:MAM"9XEE7HG
M95L\^%!,/TPRL-\NF-$G.7CR2$_KUEN/C[,6='KT,'OPW>1@<GB8NKB7WGKO
MKM<-R&#8!>\R@O_"/7[1E<TU[$>R?3[QM=<#[YS2%G@%-RQ6!LN*)==H/'@<
MB2,52M\]^@%TC*3)_WYTR#.%<K% 5:3?B.ON#I04@].4N6GRZ^-ZKN_ML6'9
MZVE>9YV@3B==DP>G6;%_7[V,'Y])2I)0^=&IHH:O_P$2X?C[P6WTZ/MO4_C/
M=[0PQX^?_"#H*[V!"4;\B;M]=+,OJY*H2XB+$7:*,*I]ZONR@1>*_'%AJ.0=
M3(S&LBF9@4&]^I$X.(Y_^.%;VYU@[O!U,W,&?<J#NCC<6WU*Y:4G4J';\U1)
M4;$3SA4A/XQ$3?CV[WX -4#?;L!M/Y^].SD)X&QZG[P24?JJJD '?5EW5_S=
MBZI9YG"W\/MB_4<%SL/C2-Z\0Y+8J?95[K:-?7YDVN :34:G(K,L%:-,M M5
MLAK)D3%3S :>%AP5I]^@O\DZF2X'#&>A!^"T8A= Y;L/K02I&\95!<EE:HKW
M6E\[*Z$,M\TI1'Q5!WFI*3H[YCDI^]M-]%KA.N4#E[NGGGS?I.YP.$P%J"84
MD?(7L)3D%%9/!5$+JI+JPJ\PW0C3^[BREMB43K=W3M=BR?%LM.AB@CQG&O>]
MNT)8-V*[JQF;QN:[6H!D:.@OT/*H*5_91.(&+Q(K#+$=*CB%OJTGWS].761O
M[DQJ1^=URZS%R0+F"6>GTW T?V"C@7%_I57K>" 3F# \,IVF2$((&]* 8TQS
M]K$DM4*(VZ?-A2NYIG\($,(3!AASSW#K&JBFA#@8 S6Z!0A63V0Q-"Y"_1.(
MOVHEPYRSWS%>NO4,J._#GP2OZ?)GDW5J?!4#0"5TOEEW@X]RQCKICJ"AM5+U
M*<D2Q;,T=S;TM&KT/.T1BX4LBKZ8.GZ!F"#EJ+348U30?+F2?\_Q&="W<P-\
MM22-4HS79M^%V&0),LI=95/M!U=6H1&>W0NKV*C1'2 BQJ@?I=1/"+;>=GQA
MXO1W08(364APAUEW_0G2/A(JX40SZMUO-^73CR441WRDB:?FJ"W+?@"PEA?N
MO)OP(RIQVRWFQ4)3LX0C74#G?4^5O8.&$GS-N$LJ82I5@8BO<"JEUB0O"@OE
M2,$08ESWR(=%MF*6(;IHR:JD\UW=IB%;HW5?JM.;,0?L[RUL?2*X2K*B5KN6
MKF[#/):3'Y-9@?N3.G"_;'(-8R,V_\E)9^-Y&-Q$:T%PL25#!4,K3D.T>#N7
M#4T^V76OOTT ;][(5#32"Q\A%9R)<(G1$7&.1)YJZF'<!2>M8NSMO3BNB&_R
MQ"?0O6!D,$N6EYY6(/C\G6,E[*/'E'P!<Z^8R)"18ERR0)''"0HT7VT'EU.5
MN8-,&/'9D7A.#J3MM2D?9P^.GQ[,#VVD:?NOGL["7PU ,0X'P]M*,6=H7>!J
M%5O&8Y%8#;:7W_"@5=QQ/0<GW@;K(\[)(ROSZ9P] Z%%+(YHV5P<1DWPD,HL
MV73H^**,\FTC,\1]4>*!7W<X_= -Q?H%S#<S,"\+&+B&UX3#0PK#2@7'H:,9
M5)D3Q@NM!<O27B!Z%C:-/0Q^5^?2.4X.M!>GW-,[+<#H5!\4X=M)#J[XRM_?
MHUH<<$$QFV>M&%0I%!BW&.D&T!<XLDI@I-M%@EMS.*GB(Q;L^(W#I^E.E&0,
MO1U %,![D4C"(= (,EOJ>W&*IG"Y\QRGS&Y7VWF/KE)=*LGOI F8\@4E;DNG
M#,H='Y8@T-\/3;FE>.AAA:+?V[C\I]92)2XCSB6U\+S;//M0DL*I?6#10+JY
M(:H.P)[:ORVBT)NU@5S57[/J9OA>IE8P^T,MOMQ/$J:Y%:8[."I%FN:;I:F
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MJ,K"W<Y 8HY @,*[<\#A603)VQ!Z>!8#KWW(.K;<='*>5UE-E%@O-2]9:%Q
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MGM=/QB2Z;@MV#L_/W>$>GNH_+D?#Q;*SV"_;U]F0W<CB34;B;4W8$E).U1[
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M.3)2((Q2B9(82/N%O QV%CX4$90XKQ@(YQ[J7E$6BU33)-I![J;*XX3RX6_
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MO?8_O[W<?+N^N?W?&?>#440;NG-/W=K<ZY_VOYH/#\\_'N_\!5!+ P04
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M@&TP]><0CE$.K8/T,&?U!9W54 ;\)GTQ9Q$F-WC$;QUS OG(;OT4PA(U<%!
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M#L*>4F"VU]_/YE*:8$RF29-A40W;*4*U$2\4>(8<R#]-RB%CW(:$YI0P-0%
M,5(]*FZ*44O@7D*!TE1FHL-!JWN91&1O,T)[DK.= PL8A085:@ _'6!L&*&G
M#!H:D'N)QX6H81F9!-H'HBBER=BIQ::_8,W-<X*RHRT(JUDC-HK!7/1A;3S.
M'-M)$*70+!BP4+>3AN(AV(P8'&%TA,W*&)F4)DWV(9^1_9G<0OLYC144()X
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MZ/_<>RA&+7$="8"?<LZ(T9E/ME0Q&N6#C.CL25@14GY8S(.LK0 G4E;N5I;
M_Y!1-LC[2WF!C IP(T"C.:O0U5*EAD8;[L(R#L0(7UB'7,QRD3FG@<HQ4=I)
M;1ENS*I!PV9CR@JZLM+<//D+!,U-03]78JZ*2G_XS"29)!_W1QS]BG[0P'LZ
M(B;!@T.:[^,#M&&?_/ \>?CP<998SYH#<Z!"LQ6EM9?/Z17O!L+;]N)9TMV=
MZ*C)/1N>,7.8]+BQYTU/7,KZRFRT?NM[C%=LC\2E8^+>)WO$W9=K3<-]DZ0%
M!XIKGL-9G!:\M40;65)@AGV%I 7@/^A G1BFH;&^'W_ZBL[/!1..U)HT4F+)
M=YHD&+2401-7&TECKL_R:X[U72I13O^13>?/Y;-BY)KDGTF[^*OCXJ:82+5$
MKS^&'?SOMD8])T ;]\!+S/9'N 9B%O\^O,;+LG)@M3XWB4,+=?>F8H6X8"$A
MSA@9[K8$SY**O:-94]S[4 P_##*PWB^8'RS9>_1 3^L&^BX?:"V@]^!^=N^'
MP=Y@?S]U85O5>-Y=+VH0P[ -WF4+MH(OVEE]#1N2#-_.>^_VUNN>5PYI#[P$
MY0HK,6;%E*N[[CV,Y)%*I1\>/ /U,JGS/P_VI:X3BL8"U=!N*Y_6W\%>YF;)
M+Y#KN;ZVPZYG+ZAQE;6"+!ZT=1X<9\5WTG'6H@14[,67IH%M??BT;RIV=QX\
M?9(F#Y[^0*T?/GST3 !P>I$0WOD3IV#IBDW+&;/YP!T&HQ66P4]]7=;S/CE$
M9SX<\ YF1N$$E';!Z&/]2%PTA\^>/;']"?81OF]D-I)/SE GC7NM3\J]]-Q"
M*(9.E>T6^^!<*?*[:/N%+__A&=QE^G*#+GQU]N[H*  4BE#<W7DI N%E68(J
M=5*U5_SE<5E/<Y"0_,+X%M=3<_\P/#3).Z3_'6IG14*O[/0#TX8SUD4Q(*LR
M%9M2;DC5%&K)Y3$SS/:I%BH6OV6?PXSN+^<FN^PQ_84W@1/37:R4!3@JNU)K
MD"N1DMO7U*ZV\0+6I1@7G%,P^*H*,IM3BMJ3RKIV9Y>53\IWR9]+<_+Q+!5P
MO4+W=G?,^Z2.K]"U*MI;@*TC+(TRQ[PHS!#EJF\2C7(:JG,<%U,.7:-A$I-&
M.M.^XZ%>[7M0,SQ-(N^#VC&D+>LO4'VN*.'=A-RL,&1RF5@:8D-4# V=<X^>
M/DQ=#&_L? *.XNZ6^:B3"<P3SDZK@6?^P,;]X@Y+J]9QXD!4,INF,DD(W-+(
M8LS\MY9\>'>GGWU8F(Z[?,APKU3T#\$\>!8*8[08TF2#EI4P#</0EFX!3Z*#
MXZ+L!$HV*!NA*"@K"8QNP!BGSIN0Q(+U-?YLL$B-KZ4'*X;>0VLU^WAFK%EM
MB ]:*'VELD_UQ^1LF#P-H@222&*915,/&$X9_J.\K9:-#Q58,"7DWV-\!K3&
MW$"/+7&I5/ V6/&(M%3BI')76;*&WI55$(0GO#.0\0#Z$%*3F:*94F KQ+NO
M4690Q=7?!9E8I.?#'6;C#4=(A4KX@R/E9'"_7<7(L"PE/>+H393P1<SK/H2[
MO.]@=V?#W80?45GL=C(N)II#)NSW@OMW\!'OSC%W4&^*N!_WC,H>2RTNXO <
M2AE 2>#"\E12I8>X]#W&89+-F7Z);EJVC>CQ-"0PM>Y7N7")8MHYK M;%0RN
MDJRHU#JCN]M0LN7DAV6J[,ZLWNU^82%O$[6<=#;V<^\F6@A82]1Q'"WG2UID
MG4NG)Y_R E-R%WVSOPF%TY)>>$X8090(RQH=$></XZFF+L9=<-(JAC]_Q4C9
M1]\\SY_9+4;4N$<^ _.80?,L\4\\8TCP^3M'H-IQF&'V(Q.K8/8>DZXR6(^K
MA"@J/\&;QI1W\TKV7B8U*-A/>4[NJ?7U;!]F]PX?[XWW;0QS_:\>C\)?]<!\
M]GNA$TJ*Z F;0 C4BI/R<# V4*Q6TCMHO8:X@HJ[=GIKJH[)X2O3Z5Q)/4%K
M+*AJ>9H<2E @J4J"6[?H5B-.@MZ1)7Y@AFDRKFWEUQW$,O1#X98!J=4([/YB
MX@*W0L\CQ:2EZFN?R QJ;@J9C=:/YFM80)(VHP![&/R.$%_8-\XN#10:UI\V
M6@!,^>R?Z[TB?#U=4'/1Q:CZ#6@.3#Q<*0Q8RJ;&#48Z&_0%CJQRD^EVD:#I
M&$ZJ.* EK>+&(01U(TJ:DE[;( K@O<@1XS" A%J>Z7MQBH:@=/$<ITS'6.WN
MF(F/=!Q=*\D0-L$-\8DZ)5UTK[#FA_Z\;\HM24@'AQ;]WH($/K7^,K&486XN
MW_!N +=P9<S($M!.L&P@HREFU8_ZM[$D#.2J_II5:D/E-+2"V1]J\13W"=,-
MS"^1IOE?DJ;Y:FDJ,)T5DM3(&TUE"GF^X0*T]:8)V+RV=VA$NM^X+BXEFHHI
MC16'P1N+15M#&XR"GXP(JI=@Y/#V4,DC9CES/-3M%"YU/FT4@<'FA?Q)7DD:
MN%8M#Y+%2?SZ\ U.D$>>:2UW-X."V/;3B*!VD,/35O.W1L;#TF&\TPUHI5 =
M&(_,95_>>N$R%"8<+X7<=/L=O!7\X ,B)'I7H:5PP<[??[E#:T&/74"A"@=2
MSKDH$-%G%/Q1*L% C1SI7ZG5X\W^IX(?]'ZQ,F;%G%9$](%B:),J/1@39GN<
M#:G@H3Q;9Y-<3"_Z%__H-RHNW207A(+>2NCU$:=\H*>)]HU3%9< -CEIFBSF
M*1C"A99B1!-5;E0R[SC,Y"*J%[YF$2T(\TAA0R(U"]^%H=_4("7-:3,T#B[J
MV>VZ#Q,\"LB9MK.7B9U!PJO)A>%Q?8YL)F?DCG8&^Y$$,0LMI[:2+X.^X9P5
MQ@\TY.GS.D(H)AD@P5<[>888Y8)'QD(/7.UA2SJ+[>OG9& WC"3;ZU^=<^?U
M3TZ<T/,[@*X:9M^#M4/%*':6E*"$5"R[LPG'8LWOP_JD5E7HE08I*D;]QQ[&
M.$KY;9(D@.]+=>R$TJ">X W4^EQXX@72XO,\<9Z!F*6)(\J/KOF^N9!2,? 2
M7!C+>5Q;!B"GX!>R;2S7JFD31[6[LWR6:*!AG#ON4\3PH\%U>9]D*./4].7#
M.1A%](IE:(9UV/R N9JDJ>\KJP;B-46)_7N&E@Z<P-G5O+7BX5U6-4J^O?=:
M@!;F0PS*!;72<!]/<SB[,+"#-'G=C Y(GJ!6A^ 1B_S6)YU+[ AZ-%4CDTVJ
MH>/I 56"281,B9=;O@L,9=B9.QX^:HSFS>KJ\8_P+[CZUC/M'(%E.2G8T]W)
MT-1G.6^=[D:7.H,\)$YX++]3)<-RT7>:\6/MECLI^( [>.:'?/A8S8]_E(I6
MUT, (9Y1YP^4G%NR^%%_C;,X9V%NT2/,KWFP[W:S<_.SOS+(R-!G I,VV"=<
MHO@K=N\]_N;>^\RJ 27"OZC*#XI(>UE0*=Q-KWX]FO&%[]T^2R_\*F?@/IR>
MAM1;<E83K-/))A]6'E ?":E)/>RCX5V]^ZECX46]#66,\IO/H_/OQ&R_.9%9
MXY=9A,=D"WP@VDP33HJENI7:-/QUHOMA#V77T&D#(M7L&\^, D4E$T'*N7*M
M3=4J,:"_?CP:+S(=HTAIVC>BU%Q2:4@-[[LYU?CF[HY4=N94SP[!GI\>1D1N
MQ?SAS-4R.1IQV!"1>6Y<MJ2Q\ P9,GG8!-$ !WES"T<H3.2F!:#$"EZKCJZ[
MP<G)D?-;'S =M'H1*(>RGQPK8^R06-:*LKV$OR>(Q"A7D(49N>,ZBK<A@CTH
M>FE^6'>\=Y3S._+\9.[G6]D!E*Q(:,P7F+PCL5_ZX-=REB^2UQDM,YYV#T,V
M86138*7+%]E'9=7A&%F?'6 PS'4[1U 7 _;9X5/1:>236%8FE4!QS>SC95<3
MDT"2J.]EY.)0> >WCQU6A=^9\%K^%E/HC]16P)D;R%0R3,Q'.?IPSG1(@J0Z
M9BM.V5_B+$G1&@F+5H1%+KK-\J/+FK*IFVAT87*:).+FR=O3XQ,,J3F//.K_
MTP&#0&6/4';S2\'"">2.\,^43 33=<:.9!$I+Q2$80X@<1Z0G^DD'^93:#4X
M?H<_I AT_"&NY4%.#WWS<5E5[1S9JK'-H9INZ/OXX8> F%I^^S\'.@)ZDOFK
M Z7"S5EG]G=W%#'E[#K*W<5B460NOH@%"&R$*1VAB3]"T8[HA[XOI;5.U4//
M$YLZ/*(#1 G;M;4O@X+)5VTQBL* O1U=#V$C"B/"\,**$#=HG8L$/WSV^ F#
M=Y\]_L$1BX/1W."T\P<OLMD'-#C@8"_XTTS*6OI]TS^%GHA7^&4U5DCJ&C<1
M@(6NJK*=,U+O*INY K7*3D2X..>P/^+KX3*K/^SNO"1(#OP9B\+4)TC2S@K(
M6=%YG4QI3[-IBY*%'V;G:N9R)V-65Z]OW#A*A-[NA^2T\ >H.(Q+LKM>+U^I
M@(,RE0&6+%"+FU@TQ&Z3($,R*'CFJJWZ X1-USZE*G=HKF:K.>$/[U-ZS6*
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M 48V&+OCE&.:@"_FRHI=;"@>8R?;4@;TM5Z8/JLR\(]0SL9=G)&()I#(M4\
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M<M&6D16+/>Z:-U-)I2QYCTG)48XP36/CH^QG@E$^B*%+24I@>_E(?DPW#/[
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MKSR;BU.@X6YAQD72O&TCDT^H?C;U<>6:A(!"_Y!"J+M6*[(.JIRR(U%0^A:
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MO'*PTBSM.27=T%/H]T*U</) )5?N(A^>P6\=#:LE> O>J\O+&']2T"VH:1]
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MFD5\O.F?E$KQ04MPD(\Y5?LV&T$-,LFHH*"6>>MJ2JG/?<5W7&^J#,GE?+G
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M)X#@L#S2;F6^6[D.1I]V3Q@1+D'1$#WQ^SW&.M##D83??S:4?'M/\?9ADC;
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M;RP/-'U"L[E+U&V^V-S>64N85QTKB,_]1J-$);;:O'36I)-VKB(/]PIE)6J
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M5N71+%F?GD!(K5E85?CL6W*)LI>LJ=)ZAKI[4BI8J?5C8UZM9I.H+_,Q,F9
MP*(TLYJW)!X5"$CAC-&":5=Y@?J/&8L@@<V#\E]8Z)#9\$I+:V#\U<! 5]&1
M81H'"$2;(;ZHRNFX@\X*=]NZSBJ%?B6L9[AIT%;F;_J3V3),#3_3)\3RNMMB
MO7W;#WPN = "W"1W*W!$V['9/L:)XM\LS'8TR;O2EJTZ4:ZN)17<E=W,*8=%
M#C*Y8W5#"R(9U67+Y%$%[T(.6T'3P8!DO 6]+_09V_G]$8]F9LF(9G;0$U4Y
M0=D0AQI4<>BY22^+4X1IE5,^=#KI.+7-9AZ0[/GZY<UMA@."K,@ D[+0SI*%
ML1'UE46>#*5(FLMT_.D#?8I%9\R!S<X--,LM$E]EQ3%F=L (9'>ST&CK)#L7
M4?;:\VR ($H@<4E\#B'/<Z*JL6#S>L11Q^=/4<=O;%M@??B[#)4DE7(1KG4
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M-?SQX,W[8_,%9\='IZ?1;^^.3HX^_?3C/P[>^&N0C0-?H[53 AFHFW$YWF5
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MC@E!36.P*;>U^P8TH1A$1 A+FH)&MHB=(JT/%U\9Y;.:SXTI"09!:X\]/$"
M?,MZ]JUBCP5OOAH7G89)1C>1YNU<'.C>4(1$CEZXTS%&'!0M&U*^ASL\W];>
MJ93$WJ HI]MV@R>.9@\P56*"<B]D@)FU.;1?SRC?)$K(S]TI;0PA&_79,G ]
M*EU2NK&YKP%SI .9/5R>1+NFNE]W-[OG4QT\#W>]J/C].'BVPFU8]R\OWL+F
MLG;A6^*_O)!@\87BRG1SZ?*AJV]9<60;%.(RSV!KT20/X>;Q@?,](9Y/1E"0
MY0$R5^36(1HS25&!L'RT)_(Z DTZ".?X _,^,NNN0#C"9P=+M+Z!M?F&[,^L
MK!W%883I(YY7E1T$L5'JG&T_'J'H(,</T &,V<=YO%>=#/Y81T/(K'(BQ= \
M$G8?(;XD@\+HGOW&F._(9%8ZKXLL*:]:UX$\$<N5W('QJ,^\N_ ?8E=%4E@=
M2=F5(>HG88D\$SVE+XW?ZP@/#_0[EM4X"]",DEFR)$8JJXHD%!3V[3<\6L37
M"5"IN?+X*=F^)+-Z'C,*N161;+L;,3T>&3&]YODNX6_7E+#8P'5HKOW,1"4B
M4C@F79JWR%M<6-?Q+<.5$(K<H[A#H<?D!J-+YW6%?G%[/LVH.-KU*KY$EQ"3
M*VJZA+3-\<=9C%YQ2<^PD;I)\!_[3RA&Q\KTP"MMI/)NX_MWZYV,?RCCK[$N
M0>$]=U%D8A7'A[CLA6A(0\?-NVY4#PI<I"%)B@A_GDQKUHE 7*-^GU#&@"P$
MY3Q<@@K4#0EBX/O+ #BI200[(.89M/@FZ#&RF749,W$7,QY<G3PH+V $D&89
M1E&!=RL1]8;69'082YCCT31&H@1MJJU3\#-F6TQ8T1 **3P4E>%-]QAYCKY_
M:XV;1\3(FLI*\+3G;)&M^K8[+SHNEK%Q>ZXL:UND=Y(VA0M42M9XA-146*W=
M+@B>8,>8_42M*2>"*=$!G^*^TMYHU2WQ;71/Y\6Y.F4&E%U>EPD3-IFHSYB9
MWMR+U*3PA?!,V^_!\649:!KCDKV'$DYX:S&;EHVEP\M$Q=I+\O7Z]AY^\^U]
M[J@.,C$=A-A%3M:C!6+*(#$/Q;NF0,B:@9E0X'@TK#IU"'".DP#1.@-8[@=I
M;A5[5L(B3?"=P*K*!&= &@;P[Y:N:7Y<D" UC!@__^$)^L9 0P,]N( !5CJN
M>15;%;&APS#;&5Q5,N?4(9PQ,$IT'Y7>%2</!4B,FP3VDT4A:PEB=VWP#H\;
MDX!*YK >K9>)3FV#!YYSM30S@V%RSHTC*S@0(V_"_!03YRC1EC=Q6Q\&K4)-
MM4_/Y&6BQ)C&WFKC2-:;%]YO5)X8,%)QAI)VZ.L.'LUV60+/D+*72,SP7]'6
M\*_)<T/>,CY]*,<RMPN$=<_2W"3QY$M)2"B#B)(3QZ.0![E$K3\3%:.NHOPF
M$^6I &)<EN1["=&, =G-0Y Z*.:/S-MR?-"A*O9PR&:7Z-P0-0N5%52Y[>;C
M1(MX ;*R9[9=&@F=O2_@X67 I];YJN(=>%-JO56^/:B,P$G+"N3\*_CDX>/@
M*J\IA=/29]]%*KOX 87Y_-1><D.P3LW'["]-W.#+A/5II?*/1THU86<CI41W
MR%?GQ) \XBYW@_*+F1!;Q2DF7<> K'2 C7Z(X^4FO,!%G>$<W#[I$,E9#>,_
MWG]"ZUW4Z26I97T^5.;+UW#2;)2(JUP,VH9F6!H+=]#CTMP.9.44I"1Y!)2=
MI#YKATGG,WC:#.N8,Y%3^=2911N%1\>CS>.CS<D^:QA%W2_L&4N\JO+BUN:9
MK,16L$Q] 1JO,7>N\Q3, *3!M7>5?S >#?P$-( L+G;R^0Z>K,U*YMNM,R*G
MQE8A Q"):?_Q8Y=2R=1!NBE19#.XPC>K)]^"PG]HV'" Q=>7W9A,K.;=_;3+
M!L9X)%&TFETP-BS/69_-W%JU]^]C,+ BS^2\6'\'MSS/L X=>/9-:0T<22L1
MWA/K%#GQ.&\[9FV^I+'ALA1U[(=00AL!&(_F(>]"#L='@0I**G2_".@'C: D
M5TPX9S<\[\4!%N$'9JHJG<;^&":68A*FN:NSI !C%8WH&8<D[24!JPJ>H1#H
MA!:V2,H4!"#LVSWEHH J<&[R":O@M%Y,65>49!&=R61=HR>B65Z+Q1ID]C')
M47;,T]'I, 6!-E'1\5(M2H+;5KIYD55ZW9"6S8A6R\,T,3XYTB@J=:)$?5A)
MQ/JSQ+HV$39 &&SXPV@W?<&D+3\/'2?DT3HF&=J_QZ/6_9"LV]!=T?XPD>?Y
M+<DI8W=+Q)+G%&H&'D ^Y'G6[\^>D%W1<&A7GI419PV'J--L>,LQ?X\6AHPQ
M+"A7=JORRK9:"^QW</<YZ#<VS6@_G,T%Q/ =S&L@$C>-@7&K -OZ76L84\Z]
M30$WV-'QZ(N8:@.+4IK^G:VT@>&[+;3QZ%Y,M(%Y?F;K3)TA^RWA/:T:Q=9T
MUIIR+(1)NR]-71FR;M;0Q<23__"6/P02P@_H(.!3. OGUI!0]'))!9=KMH@2
M_.(EQ\A-W:#1ZK^\T(I(:+U)0'YSP=11N @OT4ON!-3<UX[7\'2LMN#3!4[&
MSF0AH@83FOA*\%K_CC=POVNG^_2]-*(U1-R_@G5\=:(RAV[QDO&H?SD;4C=>
MK"V;M$2,8,";CB]?LXV428:*/"B3H-CS=455RS,%AR(D<_'.BZZOE%K1]'6=
ME&\4A)@GN^3$YDG@Z_^F$'$.2A&FM\,LZB4QO(');+/@A:NG].H#9/M(\F"^
MKSH21 *,5"2^(=IV*B 58#QGK0EUOK,_L55QM#FH-8%Y@"M^N,>N&%\6M>U"
MG=J$H=F^_![VT]LTE*X-/,BRFF[;$A/&-E[&_M[.?QNK;DLI56_!I*BP0@?,
ML9_Y;#QM"F:0^560) C(%@!6', T0XQBVIPH"E>YH PFZ& 4'_>F3VF%(TP=
M*XN8E=DZ7<K57L(44TQ^] *.,69PXDOW=_?^:L2]JSR47RW#)-J@7I6]7U]I
M1.31MXC()^SF"[0_--E2XNN Q<!D';,SI_THW8&U5_+1W@XP#W,I#5,IW+4R
MK!AO>L(U *0Z1S4EF%CV@O8^<U5Q \;-RN&7:3C[@%Z:#L_&.264FALL50F@
M7E4)535ZKBI)LB*&7!+J0Y[%%5J3Z*&)5F[CV$/'_-OY,$(IN$5?D?86>/6D
M91Q_@'O^1YTQ=RQBT";GK/WQE<;<O177"7;SCE9J^#(LPDO8]2OG8B>V@/ZH
ML+QJQ(SF^-HN<\[%XN]VNKZ<X-C\S$N";9R4<HMBH5V2F:)+YLG-7P^>>O">
M#QD65/EZ]0EAJ)3FI,+9#+U+8C<48DH1CT6< #AS3"%G:Y@VH^L$K$A ^\-1
M@-EXT5>&IBAK%TN56'E2CD?FW.9UFNX&IWF%>@DZFFQ*0#C-.0$4CY7-=9Y
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M U5]\A3P;QKU#VA<X#$2DBPCD]NQ!(VV,O4>!CO>K5Q'^G(?*ZPQ(X-*F%G
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MR*! )FVP<SNJDVAV]A1#TH24^J?M>/B\_0)/OQ&_1D/-:?D]D<DT/)Z3082
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M(OPT'>?NA->O4-R3GG3 U12W-W5 !7EW]#M\^/KB[9L7_Q]02P,$%     @
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M/3C9_O!)W#F/0H6#/4$ZJ#U*@PD5@[W.]NA,TJ9#:0+]EP> _O>O!7U;[M3
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M((9@]X#]1(1H#H)/B%Y"]$-5ONR7ZG@+[SAP&F>VX\K(J-J%,5Z\N="KCET
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MXKBS2&"O>0_-7K#$J1DR7FX.>DK2)IL+1#QJITX?,2B'1U<S W!.@(VU)NN
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M3KF\(7%5.[JH&S)90K? P-,8VU680@,C25E0;F2S3Q@9>DGT/"YB63;D4SY
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ME-]K]\@D=O'Y)VJN4_[^ 6X8>CBS/(EV+;2(*ZS=4AXRZ#C8*P"X-VH?'4[
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MT$[T,W.E:_9[(%,)'1/(KVJM$H$_K+Y@>#;Q<Q0!T*Q6A.(#7P$QS.<7]I&
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M/&4^N-D>-Z.A371,(<!]*K?%1N (E]CGCWI2 C=>,LT]H2CQ9R/Q+1K^Z\<
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M[13#6S.@'O%//E T92ORIXNB@!7\%A1B8\;H'U\SSO$&6-T JQM@=0.L_NV
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M%3W=?4)?/-T],/MQ!28_O="Z@.KYDX?&+8?'J^6.?6<ZD8&!AGT2O@%'S'-
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M[)KP<CXB<L--BM$./;?52#T>X84]'!#Y!SZF^:8L9$U8?X6^STQ=#JJ+WUJ
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MQM*D7YN=K$C@\:^>_O5N8WM[.<OJ"$?TYN+SP:=/;^W WCSF+Z(#^<6,T_Z
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ME*8S;YL6Y@[$F&>UF;N=,]R"LP("(KMDQ8CN6<15DZ7U<!#CSC6$F99Y7M[
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ML"E9E;"HX4&TIJXR5D]4?2A[5>K<CTPAW&SK2XP%*31JCU*!/4#.,2RY3GG
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M?%0O/9"=V@YVJLN*J\]'D;-V.SWK: W-\VT>Q:\7D"I.-"W<,0WR'+QR= =
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M %? KZ>'_X O/UY^_O3V?P%02P,$%     @ 0ZK96CD8C4K*$   $S0  !
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M3'42W$HB;#GK$6K',8G% -?$P]AJ8J[5UB!V@+=V:P(.!<7&&G%F.4=2"'/
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M5.\)*-N'>D-R)>EWZIK-2P6#HKI**%TLHOW_NS3_E[HT0![@X SU;/?2&&X
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M[3?=W;<;7],)W6%XV#J_>G_E?;5L;^T@-OBY/!9P"-EEGTPFCK411TEB\B3
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M9;X[<.>Q"[A>J?V13\JVX[K=OE;]_67K%[C;&5[T=JL=-/3X'U!+ P04
M" !#JME:(_-0=JH&  "D20  %    '9O<BTR,#(U,#8R-5]L86(N>&ULS9QM
M;]LV$,??#^AWN'EO-J"R8R4;4*-ID3G)$"QM@L;=A@U#(4N,34PF#5*.[6\_
M4@^-'%,R%9ZJ 'U0I+O_W5_^G<+(5MZ^WRQB>"!"4LY.>\/^40\("WE$V>RT
MMY)>($-*>R"3@$5!S!DY[6V)[+U_]^J[M]]['IQ?7GT$#^9)LI2CP6"]7O>C
M>\HDCU>)DI3]D"\&X'E%_'CR&?[(RHW@$XE)( DL ID0 ;^N:!R-_"/_9#CT
M_?ZPG"9(H/4@"A(R@E\&OOISY/\,)Z.3H]'Q$,X^P$6JPF!"%Z2<RI=;06?S
M!'X,?X(TZ9PS1N*8;.&2LH"%-(CAKNCX-5RQL ]G<0R?=)I4;4HB'DC4SU5C
MROX;Z7^FNGEX]1V .HM,IOM.>_I<Y*=B,Q5QGXN9ZO7H>%"D]!XS-GLIZ^,T
M8?CFS9M!>K0<+:DI5HD/!W]]N+X+YV01>.KLJU<KS,M(.I+I_FL>IJ?0HD&H
MC-!?>468IW=Y0]\['O8W,NJ]TP7SLQ-,27RMMB#U,!(\)C6%]>&T>B^/3[9+
M%4\V"6$1R96_:O,PCYH+<I^I:O9224G"_HP_#")"-2 G>L/3&[K#']077\9<
MX7XVE8D(PF2W7JQ/$1?%SM3$:<^0--AM2,>=B7!'*Q!AH:,V#_C/(P8A5Z_;
M,O%2Q2+]7O"%L8N\'#<<_!)/8V.;FB2UI:>;,._SW2&OF5#9F""2KX3"J\E+
MF_IYERK#/X7VOV\'C[5?2JOJ$B+)==-^W9 \6RC,U=_D,@YFMD@^2>H(27/K
MW'#0!4F#$!*27Y5!2SL#V4*C92!MNW7#\8(E--F.51D1Q%?J KSYG6QML:Q(
M[@C/>BN\)L@%UQI!)&RS"I"7@+0&J"+. +?8>AGDYOV[(7W.PY6>FXGJWI;D
MW9R. #8VSO>/N>"ZKX-$:2$,6MD93?PVRT1:]HJ#X2T1E$<7+#I7/\XTY?%)
M<L=@FJWPFB ,5 V"V,QF)4#5 %T$#=\66C=R;-T_QF+A$YE1O4AFR<=@84VT
M.;?3I4*%$5X=X[Y0,.GAKA,>*X N@;1*:*-OPR+!NGD,D*]8R,62B_16R5VB
M!F?,5VJ1LAWSJ"'7!Z0ZQ=S.)K=.<1\""WG<F=@I"&E%R$N"KHDT)-_ EV%F
MGF\.8X@N:4P^KA93(II-3#FOT_$P&.#FX^[@/]7"I5RK0R:/!#1VOP9ZK9K&
M '42;*XBM5BB]S2[.?X<:BM%.D7XD#5N$>P.=ZTP+NFJ%.S6PN6^52N&(7B&
M'XR1.(LB94#F_UU31H;-QL$HT.DHU%GB!P+=1Z!2%!?_7/]UL0&Z$MPPK'5,
M:S8,Z#_#2SOH^Z[H^R\.?=\6?;\-]/UOA_YDS5M#'\F&-?JU7A#1'ZO-&S'A
M:_8L\,OI+P%[@QT3](]A:,@_E6P)>%T&N !="!=V; -UJ-NY0,0\_7GX1MP*
M_D!9V/"V3I7&2P"^RIB)^B>Q:.@;=5OB/[NQH= IJN$.02M6ZB:A@1_$<;CE
M,@GBO^FR^3U.L\)+& 6S*=,@[$2BC8%!M:4AR"J!*H5YW[(]&W4#8.W%\3.
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MP+Y"$YGY#3R6R1]CQ *^)0,FVFU<E'=<JRW]VX7R733['3MJS_]02P,$%
M  @ 0ZK96IC9[;77!   ]"T  !0   !V;W(M,C R-3 V,C5?<')E+GAM;-6:
M;8_B-A#'WY]TW\%-W[32A9# ;KMHV1-E=T^H^R3@VJIO3B89P*IC(SLL\.UO
M''!+(.S!WJJ*5RL>',_X/_-S3#S)Y<=ERLDS*,VD:'MAK>X1$+%,F)BTO;GV
MJ8X9\XC.J$@HEP+:W@JT]_'J_;O+'WR?7-_V'HA/IEDVTZT@6"P6M63,A)9\
MGJ%+78ME&A#?M_V[P\_DC_5P+=('#E0#2:G.0)'?YHPGK:@>-<,PBFKAMID"
M:OR1A&;0(N=!A/_UZ(PT6\UZJQ&2SCVYR;T(,F0I;)O*V4JQR30C/\4_D]SH
M6@H!G,.*W#)!1<PH)P.K^ /IB;A&.IR3OC'3*%.#>H:DMO'*F?BG95Y&1CQY
M_X[@'^91Z+RU[9EL;)*Q'"E>DVJ":NN-P!IYVS;+/:-%(S<)+RXN@OQHL;]F
M9;UQ@##XZ_YN$$\AI3XR0&;QSE"H)LG^M=X6=Q:L#]K^FK5T[NE.QGGJCPB+
M'.QAOOFVFV^:_##R&V%MJ1/OR@RYSJJ2'/HP)N;]<[]7&/-9JGPVY>#KY]%9
MD-&E%#)=!:9[<"WC>0HBL^\=D=R(C&6KGAA+E>9!>"3/9VNJ8-SVT*-OG1DE
M/_;1SY=3_&2K&9X1FJ4S#AX)MB*9*9PU(LM[WV%#P0"6&8@$$NO&Z'_[6*_6
M*#?S5<:%V.T9FW/2$-<F\CE(@)D1F^:#R4PSSPI^^=*5N$AT1CI3-,Z*T7,S
M0:2RC9R.@+>]$J/@+05U,.S$A'[+Z>1803M&14';Q#HJ+KBD*K;N\.,>KN)D
MW_0(9E2A/S^>XK)FK<=*IJ7)V8PF2X5*E8!J>[@HXDGND9EB4B%L;/'(7*,6
M.3.J*3?'8 Q*07*W#ON@REPB+I@:\IYOC&<]&[L8@:*\AW-]^3NLCL5TP+BZ
MN X(MM@:SF"SZ\D0TW@LK:)-=2$5=5HV9\ZQ>0+4BLM]<HW70J="VC&N/JT=
MP1;;N3/8UFM#'R;,!"JR!YH>3:W<MKK0RO5:9K\XQ@SW 5+-I,I3.\ ,0U?.
M<8E?=65R(L)ON*HZT6_(MX!_=0SP+>/P,$]'H$ZCN6U7=73;6BVG"\<X#>FR
MEV :V)BM]Z*O@7;02=4)'A2^P=FH.X:SDR289+UYP\TQA*>A+'50=8REHBW"
MT'F$T?<BC%Q$&/V'T+6]^2:*+GY\5$.Y$*\"N&WN"+YMR1:>.SOT0BCYI=BC
M>E+RF9E:[VL([OEP!..>;LNRZ2;+)ZDSRO]FL]-W%^4>'.&XH]I2=*<N8]:3
MC@)Z"K>B375)%75:-NX47\S-*_XTE>+$?=Z^7749[6NUG-PIN/R)^C(079FF
M<['9YNAC81TPKBZQ X(M-G?** /)6<PR)B;W^&.LF)%V'+,RR^H"*U-K:;E3
M3'E28*8<X-52?A_$W()6C^/Q\<OB2QZJ2^\EU1N*37=J*#O1]+2>@_I^EB5^
MG"%:HMUR=:>P,H!X;B2&T6C(,G[TI>2^776Y[6NUG-RIG@P5-4_'#5;I2![]
M<[=C5%U".T(M'G?J(W:*W2SC*143..5V:[EM=6&5Z[7,7*N#W*2@)CCW/BFY
MR*:XOL^H./&1H0,NJDOP1=D6I#NED$TX2UQ%A&9&W/KQC1,IEMA7'F&)9LOO
M?RB77 9[>;G#!O.T\OJ(>3'/WF++5U!+ 0(4 Q0    ( $.JV5K3'55$=BD
M !_U   -              "  0    !D,C<P,C9D.&LN:'1M4$L! A0#%
M  @ 0ZK96LEZ&:TN2   WCT! !               ( !H2D  &0R-S R-F1E
M>#$P,2YH=&U02P$"% ,4    " !#JME:ZTM.0!V(  "P:@( $
M    @ ']<0  9#(W,#(V9&5X,3 R+FAT;5!+ 0(4 Q0    ( $.JV5J]I(RC
M:Y<  #^^ @ 0              "  4CZ  !D,C<P,C9D97@Q,#,N:'1M4$L!
M A0#%     @ 0ZK96M@,:$?_1   @3\! !               ( !X9$! &0R
M-S R-F1E>#$P-"YH=&U02P$"% ,4    " !#JME:O9:2S5HC  "ZDP  $
M            @ $.UP$ 9#(W,#(V9&5X,3 U+FAT;5!+ 0(4 Q0    ( $.J
MV5I*1>OJL30  +#J   0              "  9;Z 0!D,C<P,C9D97@Q,#8N
M:'1M4$L! A0#%     @ 0ZK96FS'?Q5F/P  !0\! !               ( !
M=2\" &0R-S R-F1E>#$P-RYH=&U02P$"% ,4    " !#JME:.1B-2LH0   3
M-   $               @ $);P( 9#(W,#(V9&5X.3DQ+FAT;5!+ 0(4 Q0
M   ( $.JV5IK7D8\1PH  !$?   0              "  0&  @!D,C<P,C9D
M97@Y.3(N:'1M4$L! A0#%     @ 0ZK96H0$Q( \ P  .@L  !
M     ( !=HH" '9O<BTR,#(U,#8R-2YX<V102P$"% ,4    " !#JME:(_-0
M=JH&  "D20  %               @ '@C0( =F]R+3(P,C4P-C(U7VQA8BYX
M;6Q02P$"% ,4    " !#JME:F-GMM=<$  #T+0  %               @ &\
ME ( =F]R+3(P,C4P-C(U7W!R92YX;6Q02P4&      T #0 K P  Q9D"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>d27026d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vor-20250625.xsd" xlink:type="simple"/>
    <context id="duration_2025-06-25_to_2025-06-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817229</identifier>
        </entity>
        <period>
            <startDate>2025-06-25</startDate>
            <endDate>2025-06-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-522">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-06-25_to_2025-06-25"
      id="Hidden_dei_EntityCentralIndexKey">0001817229</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-533">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-534">2025-06-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-535">Vor Biopharma Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-536">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-537">001-39979</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-538">81-1591163</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-539">100 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-540">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-541">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-542">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-543">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-544">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-545">655-6580</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-546">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-547">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-548">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-549">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-550">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-551">VOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-552">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-553">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-06-25_to_2025-06-25" id="ixv-554">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
